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Despite the significant progress the world has made over the past few decades, 
millions of children in low- and middle-income countries still suffer from poor growth 
and development. Growth faltering during the critical window period of the first 1,000 
days after conception is associated with multiple adverse consequences limiting 
human potential and economic growth. Recognizing the magnitude of the problem 
and its severe consequences, the World Health Assembly in 2012 endorsed a 
Comprehensive Implementation Plan on Maternal, Infant, and Young Child Nutrition 
with six global targets, chief among which is the target to reduce the number of 
stunted children by 40% in 2025. 
Identifying priority areas of action in high nutrition-burden countries is the first step to 
accelerate current progress and achieve the global nutrition targets. For the purpose 
of facilitating evidence-based decision-making, the first part of this PhD thesis  
explores nutrition-specific and -sensitive factors that can contribute to a reduction in 
chronic child undernutrition in low- and middle-income countries. We pooled data 
from 50 Demographic and Health Surveys conducted in 14 low- and middle-income 
countries to explain the trend in under-five stunting prevalence over the past two 
decades. A four-level mixed-effects linear probability model, accounting for clustering 
of data by sampling clusters, survey-rounds and countries, was fitted to estimate the 
association between the change in a range of distal to proximal determinants at a 
country-level and stunting risk for an individual child while adjusting for time trend 
and child-level covariates. 
Furthermore, innovative approaches that maximize the impact of existing nutrition 
interventions are highly required to assist the progress in low- and middle-income 
countries. Complementary feeding interventions in low-income settings to date have 
been focused on energy and micronutrient content of diets and yielded only small to 
moderate effects on growth and development. Increasing evidence support the 
hypothesis that environmental enteric dysfunction, a chronic gut inflammation with 
morphological and functional derangements and systemic inflammation occurring at 
a high prevalence in children living in poor settings, could be an important missing 
link that mediates and reduces the expected benefits from interventions. There is 




improve gut integrity, reduce inflammation and enhance maturation of the immune 
system, which could lead to amelioration of this condition and the associated growth 
impairment. Additionally, some studies in high-income populations showed that n-3 
LCPs may have benefits for infant neurocognitive development. However, there is 
limited evidence from studies testing these potential benefits in infants and young 
children in a low-income setting. 
Therefore, in the second part of the PhD thesis, we hypothesized that an increased 
intake of n-3 LCPs would result in reduced morbidity and inflammation, and 
improved growth and development of children aged 6-24 months in a low-income 
setting. To test these proposed hypotheses, we conducted the OME3JIM project 
involving a 2 x 2 factorial randomized controlled trial of n-3 LCPs-rich fish-oil 
supplementation (500 mg/day n-3-LCPs) through lactation (MI), complementary 
feeding (CI), or a combination of both (MCI). We enrolled 360 pairs of lactating 
mothers and their infants 6-12 months old from three rural communities in Jimma 
district, southwest Ethiopia. The primary study outcomes were child linear growth, 
i.e., monthly changes in length-for-age z score (LAZ) over the 12 months intervention 
follow-up, and the evolution of developmental performance from baseline through 6 
and 12 months of the intervention, using the Denver II and the Ages and Stages 
Questionnaire: Social Emotional tools. Secondary outcomes included LCP 
concentrations in maternal milk and child blood, anthropometry measurements of 
weight-for-length z score (WLZ), head-circumference and mid-upper arm 
circumference (MUAC), nutritional status (stunting, wasting and anemia), common 
childhood morbidities, and inflammation using C-reactive protein. 
Chapter 3 presents results of the study on the trend in child stunting. Stunting 
followed a declining trend in all the 14 countries studied at an average annual 
reduction rate of 1.04 percentage points (pp). Among the distal factors assessed, a 
decrease in the Gini coefficient, an improvement in women’s decision-making, and 
an increase in urbanization over time within a country were significantly associated 
with a lower risk of stunting. Improvements in households’ access to improved 
sanitation facilities and drinking water sources, and children’s access to basic 
vaccinations were the important intermediate service-related drivers of stunting risk 
identified, whereas an improvement in early initiation of breastfeeding and a 




Our findings indicate that although there has been progress in reducing stunting, the 
rate of reduction in the studied countries was below the average 3.9 pp annual 
reduction rate required to meet the global target set for 2025. Furthermore, our 
findings reinforce the need for a combination of nutrition-specific and -sensitive 
interventions on top of economic development to tackle the problem of chronic 
childhood undernutrition. The identified drivers will help to guide global efforts to 
further accelerate stunting reduction and monitor progress against chronic child 
undernutrition. 
Results of the OME3JIM study are presented and discussed in Chapters 4-6. From 
the total of 360 mother-infant pairs enrolled, 87% completed all the 12 months study 
follow-ups and the mean (SD) duration of supplementation was 11.0 (2.9) months. 
Compliance rate for the child and the maternal interventions were ~80% and ~70%, 
with no difference between study arms. All statistical analyses were conducted 
following the intention-to-treat principle. In Chapter 4, we present the efficacy of fish-
oil supplementation of lactating mothers on human milk LCP concentrations using a 
random sub-sample of 154 study participants. Fish-oil supplementation during 
lactation increased maternal milk concentrations of docosahexaenoic acid (DHA) by 
39.0% (P < 0.001) and eicosapentaenoic acid (EPA) by 36.2% (P < 0.001), whereas 
the ratio of arachidonic acid (AA)/(DHA + EPA) decreased by 53.5% (P < 0.001), 
compared to the control. However, the maternal milk DHA concentration still 
remained lower than international norms after the intervention. The results 
demonstrate that fish-oil supplementation during lactation improves n-3 LCPs status 
of the maternal milk. In these mothers with a very low baseline breastmilk DHA 
status, which further declines over the course of lactation, a higher dose of 
supplementation may be required to attain optimal breastmilk DHA levels. 
Chapter 5 presents the independent and combined effects of the fish-oil intervention 
through lactation and complementary food on child n-3 LCPs status, health and 
growth. Fish-oil supplementation significantly increased child blood n-3 LCPs 
concentrations (P < 0.01) and decreased the AA/(DHA + EPA) ratio (P < 0.001) in all 
the MI, CI and MCI intervention arms as compared to the control. Fish-oil 
intervention also resulted in a better ponderal growth of children, as indicated by the 
small, but statistically significant, positive effects on monthly WLZ changes in the CI 




(effect size: 0.018/month; 95% CI: 0.001, 0.034/month; P = 0.041). We also noted a 
non-significant trend towards larger monthly MUAC increments in the CI and MCI 
arms compared to the control. No further effects were detected on the primary study 
outcome linear growth or on the other secondary outcomes of growth, nutritional 
status, morbidity, and inflammation. Chapter 6 presents the effects of the same 
intervention on child development performance. There was no difference between 
study arms on the evolution of overall and social-emotional developmental 
performance over time (intervention by time interaction: F = 1.09; P = 0.35, and F = 
0.61; P = 0.61, respectively). Overall, the findings from the OME3JIM trial did not 
support our primary study hypotheses that dietary n-3 LCPs supplementation 
through lactation and/or complementary feeding improves linear growth and 
development of infants and young children from a rural setting in Ethiopia. n-3 LCP 
supplementation given directly to children or in combination with maternal 
supplementation was found to modestly increase relative weight gain.  
In conclusion, this PhD research provides evidence on a set of potentially important 
proximal to distal factors that can contribute to reduction in chronic childhood 
undernutrition in low- and middle-income countries. It also contributes to the limited 
literature on the effects of n-3 LCP supplementation in infants and young children in 
a rural sub-Saharan African setting. In Chapter 7 the implications of the study 
findings are discussed and recommendations for future research and policy are 
provided. It is underlined that economic development and nutrition-sensitive 
interventions, on top of nutrition-specific programs, could play an important role in 
further reduction of the high stunting burden in low- and middle-income countries. 
Future follow-up of the OME3JIM cohort is also recommended to determine whether 





Ondanks de aanzienlijke vooruitgang die de wereld afgelopen decennia heeft 
gemaakt, zijn miljoenen kinderen in lage- en middeninkomenslanden nog steeds 
belemmerd in hun groei en ontwikkeling. Een slecht verloop van de groei tijdens de 
kritieke periode, van de eerste 1000 dagen na conceptie, gaat gepaard met 
meerdere nadelige gevolgen die het menselijk potentieel en de economische groei 
beperken. De Wereldgezondheidsassemblee herkende de omvang van het 
probleem en de ernstige gevolgen ervan en keurde in 2012 een alomvattend 
uitvoeringsplan voor de voeding van moeders, zuigelingen, en jonge kinderen goed, 
met zes wereldwijde doelstellingen, waaronder het hoofddoel om het aantal kinderen 
met groeiachterstand te verminderen met 40% tegen 2025. 
 
Het identificeren van prioritaire actiegebieden, in landen waar het risico op 
ondervoeding groot is, is de eerste stap om de huidige vooruitgang te versnellen en 
de wereldwijde voedingsdoelstellingen te halen. Het eerste deel van dit 
doctoraatswerk heeft als doel het faciliteren van evidence-based besluitvorming en is 
gericht op het onderzoeken van voedingsspecifieke en -gevoelige factoren die 
kunnen bijdragen aan het verminderen van chronische ondervoeding in lage- en 
middeninkomenslanden . We hebben gegevens verzameld van 50 Demographic and 
Health Surveys uitgevoerd in 14 lage- en middeninkomenslanden  om de trend in de 
prevalentie van groeiachterstand in kinderen, jonger dan vijf jaar, in de afgelopen 
twee decennia te verklaren. Een lineair waarschijnlijkheidsmodel met vier niveaus 
voor gemengde effecten, dat rekening houdt met de clustering van gegevens door 
steekproefclusters, enquêterondes en landen, werd opgesteld om de associatie 
tussen de verandering in een reeks distale en proximale determinanten op 
landenniveau en de kans op groeiachterstand voor een individueel kind te schatten, 
met een correctie voor tijdtrend en covariabelen op kindniveau. 
Bovendien zijn innovatieve benaderingen die de impact van bestaande 
voedingsinterventies maximaliseren vereist om de vooruitgang in lage- en 
middeninkomenslanden  te ondersteunen. Complementaire voedingsinterventies in 
lage- en middeninkomenslanden  waren tot nu toe eerder gericht op het energie- en 
micronutriëntengehalte van diëten en leverden slechts kleine tot matige effecten op 




omgeving gerelateerde enterische dysfunctie, een chronische darmontsteking met 
morfologische en functionele verstoringen en systemische ontsteking die veel 
voorkomen bij kinderen in slechte omstandigheden in arme regio’s, een belangrijke 
ontbrekende schakel is die de verwachte voordelen van interventies bemiddelt en 
vermindert. Er zijn aanwijzingen dat omega-3 meervoudig onverzadigde vetzuren 
met lange keten (n-3 LCPs) de darmintegriteit kunnen verbeteren, ontstekingen 
kunnen verminderen en de rijping van het immuunsysteem kunnen verbeteren, wat 
zou kunnen leiden tot verbetering van deze aandoening en de daarmee 
samenhangende groeiachterstand. Bovendien is aangetoond dat n-3 LCPs de 
neurocognitieve ontwikkeling van zuigelingen in ontwikkelde landen ten goede komt. 
Er is echter beperkt bewijs uit studies die deze potentiële voordelen testen bij 
zuigelingen en jonge kinderen uit ontwikkelingslanden. 
Daarom werd in het tweede deel van het doctoraatswerk de hypothese opgesteld dat 
een verhoogde inname van n-3 LCPs zou leiden tot verminderde morbiditeit en 
ontsteking en tot verbeterde groei en ontwikkeling van kinderen 6-24 maanden in 
een laag inkomen gebied. Om deze voorgestelde hypothesen te testen, hebben we 
de OME3JIM-studie uitgevoerd. De studie is een gerandomiseerde gecontroleerde 
studie met een 2 x 2 factorieel ontwerp van n-3 LCPs-rijke visolie-supplementatie 
(500 mg/dag n-3-LCPs) via borstvoeding (MI), aanvullende voeding (CI) of beide 
(MCI), door zogende moeders en hun zuigelingen 6-12 months uit drie rurale 
gemeenschappen in het district Jimma, in het zuidwesten van Ethiopië. De primaire 
uitkomsten van het onderzoek waren lineaire groei van het kind (d.w.z. maandelijkse 
veranderingen in lengte-voor-leeftijd z-score (LAZ) over 12 months) en 
ontwikkelingsprestaties op 6 en 12 months met behulp van de Denver II en de Ages 
and Stages Questionnaire: Social Emotional hulpmiddelen. Secundaire uitkomsten 
waren onder meer LCP-concentraties in moedermelk en bloed van de kinderen, 
antropometriemetingen van de gewicht-voor-lengte z-score (WLZ), hoofdomtrek en 
midden bovenarmomtrek (MUAC), voedingsstatus (groeiachterstand, ‘wasting’, en 
bloedarmoede), veelvoorkomende morbiditeiten bij kinderen en ontstekingen met 
behulp van C-reactief proteïne. 
Hoofdstuk 3 presenteert de resultaten van de groeiachterstand trendstudie. 
Groeiachterstand volgde een dalende trend in alle 14 onderzochte lage- en 




procentpunt (pp). Onder de beoordeelde distale factoren waren een afname van de 
Gini-coëfficiënt, een verbetering van de besluitvorming van vrouwen, en een 
toename van verstedelijking in de tijd binnen een land significant geassocieerd met 
een lagere kans op groeiachterstand. Verbeteringen in de toegang van huishoudens 
tot sanitaire voorzieningen en drinkwaterbronnen, en de toegang van kinderen tot 
basisvaccinaties waren de belangrijke tussenliggende service gerelateerde 
drijfveren, terwijl verbetering in het vroeg starten met borstvoeding en een afname in 
de prevalentie van laag geboortegewicht de belangrijke proximale drijfveren waren. 
De resultaten geven aan dat, hoewel er vooruitgang is geboekt in het verminderen 
van groeiachterstand, het huidige reductiepercentage in de bestudeerde landen 
lager is dan de jaarlijkse vermindering van 3,9 pp die nodig is om de doelstelling van 
2025 te halen. De resultaten versterken de behoefte aan een combinatie van 
voedingsgevoelige en -specifieke interventies bovenop economische ontwikkelingen 
om het probleem van chronische ondervoeding bij kinderen aan te pakken. De 
geïdentificeerde drijfveren helpen de wereldwijde inspanningen te begeleiden om de 
groeiachterstand reductie verder te versnellen en de voortgang tegen chronische 
ondervoeding bij kinderen te volgen. 
De resultaten van de OME3JIM-studie worden gepresenteerd en besproken in 
Hoofdstukken 4-6. Van de in totaal 360 ingeschreven moeder-kindparen, voltooide 
87% de follow-up periode van 12 months van het onderzoek. De gemiddelde (SD) 
duur van supplementatie was 11,0 (2,9) months. De nalevingspercentages voor kind 
en maternale interventies waren 80% en 70%, zonder verschil tussen studiearmen. 
Alle statistische analyses zijn uitgevoerd volgens het intention-to-treat-principe. In 
Hoofdstuk 4 hebben we de werkzaamheid van supplementatie met visolie van 
zogende moeders op LCP-concentraties in moedermelk (HM) in een willekeurig 
deelmonster van 154 deelnemers gepresenteerd. Supplementatie met maternale 
visolie verhoogde de HM-concentraties van docosahexaeenzuur (DHA) met 39,0% 
(P <0,001) en eicosapentaeenzuur (EPA) met 36,2% (P <0,001), terwijl het 
arachidonzuur (AA)/(DHA + EPA) ratio afnam met 53,5% (P <0,001), vergeleken met 
de controlegroep. We vonden significante verbanden tussen de verandering in de 
verhouding tussen HM en kinderbloed (DHA + EPA)/AA na de supplementatie (P 
<0.001). De HM DHA-concentraties bleven na de interventie echter nog steeds lager 




visolie tijdens borstvoeding de status van HM n-3 LCPs verbetert. Bij deze moeders 
met een zeer lage HM DHA-baseline-status, die verder afneemt tijdens het geven 
van borstvoeding, kan een hogere dosis supplementatie nodig zijn om adequate HM-
spiegels te bereiken. 
Hoofdstuk 5 presenteert de onafhankelijke en gecombineerde effecten van de 
visolie-interventie door borstvoeding en complementaire voeding op de status van 
kind n-3 LCPs, en gezondheids- en groeiresultaten. Supplementatie met visolie 
verhoogde significant de bloedconcentraties van n–3 LCPs van kinderen (P <0,01) 
en verlaagde de AA/(DHA + EPA) -ratio (P <0,001) in alle interventiearmen. De 
visolie-interventie resulteerde in een klein positief effect op maandelijkse 
veranderingen in WLZ in de CI- (effectgrootte: 0,022/month; 95% CI: 0,005, 
0,039/month; P = 0,012) en MCI-armen (effectgrootte: 0,018/month ; 95% CI: 0,001, 
0,034/month; P = 0,041). We merkten ook een niet-significante trend op van grotere 
maandelijkse MUAC-verhogingen in dezelfde interventiearmen. Er werden geen 
verdere effecten gedetecteerd op de primaire uitkomst lineaire groei of op de andere 
secundaire uitkomsten van groei, voedingstoestand, morbiditeit en ontsteking. 
Hoofdstuk 6 presenteert het effect van dezelfde interventie op de 
ontwikkelingsprestaties van kinderen. Er was geen verschil tussen de 
onderzoekarmen wat betreft de evolutie van de algemene en sociaal-emotionele 
ontwikkelingsprestaties over tijd (interventie × tijd: F = 1,09; P = 0,35 en F = 0,61; P 
= 0,61, respectievelijk). Over het algemeen ondersteunden de resultaten van de 
OME3JIM-studie de hypothesen van de primaire studie niet dat supplementatie met 
n-3 LCPs via lactatie en/of complementaire voeding de lineaire groei en ontwikkeling 
van  zuigelingen en jonge kinderen in een landelijke Ethiopische omgeving verbetert. 
n–3 LCP-supplementatie direct aan kinderen gegeven, verhoogde in bescheiden 
mate de relatieve gewichtstoename. 
Samenvattend, dit doctoraatsonderzoek leverde bewijs op over belangrijke drijfveren 
voor de vermindering van chronische ondervoeding in kinderen in lage- en 
middeninkomenslanden  en heeft bijgedragen aan het beperkte bewijs over n-3 LCP-
supplementatie van zuigelingen en jonge kinderen in een rurale sub-Sahara 
Afrikaanse setting. In Hoofdstuk 7 worden de implicaties van de bevindingen 
besproken en worden aanbevelingen voor toekomstig onderzoek gedaan. Benadrukt 




voedingsspecifieke programma's, een belangrijke rol zouden kunnen spelen bij het 
verder verminderen van groeiachterstand in lage- en middeninkomenslanden . 
Opvolging van het OME3JIM-cohort wordt aanbevolen om te bepalen of er 
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1.1. The epidemiology of childhood undernutrition and developmental delay 
1.1.1. Magnitude and consequences 
Poor child growth and development are major public health problems in low- and 
middle-income countries (LMICs). According to the 2018 estimates of the global 
burden of malnutrition, 149 million (22%) children younger than five years old suffer 
from stunted growth, indicating chronic undernutrition (1). During the same period, 
an estimated 49 million (7.3%) children were affected by acute malnutrition (wasting) 
from which nearly 17 million were severely wasted, seriously jeopardizing their 
survival. South Asia and sub-Saharan Africa are the two most affected regions, 
contributing to 55% and 39% of the global burden of stunting, and 68% and 28% of 
the wasting burden, respectively. 
Although there is a lack of data to directly estimate the global burden of childhood 
developmental problems, children in LMICs have increased risk of poor 
developmental outcomes because of a combination of risk factors such as poverty, 
poor health and nutrition, and inadequate caring practice. Estimates based on proxy 
measures of stunting and extreme poverty in 2010 indicated that 250 million (43%) 
children younger than five years in LMICs are at risk of not reaching their 
developmental potential, with Sub-Saharan Africa (66%) and South Asia (53%) being 
the regions with the highest percentage of disadvantaged children (2). 
Undernutrition and poor development during early-life have far reaching negative 
consequences on the health and wellbeing of individuals as well as on the human 
and economic development of societies and countries at large (3–5). Undernutrition 
increases children’s susceptibility to illness and mortality (6). It has been estimated 
that undernutrition in the aggregate, including intrauterine growth retardation, 
stunting, wasting, and deficiencies of vitamin A and zinc along with suboptimal 
breastfeeding, underlies 45% of the global burden of under-five mortality, resulting in 
3.1 million deaths in 2011, and contributes to 80% of the neonatal mortality occurring 
among low birthweight babies (7,8). 
Children surviving from malnutrition encounter short-, medium- and long-term 
adverse consequences. Children with suboptimal nutritional status and development 
will subsequently have diminished cognitive performance and school achievement, 
which have a knock-on effect for adult wages and productivity (5,9–15). Early 
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nutritional insult also has irreversible negative effects on physical strength and work 
capacity, resulting in reduced adult earnings (16). The loss of human potential 
associated with stunted growth in early-life has been estimated to be more than a 
20% deficit in adult income, which has substantial implications for national 
development (11). Furthermore, evidence shows that physiological changes related 
to early-life nutritional insults could contribute to increased risk of nutrition-related 
chronic diseases and related mortality into adulthood (5,14,17–19). 
Undernutrition is a cyclical process because children who are stunted usually grow-
up to be stunted mothers and likely to transfer this status to their offspring, creating 
an intergenerational cycle of poor health, poverty and reduced human capital (20–
23). Short statured mothers have increased risk of cephalopelvic disproportion 
leading to obstructed labor, maternal morbidity and mortality, and stillbirths 
(5,7,14,24). Newborns from stunted mothers are more likely to face intrauterine 
growth restriction that increases their risk of perinatal mortality and their later risks of 
morbidity and mortality, and impaired growth and development (5,8,21,24–26). 
1.1.2. The determinants of child nutritional status and development 
A complex interrelationship of multiple factors determines children’s risk of 
suboptimal health, nutrition and development in LMICs. The United Nations 
Children’s Fund (UNICEF) (27) in 1990 proposed a conceptual framework for ‘the 
causes of child malnutrition and death in developing countries’, explaining how the 
hierarchical relationship of multiple factors operate at the immediate (individual 
child), underlying (household), and basic (societal) levels. The more recent Lancet 
2013 Framework for Action (7) also reflected on this framework to elucidate the 
potential means to achieve optimum fetal and child nutrition and development 
(Figure 1.1). 
In short, the framework identifies the dietary, health, and caregiving determinants of 
child nutrition, growth and development, which manifest themselves at the level of 
the individual child, and how these factors are influenced by underlying resources of 
household food security, caregiving resources, and the health environment 
determinants, which are in turn shaped by structural and contextual factors at the 
wider national and global level (7,27). Accordingly, it has been emphasized that 
combinations of nutrition-specific interventions, that address the immediate causes 
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of suboptimum growth and development, and nutrition-sensitive interventions, that 
address the underlying factors, on top of structural actions to create enabling 
environment for policy changes and to support interventions and programs are 
required to improve the wellbeing of children in LMICs (7,28–30). 
 
Figure 1.1. Conceptual framework of the immediate, underlying, and basic 
determinants, and relevant actions to achieve optimum child nutrition and 
development (from Black et al. (7)). 
Inadequate dietary intake and poor health are the immediate causes of suboptimal 
child growth and development. Optimal breastfeeding and complementary feeding 
are crucial to secure the high energy and nutrients requirements of infants and 
young children (IYC) who are in rapid growth and development (31,32). The World 
Health Organization (WHO) (33) in 2010 proposed global recommendations for 
infant and young child feeding (IYCF), which included eight core and seven optional 
indicators of optimal feeding practices. Subsequently, several studies showed that 
adherence to the recommended IYCF indicators and interventions targeted at 
improving optimal IYCF practices resulted in improved growth and nutritional status 
of children in LMICs (34–39). Prenatal nutrition, which is mainly determined by 
maternal health and nutritional status at the time of conception and during 
pregnancy, also plays a critical role in the status of children at birth and their 
subsequent growth and development. It has been estimated that 20% of the stunting 
 
Chapter 1: General Introduction 
5 
 
and 30% of the wasting burden in under-five children have prenatal origins (26).The 
high burden of infectious diseases like diarrhea in low-income settings compromise 
the healthy growth and development of children (40,41). Furthermore, in children 
living under poor environmental and food hygienic conditions, even when there are 
no obvious symptoms, physiological conditions associated with persistent 
asymptomatic gut inflammation can result in growth faltering by impairing absorption 
of nutrients, increasing nutrient losses and diverting nutrients away from growth and 
development towards the requirements for immune response (17,41–43). 
The three underlying determinants that influence child nutrition and development 
through the immediate causes are the availability, economic accessibility, and 
utilization of resources including household food security; resources for care to 
children and women; and the health environment. Food security is crucial to ensure 
access to sufficient amounts of safe and nutritious food for healthy growth and 
development (44,45). Household food insecurity could be caused by unavailability of 
food, insufficient purchasing power, inappropriate intrahousehold distribution, or 
inadequate body utilization of food (46). Care is the provision in the household and 
the community of adequate time, attention, and support to meet the physical, mental, 
and social needs of the growing child and other household members (47). Examples 
of caring practices are child feeding (including feeding during illness), child cognitive 
stimulation, health-seeking behavior, and caring and support for mothers during 
pregnancy and lactation. Resources for care for children and women include 
women’s empowerment through education, work opportunity, autonomy and control 
of resources, caregiver knowledge and beliefs, caregiver physical health and 
nutritional status, caregiver mental health and protection from abuse, and family and 
community social support (47–50). The third underlying determinant is the health 
environment surrounding a child, including hygiene and sanitation conditions and 
access to health care services, which determine a child’s exposure to pathogens and 
risk of morbidity as well as utilization of preventive and curative health care services. 
Important aspects of the health environment include access to safe water, sanitation 
facilities, safe housing and food hygiene, and access to basic health services such 
as child immunization and growth monitoring, deworming, treatment of sick child, 
and maternal health care services (51–53). 
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Finally, the basic determinants that impact child nutrition and development through the 
underlying and immediate determinants, are structural and contextual factors at the 
wider national and global level. They form the economic, political, environmental, social, 
and cultural context in which children’s health, nutrition and development is determined. 
Economic progress in a country, for instance, can influence child nutrition and health 
through different routes. Higher national income is related to poverty reduction and thus, 
can be considered as a proxy indicator of a household’s expenditure on health and 
nutrition inputs such as food, water, sanitation, and health care (28,54). On top of this, 
increasing national income can be exploited for investment in pro-poor public services 
such as health services, social protection and education (52). The political, social, and 
cultural contexts of a country, as well as the leadership taken, also play numerous roles 
as basic drivers of the wellbeing of children and women. For instance, responsiveness 
and accountability of the government and the bureaucracy are important in designing, 
implementing, and monitoring policies addressing the needs of vulnerable groups such 
as the health and nutrition needs of children and women (29,52,55). 
1.1.3. Global trends in child undernutrition 
Recently, reducing the scourge of childhood undernutrition has been gaining 
increasing priority on the international development agenda both as a maker and a 
marker of sustainable development in LMICs. In this regard, stunting, defined as 
length/height-for-age falling below 2 standard deviations from the WHO Child Growth 
Standards median, emerged as a key indicator to follow progress on the situation of 
children globally (56,57). Stunting is not only the most prevalent form of 
undernutrition globally, but it is also the best overall proxy index of children’s physical 
and developmental well-being and has concurrent short- and long-term health and 
economic consequences (11,56). 
The World Health Assembly (WHA) in 2012 adopted a resolution to reduce by 40% 
the number of under-five children who are stunted between 2010 and 2025 (58). 
Significant progress has been made towards reducing the global burden of stunting 
over the past few decades. The prevalence of childhood stunting decreased from 
about 33% in 2000 to less than 22% in 2018 (Table 1.1) (1). However, the 
prevalence rates and trends vary greatly across countries and world regions and 
while there has been progress, millions of children are still suffering from stunted 
 
Chapter 1: General Introduction 
7 
 
growth and its functional consequences. In South Asia and sub-Saharan Africa, 
stunting still remains unacceptably high, affecting more than one-third of under-five 
children. In Africa, where population growth outpaces the reduction in stunting 
prevalence, the absolute number of stunted children is increasing. At the current 
rates of stunting reduction, it is estimated that there will be 127 million stunted 
children globally by 2025, a reduction of only 26% in contrast to the global target of 
40% reduction (56). 
Table 1.1. Global trends in stunting prevalence among under-five 
children, 2000-20181 
Regions 2000 
% (nr in 
million) 
2018 










South Asia 51.4 (89.4) 34.4 (58.7) 17.0 33.1 
Sub-Saharan Africa 43.0 (50.0) 33.3 (57.9) 9.7 22.6 
East Asia & the Pacific 24.5 (36.9) 8.4 (13.0) 16.1 65.7 
Middle East & North Africa 22.8 (8.5) 14.7 (7.1) 8.1 35.5 
Latin America & the Caribbean 16.7 (9.6) 9.0 (4.8) 7.7 46.1 
Europe and Central Asia - - - - 
Low- and middle-income countries 35.9 (195.0) 23.9 (145.9) 12.0 33.4 
Global  32.5 (198.2) 21.9 (149.0) 10.6 32.6 
1Source: UNICEF, WHO, The World Bank. Levels and trends in child malnutrition: key findings of the 2019 
Edition of the Joint Child Malnutrition Estimates; WHO: Geneva, Switzerland, 2019 (1). 
Several studies have evaluated which of the determinants in the UNICEF’s 
conceptual framework of childhood undernutrition were the most important drivers for 
the stunting reduction observed over the past three decades. It has been shown that 
both progress in specific interventions and changes in general developmental factors 
were associated with the improvements in child undernutrition in LMICs (45,51–
54,59–65). The important proximal and underlying drivers of stunting reduction that 
were reported across settings included improvements in access to sanitation 
infrastructure (52,53,59,60), safe water (45,52,61), child immunization (45,51), 
deworming medication (51), antenatal care service (53,59,60), maternal iron 
supplementation (51), increases in women’s education (45,52–54,59–61,65), 
improvements in household income or asset ownership (53,54,59,60,65), 
improvements in women status such as gender equality (52,61) and maternal 
nutrition (59,60), and improvements in food availability (i.e., per capita national 
energy supply (45,52,61). 
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The studies also noted the important facilitating role of basic factors such as 
economic growth (45,52,54,61), good governance and democracy (52,61), and 
urbanization (45) for the observed reduction in child undernutrition. On the other 
hand, whether general economic growth alone can result in a rapid reduction in 
undernutrition is questionable (62,63,65,66). Economic growth may not necessarily 
result in improvements in nutrition when income distribution is very unequal and 
benefits of increased national income do not adequately reach the poor. Analysis of 
the trends in stunting prevalence and gross domestic product (GDP) in 85 LMICs 
found equitable income distribution to be a necessary condition for increases in GDP 
to have an impact on stunting reduction (45). Furthermore, a higher national income 
may not be efficiently directed towards nutrition-specific and -sensitive investments. 
Harttgen et al. (65) showed that GDP growth in 28 Sub-Saharan African countries 
had a smaller contribution in explaining the differential improvements in child 
undernutrition across countries as compared to other factors such as progresses in 
women’s education and access to health services, and reduction in socioeconomic 
inequality. 
1.2. Omega-3 long-chain polyunsaturated fatty acids as essential nutrients 
1.2.1. Metabolism and dietary sources 
Essential fatty acids (FAs) are FAs that are required for important body functions but 
cannot be synthesized by the human body and, as such, must be provided in the 
diet. Linoleic acid (LA; 18:2n-6) and α-linolenic acid (ALA; 18:3n-3) are the two 
polyunsaturated fatty acids (PUFA) that are considered essential in the diet and the 
parent FAs for the omega-6 (n-6) and omega-3 (n-3) PUFA families, respectively. 
The distinction between the n-6 and n-3 PUFA families is based on the location of 
the first unsaturated bond from the methyl end (i.e. delta (Δ) position) of the FA 
molecule, which also determines their metabolic pathways. Mammals cannot 
synthesize the two essential FAs because they lack the FA desaturase enzymes 
(FADSs) introducing double bonds beyond the Δ9 positions, i.e. the Δ12- and Δ15-
FADSs catalyzing the synthesis of LA from oleic acid and ALA from linoleic acid (67). 
Much of the principal biological roles of LA and ALA in the body come from their 
conversion into the more biologically active long-chain PUFA (LCP) derivatives 
through a series of FA elongation, desaturation, and beta-oxidation steps which are 
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summarized in Figure 1.2 (67). The most important n-6 LCP is arachidonic acid (AA; 
20:4n-6) for which LA serves as the parent FA. ALA is converted to 
eicosapentaenoic acid (EPA; 20:5n-3) and further to docosahexaenoic acid (DHA; 
22:6n-3), which are the two major n-3 LCPs. 
 
Figure 1.2. Metabolism of essential FAs to their LCP derivatives (from Gibson 
et al. (67)). DPA; docosapentaenoic acid. 
The n-3 and n-6 PUFA families compete with one another for shared enzymes in the 
metabolic pathway and no interconversion occurs between the two families. 
Therefore, the balance between LA and ALA in the diet determines the balance 
between their biologically active n-6 and n-3 LCP derivatives in body tissues (67–
70). Despite desaturase enzymes show better affinity for ALA over LA, the 
metabolism of LA is generally favored over ALA due to the greater abundance of LA 
in human diets (67,71).The Δ6-desaturase is thought to be the rate limiting enzyme 
in the metabolic pathway and is required twice in the conversion of DHA from ALA, 
i.e., for desaturation of ALA to 18:4n-3 and 24:5n-3 to 24:6n-3 (67). The later use of 
the enzyme for desaturation of 24:5n-3 which subsequently leads to DHA synthesis 
thus faces competition from both LA and ALA in the diet. As a result, DHA synthesis 
may be inhibited not only by high dietary LA: ALA ratio, but also when diets contain 
very high amounts of ALA. Dose-response studies showed that while dietary ALA 
intake and tissue EPA content have a linear relationship, DHA status followed a 
curvilinear relationship with increasing dietary ALA intake (72,73). The synthesis of 
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DHA from ALA in weaning rats was inhibited when their diet contained high amounts 
of PUFA (LA + ALA), and the maximum conversion to DHA occurred when the diet 
contained low LA: ALA ratio and the total PUFA intake did not exceed 2% of the total 
dietary energy intake (%E) (74). Furthermore, the two PUFA families may also 
compete for incorporation into tissue phospholipids (75,76). 
LA and ALA can be synthesized de novo only in plants and thus their dietary sources 
are principally plants (77). LA is the most abundant PUFA in human diet and rich in 
the four main vegetable oils (palm, soybean, rapeseed and sunflower). It is also 
obtained from various other oils, such as safflower, corn and cottonseed oils, as well 
as poultry and certain grains and cereals. ALA is produced by terrestrial plants and 
also cold water vegetation such as algae and phytoplankton. The chloroplast 
membranes of green leaves contain ALA, often representing more than 50% of the 
total FAs, but green leaves are not high in total fat and therefore, not considered as 
major dietary sources of ALA. Major sources of ALA in human diet are oils such as 
flaxseeds, rapeseeds and soybeans oil, and nuts like walnuts. The n-6 LCP AA is 
found in most animal tissues and can be obtained from animal-based foods including 
eggs, poultry, meat, and milk. In contrast, the n-3 LCPs DHA and EPA are not widely 
distributed in the food chain and obtained almost exclusively from marine foods such 
as fish, shellfish, and fish-oils particularly those derived from cold water fatty-fish. 
Organ meats like brain and some egg yolks, depending on the content of the chicken 
feed, are the only other important dietary sources of the n-3 LCPs (78). 
The fact that the two PUFA families compete for metabolic conversion and 
incorporation into tissue phospholipids, subsequently influencing their distinct and 
sometimes competing physiological effects, makes the n-6 to n-3 ratio an important 
feature in PUFA status (67–70,75,76). Several sources of information suggest that 
humans evolved on a diet with a balanced ratio of n-6 to n-3 FAs, whereas great 
changes that took place in the human diet resulted in an increase in n-6 and a 
decline in n-3 PUFAs consumption (79–81). The balanced n-6/n-3 FA ratio provided 
by early human diet (a ratio of 1:1 to 4:1) is believed to be more beneficial to human 
health than the ratios provided by the typical modern day human diet of between 
15:1 and 20:1 (79,80,82–84). Particularly, a concern has been raised that n-3 LCPs 
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may be one of the limiting nutrients for optimal development of the central nervous 
system (CNS) and visual system in contemporary populations. 
DHA and AA are major structural components of the CNS and are rapidly 
incorporated into the brain from the last trimester of pregnancy up to two years after 
birth (85,86). Although infants can synthesize DHA and AA from their precursor 
essential FAs, due to the low and rate limited enzymatic conversion and the high 
rates of PUFA oxidation, most evidence indicate that this endogenous synthesis 
cannot sufficiently meet infants' CNS accretion needs. This appears to be particularly 
true for DHA, and therefore, the consumption of preformed n-3 LCPs is suggested to 
be essential (67,87–89). Isotopic tracer studies estimated that 15-35% of dietary ALA 
is rapidly catabolized to carbon dioxide for energy, and that only a small proportion 
(~1%) is converted to DHA (90–94). Furthermore, diets high in ALA appear to 
increase the rate of ALA oxidation, limiting its accumulation in plasma and reducing 
its conversion rate to EPA and DHA, suggesting that a higher intake of ALA does not 
necessarily lead to higher EPA and, particularly, DHA concentrations in the body 
(74,90). Consistent with the isotopic tracer studies, blood and human milk (HM) DHA 
concentrations in adults increase with increased dietary intake of DHA, which is less 
the case with consumption of precursors (87,95,96). Similarly, infant formulas 
containing ALA appear ineffective in improving infant DHA status in blood and 
cerebral cortex as compared to when infants receive formulas containing pre-formed 
DHA or maternal milk which normally contains DHA (86,97). More recent studies 
also indicate that the genetic make-up in the FADS gene cluster of individuals may 
have substantial effect on the extent to which endogenous synthesis contribute to 
tissue DHA accumulation (98,99). 
1.2.2. Mechanisms of action 
LCPs have a range of physiological roles that relate to optimal cell membrane 
structure and optimal cell function and responses. These include being a component 
of cell membrane phospholipids influencing membrane order and lipid raft formation, 
being a precursor of lipid mediators with different biological activities and potency, 
being a potent activator of a number of gene transcription factors, and acting as 
signaling molecules and modulators of membrane protein functions that are 
summarized in Figure 1.3 (71,100,101). Through these mechanisms, n-3 LCPs play 
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several important roles in the body including the development of neurocognitive and 
visual functions, controlling inflammation and modulating other immune functions, 
and optimizing cellular differentiation and metabolism. 
 
Figure 1.3. Summary of n-3 LCP mechanisms of action (from Calder et al. (71)). 
DHA is relatively protected from beta-oxidation and preferentially incorporated into 
cell membrane phospholipids throughout the body. Due to its highly unsaturated 
structure, DHA containing cell membranes show increased membrane dynamics 
(fluidity and flexibility) and a more compact lipid bilayer compared to membranes 
containing saturated and mono unsaturated FAs (100,102,103). The incorporation of 
DHA in the membrane lipid bilayer displaces saturated and n-6 FAs, facilitating a 
variety of membrane functions requiring membrane flexibility such as the processes 
of cell fusion and fission, endocytosis and exocytosis, ion channels and transport, 
and the activities of membrane-bound proteins (71,100,104–107).  
DHA embedded in cell membrane phospholipids grants a conducive environment for 
membrane protein function, such as lateral diffusion and conformational changes of 
membrane proteins, and play a major role in altering the size and stability of 
membrane signaling platforms termed “lipid rafts” (71,100,104–108). Lipid rafts are 
specialized subdomains in plasma membranes that are comprised of tightly packed 
combinations of sphingolipids, cholesterol and saturated FAs, and contain many of 
the proteins involved in signal transduction (109). They facilitate molecular 
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interactions and response with sensing protein motifs influencing numerous signaling 
actions. Although not directly incorporated into raft lipids, DHA found in non-raft 
regions of the cell membrane modulate raft structure and function, by displacing key 
signaling proteins and altering membrane protein trafficking (108,110)  
n-3 LCPs released from membrane phospholipids act as cell surface and 
intracellular signaling molecules and ligands for gene transcription factors such as 
peroxisome proliferator activated receptors (PPARs) (71,111,112). PPAR-α and 
PPAR-γ are among the several PPAR isoforms that are well investigated. PPAR-α is 
involved in regulating gene expression encoding key enzymes of β-oxidation and 
lipoprotein metabolism, facilitating partitioning of FAs towards hepatic oxidation and 
away from triglyceride synthesis (71,101,113). PPAR-γ is involved in regulating 
adipocyte differentiation and metabolic responses of adipocytes including promoting 
insulin sensitivity. PPAR-γ, when expressed in immune cells, is involved in regulating 
the production of inflammatory mediators having anti-inflammatory actions (71,114). 
DHA and EPA can induce and activate PPARs and upregulate PPAR target genes, 
thus influencing metabolic and inflammatory responses. This may explain some of 
the effects of dietary n-3 FAs such as reducing inflammation, lowering plasma 
triglyceride, and increasing insulin sensitivity (71,115–119). 
n-3 LCPs also influence the nuclear transcription factor kappa B (NFkB) pro-
inflammatory signaling pathway, leading to suppression of apoptotic pathways and 
the production of various pro-inflammatory compounds (101,120). NFkB is a key 
transcription factor involved in inducing the expression of genes encoding a range of 
pro-inflammatory proteins including several cytokines, adhesion molecules, and 
enzymes, such as cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase 
(iNOS) (120,121). In response to inflammatory stimuli, NFkB is activated by 
phosphorylation reaction and subsequently translocate to the nucleus (120). 
Activated PPAR, through receptor-ligand interaction with n-3 LCPs, can inhibit NFkB 
pro-inflammatory gene expression by preventing translocation of NFkB to the 
nucleus and downregulating NFkB target genes (101,120,122). Additionally, n-3 
LCPs interact with membrane associated G-coupled protein receptors (GPRs) 
promoting GPR120-mediated gene activation that has an inhibitory action on 
phosphorylation of NFkB (101,123). Furthermore, NFkB can be activated by pro-
inflammatory cytokines such as interleukins (IL) and tumor necrosis factor α (TNFα), 
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which their production has been shown to decrease with dietary n-3 LCPs (101,124–
126). 
Free LCPs from membrane phospholipids are substrates for biosynthesis of 
bioactive lipid mediators. These signaling molecules act in diverse physiological and 
pathological processes such as inflammation and immunity, platelet reactivity, 
smooth muscle contraction and controlling blood pressure, and regulation of cell 
growth, pregnancy and normal child birth among others (119,127–129). Historically, 
most attention has been given to prostaglandins and thromboxanes, which are cyclo-
oxygenase products, and leukotrienes, lipoxygenase products (Figure 1.4). The lipid 
mediators derived from AA have predominantly pro-inflammatory actions and are 
involved in vasoconstriction and platelet aggregation, and leukocyte chemotaxis and 
adhesion. The less potent eicosanoids from EPA have inflammation-lowering effects 
and are involved in attenuation of platelet aggregation and vasoconstriction, and 
inhibit the production of AA-derived mediators (127,129). More recently, new families 
of bioactive lipid mediators were also discovered that have potent anti-inflammatory 
and pro-resolving actions. They include the resolvins produced from DHA (D-series) 
and EPA (E-series), and the protectins and maresins produced from DHA 
(71,128,130). These mediators acting through specific GPRs are able to induce 
resolution of inflammation (i.e., ‘turn inflammation off’) and to promote immune 
functions, resulting in improved host defense and diminished pathological effect of 
inflammation (131,132). 
 
Figure 1.4. Overview of the synthesis and actions of lipid mediators (Calder et al. 
(128)). 
The essentiality of preformed n-3 LCP in the diet during early-life is mainly in 
consideration of the uniquely high DHA incorporation in the CNS, although DHA is 
also incorporated in most other tissues where it has important functional effects (98). 
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Lipids make up 50-60% of the dry brain matter and DHA is one of the most abundant 
FAs, comprising 10-20% of the total brain FAs, with amounts reaching as high as 
35% of the FAs in phospholipids of neural synapses (133–135). Its accumulation in 
the fetal brain takes place mainly during the last trimester of pregnancy and 
continues at very high rates up to the end of the second year of life, when the rate of 
brain growth is maximal and therefore vulnerable to the effects of nutritional 
deficiencies (85,86). Over this period, the total brain DHA content is normally 
increased by 35-fold, signifying its critical role in the substantial structural and 
functional development of the CNS occurring during the brain growth spurt (86). 
Although much remains to be understood, DHA can influence brain function by 
modifications of neuronal membrane fluidity, regulating the activity of membrane 
bound proteins and function of neuronal ionic channels, and acting as a ligand to 
gene transcription factors involved in inflammation, oxidative stress, neurogenesis, 
differentiation and FA metabolism, and influencing neurotransmitters and brain 
peptides production that can reasonably be considered fundamental for the 
synthesis, functionality, and protection of neural tissues (85,98,134,136–140). 
As a ligand for nuclear hormone transcription factors regulating the patterns of gene 
expression throughout the CNS, DHA is involved in neurogenesis, synaptogenesis, 
synaptic plasticity, endocytosis, neurochemistry, and synaptic vesicle recycling 
(141). Although it is rarely found in the adult brain, PPARγ is expressed abundantly 
in the developing brain in association with the rapid brain DHA accretion and 
appears to be important in regulating stem cell proliferation in early CNS 
development (142). DHA and AA also act as ligands affecting the activity of brain 
retinoid X receptor (RXR), which has important roles in neurogenesis, neuronal 
differentiation, and neurotransmission specifically within the hippocampus (112,143).  
DHA in neural membrane phospholipids optimizes membrane fluidity and may 
positively impact the speed of signal transduction that theoretically lead to improved 
cognitive development (137). Memory and processing speed, two specific processes 
thought to underlie early cognitive development, are influenced by synaptic efficiency 
and transmission speed (137). DHA is especially enriched in synaptic terminal 
membranes of the prefrontal cortex where it has important roles in enhancing 
neurogenesis, neurite outgrowth, dendritic complexity, and metabolism of several 
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neurotransmitters including dopamine, serotonin and acetylcholine (134,144,145). 
DHA may also influence the timing of neural tissue myelination, potentially 
influencing the speed of signal transduction (146).  
In addition, DHA enhances the function of N-methyl-D-aspartate channels, which 
may in turn alter long-term potentiation in the hippocampus, a plasticity process 
thought to be essential in the establishment of an explicit memory trace 
(137,147,148). In animal models, DHA-depleted rats performed poorly in 
hippocampal- and frontal-based memory and learning tasks, while DHA-
supplemented rats experienced improvements in memory and learning (138,149–
152). Cortical neuroplasticity, which is key to learning and memory, was shown to be 
reduced in children born preterm, which might have resulted from a lower prenatal 
DHA accretion (153). DHA supplementation in older boys aged 8-10 years was also 
shown to increase prefrontal cortex activation in Magnetic Resonance Imaging (154). 
Therefore, it is plausible that DHA has a role in increasing the speed at which 
information is acquired and the efficacy with which such information is retained, 
subsequently facilitating early cognitive development. 
In addition to neurogenesis and signal transduction, n-3 LCPs also play important 
roles in neuroinflammation and neuronal cell survival (140,155–158). Pro-
inflammatory COX-2 expression, and the production of IL-6, TNFα and PGE2 have 
been associated with cognitive impairment (159–161), where n-3 LCPs provide 
protections by downregulating NFκB pro-inflammatory signaling pathway and COX-2 
mediated inflammation (101,120,155,162). Several brain specialized pro-resolving 
derivatives of DHA such as neuroprotectin D1 were also identified (140). In brain 
injury models, neuroprotectin D1 has been shown to have potent neuroprotective 
and pro-resolving effects reducing damages to neuronal tissues and synaptic 
transmission dysfunction resulting in improvements in cognitive function and 
neurobehavioral scores (163–167). 
1.2.3. n-3 PUFA intake and status in low-income settings 
Dietary fats contribute to 45-55 percent of energy (%E) in human milk (HM) and 
increase energy density of complementary foods, which makes them vital for 
meeting the high energy requirements of IYC to support their rapid growth and 
physical activity (168–170). In addition to the total fat content, there is interest in the 
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FA composition of diets including essential FAs which have specific physiological 
roles that cannot be replaced by other FAs in the diet. 
Various authorities have proposed dietary recommendations on total fat and specific 
PUFA intakes for vulnerable groups (89,95,171–173). A joint expert consultation 
group organized by the Food and Agriculture Organization (FAO) and the WHO 
recommended that fats should constitute 40-60%E in young infants less than 6 
months old with gradual reduction to 35%E in older IYC 6-24 months (171). The 
same group recommended an adequate intake of DHA at 0.1-0.18%E (equivalent to 
a mean of 102 mg DHA/d) for young infants and 10-12 mg/d/kg body weight for older 
IYC. The European Food Safety Authority recommended a DHA content of 0.3% 
total fat (%TF) in infant formula and an adequate intake of 100 mg DHA/d for older 
IYC (172). For pregnant and lactating women, an adequate intake of 300 mg/d DHA 
+ EPA of which at least 200 mg as DHA is recommended to support optimal transfer 
to the fetus during pregnancy and to the infant through lactation (95,173).  
There is a lack of data on the PUFA status of populations in low-income countries 
(LICs) in general, and in Ethiopia in particular. Unlike cellular proteins which are 
genetically determined, the FA composition of cell membranes is largely dependent 
on dietary intake (81). In many LIC populations, particularly those living far from 
coastal areas, diets are too low in n-3 LCPs to meet the recommended intake levels 
by vulnerable groups. A review of PUFA intakes in 13 selected LICs showed that the 
total n-3 FA supply in the diet was below the recommended intake range for IYC and 
below the minimum recommended level for pregnant and lactating women in the 
nine countries with the lowest GDP including Ethiopia (174). A more comprehensive 
review of LCPs availability in 175 countries also disclosed that the availability of fish 
and seafood in the food supply of several LICs is too low to meet the recommended 
intake levels (175). The average per capita DHA availability in the 47 LICs assessed 
was estimated at 96 mg/d, in contrast with the range of 184-473 mg/d in 128 high-
income countries (HICs), and the consumption rate was even negligible in the 
countries with the lowest GDP such as Ethiopia (7.0 mg/d) (Figure 1.5). 
As HM is one of the best sources of ALA and DHA, infants in low-income settings 
who are usually breastfed for longer period may be considered to have a relative 
protection from insufficient intakes. However, it should be noted that DHA 
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concentration in HM varies widely, mainly depending on the maternal dietary intake 
of preformed n-3 LCP (176–178). In Ethiopia where the availability of DHA in the food 
supply is reported to be the lowest globally (175), breastfed infants also could be 
susceptible to a suboptimal intake of n-3 LCP. More importantly, the period of 
transition from exclusive breastfeeding seems to be important for n-3 LCP status of 
infants in low-income settings as most local complementary diets are very low in n-3 
LCP content (169,179,180). The average per capita DHA intake from both 
breastfeeding and complementary foods among older IYC in 78 LMICs has been 
estimated to be 50 mg/d which is well below the recommended intake level in this 
group (100 mg/d) and with the cessation of breastfeeding, the per capita 
consumption rate further falls to 14.6 mg/d (172,179,180). In Ethiopia, the estimated 
contribution of complementary foods for DHA intake was found to be the lowest (1.1 
mg/d) of the 78 LMICs evaluated. 
During pregnancy, the substantial LCP requirement to support accretion to the 
developing fetus via preferential placental transfer and later to the infant via lactation 
(86,181,182) may lead to maternal n-3 FA depletion if these requirements are not 
met by adequate dietary intake (183). Studies found that maternal DHA status 
declines starting from late pregnancy and continues over the course of lactation 
(181,184–187). DHA status was significantly lower in multigravidae mothers and their 
newborns compared to primigravidae, and in mothers who were breastfeeding 
compared to those that did not (185,187,188). Although DHA status may normalize 
between pregnancies (189), the high fertility rate in LICs like in rural Ethiopia (5.2 
births/woman) (190) may limit the time to replenish maternal stores between closely 
spaced pregnancies, and in the presence of very low dietary intake can increase the 
susceptibility of multigravidae women for DHA depletion, which could then be 
reflected in a lower neonatal and infant status (181). 
In addition to the low n-3 LCP intake from complementary foods and the possible 
higher risk of deficiency in those born from multigravidae mothers, children in low-
income settings who live under poor environmental and hygienic conditions may have 
increased n-3 LCPs requirements. Recurrent infections and prevalent asymptomatic 
chronic immune stimulation could divert LCPs that are normally used to support 
growth and development towards the increased requirements for inflammatory and 
other immune responses (128,191,192). Furthermore, in nutritionally vulnerable 
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populations, the synthesis of LCPs from precursors in the body could be hampered 
by other dietary factors. Iron, zinc, vitamin B6 and vitamin E are required as co-
factors for elongation enzymes in PUFA metabolism and therefore, it is possible that 
micronutrient deficient populations may have a lower LCPs conversion rate and 
status than well-nourished populations (71,193). Additionally, when total energy 
intake (especially fat) in the diet is low, ALA could be used for energy expenditure 
rather than conversion to EPA and DHA (194). 
In general, despite the lack of evidence from biochemical studies of n-3 FA status, a 
combination of very low dietary availability and potential stressors that might 
increase n-3 FA requirements discussed above suggest that Ethiopian mothers and 
their IYC in rural areas are likely to have a sub-optimal n-3 LCP status. Detrimental 
child outcomes that might be caused by poor n-3 LCP status include diminished 
neurodevelopment and cognitive performance, and poor health with associated 
growth failure, which might benefit from dietary supplementation of preformed n-3 
LCP. The transition from exclusive breastfeeding to complementary feeding, starting 
from around 4-5 months of age, typically puts Ethiopian infants at risk as this is the 
period where they are introduced to foods with very low n-3 LCP content. The 
introduction of unhygienically prepared complementary foods can also lead to 
intestinal inflammation and associated local and systemic immune stimulations, 
which presents an additional burden to the infant. 
Together with the n-3 LCPs, the n-6 LCP AA also plays important roles for early-life 
CNS development, growth, and immune function (195,196). Unlike DHA, maternal 
tissue and HM AA contents are relatively stable and less affected by maternal diet 
including in most cases of supplementation with DHA (176–178,197,198), and it is 
thus expected that AA status is less likely to be compromised in children who receive 
breastfeeding. Currently, there is no indication that women of childbearing age with 
an adequate dietary intake of the precursor LA would require an additional dietary 
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1.3. Dietary n-3 LCP in relation to healthy growth and development 
1.3.1. Neurodevelopment 
The evidence for the importance of dietary n-3 LCP for early cognitive and visual 
development in humans first emerged from epidemiological studies. In prospective 
observational studies, the children of mothers with higher consumption of seafood 
during pregnancy have exhibited better cognitive outcomes (199–201). Studies 
demonstrated higher DHA concentration in the cerebral cortex of breastfed infants 
than their counterparts who received formulas that did not contain LCPs (135,202), 
and several individual studies and meta-analysis of these studies also found the 
former group having cognitive and visual advantages over the latter group (203–
207). Earlier experiments in animals also demonstrated that changes in brain DHA 
concentrations are positively associated with changes in cognitive and behavioral 
performance in rodents and nonhuman primates (85,138). 
Neurodevelopmental benefits observed in breastfed infants and infants with higher 
prenatal seafood exposure have been attributed to the biologically plausible roles of 
DHA for early development and maturation of the CNS and visual system. However, 
as these studies were not randomized, potential confounding from several factors 
precluded the causality of evidence for the observed association between dietary n-3 
LCPs and neurodevelopmental benefits in humans (208,209). Subsequently, 
randomized controlled trial (RCT) of n-3 LCP supplementation in relation to infant 
neurocognitive and visual development has remained the subject of intense 
investigation over the past two decades including several reviews of these 
experimental trials (210–220). 
Systematic reviews and meta-analyses in the Cochrane library summarized the 
effects of LCP supplementation of formula-milk in term (211) and preterm infants 
(213), and maternal n-3 LCP supplementation during lactation (221). The latest 2017 
Cochran review (211) of formula-milk LCP supplementation in term infants included 
15 RCTs of which eleven measured neurodevelopmental outcomes (222–234). From 
9 studies that used Bayley Scales of Infant Development (BSID) (222,223,227–233), 
only 2 showed benefits of LCP supplementation for mental development index (MDI) 
scores at 18 months of age (232,233). One study, using the Brunet-Lezine 
developmental quotient, reported a positive effect of supplementation at age of 4 
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months (234), but not in later follow-up of the same cohort at 12 and 24 months of 
age (225). Meta-analysis of 4 studies (230,231,235,236) that used BSID at 18 
months of age did not find significant benefits of LCP supplementation for MDI or 
psychomotor development index (PDI). Some trials assessed specific tests of infant 
cognitive development, with only few finding positive results (224–
226,228,231,234,237). In one study (224), LCP supplementation improved quality of 
attention (a cognitive index derived from the convergence of behavioral and cardiac 
responses) in infants at the age of 4-9 months, and another study (237) found better 
novelty preference measured by the Fagan test of infant intelligence at 9 months of 
age. Willatts et al. (226) demonstrated LCP supplementation improved infant 
problem-solving skills at 10 months of age. 
Few of the above trials reported follow-up data on long-term effects of LCP 
supplementation (238–243). The further follow-up of the study sample used by 
Willatts et al. (240), cited above, found a positive effect on information processing at 
6 years of age, but not on IQ score. Colombo et al. (242) evaluated the effect of 
infant formula fortified with LCP on later cognitive development between 18 months 
and 6 years of age. LCP supplementation did not influence standardized 
developmental measures at 18 months of age using the BSID and MacArthur-Bates 
Communicative Development Inventory. However, between 3 to 6 years of age, 
positive effects were observed on specific tests of executive functions, vocabulary, 
and IQ measures. de Jong et al. (238,243) found no consistent long-term effect of a 
two-month postnatal LCP supplementation on cognitive development and 
neurological functions at 9 years of age. The results, however, suggested a 
beneficial effect on cognitive function in the subgroup of children who were exposed 
to maternal smoking during pregnancy. Two other studies failed to detect long-term 
effects on tests of IQ, language development, or school readiness at 3 years of age 
(239,241).  
With regard to visual development, the review included 6 RCTs that assessed visual 
acuity using visual evoked potentials (VEP) (222,223,235,236,244,245), 2 using 
Teller acuity cards (228,246), and 1 using both (227). Five of these studies reported 
beneficial effects on visual acuity (223,235,236,244,245), while others did not 
(222,227,228,246). Meta-analysis of 3 RCTs showed significant benefit for sweep 
VEP acuity at 12 months of age, whereas meta-analysis of 3 other RCTs found no 
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benefit for visual acuity measured using Teller acuity cards at the same age. The 
review authors concluded that most of the included RCTs reported no beneficial 
effects or harms of LCP supplementation on neurodevelopmental outcomes of 
formula-fed full-term infants and no consistent beneficial effects on visual acuity. 
Therefore, routine supplementation of full-term infant milk-formula with LCP cannot 
be recommended at this time. 
Dietary LCP may be particularly important for infants who are born preterm and had 
a limited exposure to the rapid in utero DHA accretion that occurs during the last 
weeks of pregnancy. The latest 2016 Cochrane review (213) of formula-milk LCP 
supplementation in preterm infants examined 17 RCTs with 7 studies having 
neurodevelopmental outcomes (247–254). Three of the 7 studies reported benefits 
of LCP using BSID at different infant ages (252–254). However, meta-analysis of 4 
studies (247,250,251,253) at 12 months of age and 3 studies (249,252,254) at 18 
months of age found no significant effect of LCP supplementation on MDI or PDI. 
The authors of this review therefore concluded that there are no clear long-term 
benefits of LCP supplementation of formula-milk for visual or intellectual 
development in preterm infants. 
HM is an important source of both DHA and AA for breastfed infants. Compared to 
other dietary sources, it is safe from environmental contaminants and contains a 
higher fraction of LCPs in phospholipid form which increases their bioavailability 
(255,256). The high variability in HM n-3 LCPs levels which mainly depend on the 
maternal diet led some investigators to evaluate the effects of maternal 
supplementation during lactation on child outcomes. The latest 2015 Cochrane 
review (221) of maternal n-3 LCP supplementation summarized 8 RCTs that 
provided supplementation either starting from pregnancy and continued postpartum 
(257–261), or starting at the beginning of lactation (262–264). When pooling 5 RCTs 
having neurodevelopmental outcomes, except a beneficial effect detected on child 
attention scores at the age of 5 years based on data from only one study (265), the 
review failed to find evidence of a long-term benefit beyond 24 months of age on 
other neurodevelopmental outcomes, including language (262,263), intelligence or 
problem-solving skills (257,261–263), psychomotor development (261,263,264), 
motor development (262,263), general movements (261), working memory and 
inhibitory control (262), neurological optimality score (261), or on measures of visual 
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acuity (262–264). Results were inconsistent within a trial when outcomes were 
assessed at different age. Helland et al. (257), for instance, found no effect of fish-oil 
supplementation starting from pregnancy until 3 months after birth on infant cognitive 
development at 6 months of age using the Fagan Test of Infant Intelligence. 
However, in a follow-up study on this sample using the Kaufman Assessment Battery 
for children, the authors found improved cognitive function at the age of 4 years 
(266), but this effect was not sustained at the age of 7 years of age (267).Jensen et 
al. (263) similarly reported a beneficial effect of maternal DHA supplementation 
during lactation on child neurodevelopment at 30 months of age despite this effect 
not being detected during infancy. On further follow-up of the same cohort at 5 years 
of age, they also found a benefit using the test of sustained attention (265). Overall, 
the authors of this review concluded that there is inconclusive evidence at this time 
to support or refute the practice of giving n-3 LCP supplementation to breastfeeding 
mothers in order to improve child neurodevelopment or visual acuity at this time. 
Shulkin et al. (210) reported relatively encouraging evidence of benefit in their most 
recent comprehensive systematic review and meta-analysis of n-3 LCP 
supplementation via supplements, fortified foods or diet in pregnant and/or lactating 
women and children below 24 months of age. The review included 38 RCTs across 
the critical period of CNS development, with13 trials in mothers (262–265,267–278), 
18 in term infants (222,223,225,228,229,231–233,236,239,240,242,244,246,279–
286) and 7 in preterm infants (250–254,287–289), and evaluated standardized 
measures of cognitive and visual development reported up to the age of 18 years. In 
the meta-analysis stratified by intervention, MDI was significantly improved in 
preterm infants without statistically significant effects for term infants and for 
maternal supplementation. No significant effect was found for PDI and overall IQ in 
the stratified analyses. Visual acuity, measured as the logarithm of the minimum 
angle of resolution, was significantly improved by supplementation in preterm and in 
term infants, but not in mothers. In the main analysis pooling all supplementation 
periods, n-3 LCP supplementation significantly improved MDI (n = 21 trials), PDI (n = 
21), and visual acuity (n = 24), but not overall IQ (n = 7). Potential publication bias 
was identified only for the MDI outcome. The authors therefore concluded that n-3 
LCP supplementation improves childhood psychomotor and visual development, 
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without significant effects on later global IQ, although the latter conclusion is based 
on fewer studies. 
In general, while some studies provide evidence that n-3 LCP may benefit early-life 
visual and neurocognitive development, systematic reviews of numerous RCTs in 
HICs remain inconclusive about whether or not infants should receive n-3 LCP 
supplementation (210–221). On the other hand, research investigating n-3 LCP 
supplementation in LMIC settings remains largely absent. However, possible 
benefits might be more noticeable in populations with high exposure to 
developmental risk factors, such as intrauterine growth restriction, stunting, 
inadequate stimulation, and infections (98,194,277,290). Only one trial in a low-
income setting reported on a postnatal n-3 LCP supplementation in Gambian 
breastfed infants which failed to detect any benefits on cognitive function (291). 
However, the authors found that the Gambian study mothers had considerably high 
HM DHA concentrations similar to those reported in populations with high fish 
consumption and thus, the intervention appears to be targeted to infants who already 
had an adequate dietary intake via breastfeeding. If gains in neurocognitive 
development from n-3 LCP supplementation could be detected in Ethiopian IYC, it 
would provide important evidence for future research and interventions in 
populations in low-income setting, where the availability of n-3 LCP in the diets is 
very low. 
1.3.2. Physical growth 
LCP supplementation has also been investigated extensively with child physical 
growth as an endpoint. The Cochrane review (211) of formula supplementation in 
term infants cited 13 RCTs with child growth measurements. None of the included 
trials reported a beneficial or harmful effect of LCP supplementation on weight, 
length, or head circumference (HC) measurements until 9 years of age (223,227–
231,234–236,244,292–294). Meta-analysis of 5 RCTs (227,228,234,236,244) 
showed that the LCP supplemented group had a lower weight z-score at 12 months 
of age, whereas no significant differences found with respect to length or HC. Meta-
analyses at 18 and 24 months of age found no effect on any child growth outcome. 
The authors concluded that even though meta-analysis of pooled data revealed a 
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marginally lower weight z-score in the LCP supplemented group at 12 months of 
age, these differences are small and unlikely to be of clinical significance. 
Similarly, the Cochrane review (221) of maternal n-3 LCP supplementation during 
pregnancy and/or lactation found no evidence of a long-term growth benefit in any of 
the trials included (257,258,262,265,267,295–299) as well as in the meta-analysis of 
pooled data. At short term follow-up, n-3 LCP supplementation significantly 
increased weight and BMI at birth in 1 trial (297), and weight and HC at 12 months of 
age in a meta-analysis of 3 trials (257,260,262); whereas child length was not 
affected during the follow-up period. The fact that some of the included trials started 
supplementation prenatally might explain the positive results at short-term follow-ups 
as other studies also detected a longer gestation period and a small increase in 
birthweight resulting from increased maternal dietary n-3 LCP intake during 
pregnancy (300,301). 
Studies on LCP supplementation in preterm infants produced mixed results on child 
growth, which is possibly due to differences in combinations of LCPs used in 
different test formulas. From 15 RCTs evaluated in the latest Cochrane review (213), 
4 reported positive effects on growth (child weight and/or length) at different child 
ages(252,254,302,303), 2 reported negative effects on growth (weight-for-age, 
weight-for-length and/or HC-for-age) using formulas containing only n-3 LCP and no 
AA(247,248), 1 reported mild reductions in weight and length values using a formula 
supplemented with both n-3 LCP and AA (249), and the rest found no effect 
(250,253,288,304–309). Meta-analysis of 5 trials (248,288,302,303,307) having 
measurements at 2 months post-term showed increased length and weight as a 
result of LCP supplementation. Meta-analysis of 4 trials (247,248,252,306,307) at 
child age of 12 months and 2 trials (249,254) at age of 18 months, however, found 
no significant effect on any growth indicator. The authors concluded that this meta-
analysis of trials does not support a long-term growth benefit of LCP 
supplementation of formula in preterm infants, while the authors also recognized that 
most trials enrolled relatively mature and healthy preterm infants. 
The most likely reason for the impaired growth experienced by supplemented 
preterm infants in few trials was a reduction in body AA levels resulting from 
supplementation using only n-3 LCP (213). Considering that exclusively formula-fed 
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infants may not secure an adequate supply of AA depending entirely on metabolic 
conversion from LA, some investigators recommend a balanced combination of DHA 
and AA in infant formulas (310). A risk of n-3 LCP supplementation-induced AA 
inadequacy is, however, unlikely in the case of breastfed infants who receive 
preformed AA through breastmilk. 
Overall, the current body of literature does not support any growth benefit of LCP 
supplementation in term infants. However, the existing evidence is exclusively based 
on trials in infants from HICs consisting of child populations that are generally well-
nourished and follow the optimal growth trajectory. Therefore, the potential to reveal 
any benefit on child growth of an intervention is expected to be limited. In contrast, 
IYC in low-income settings who have a high risk of impaired growth and a suboptimal 
dietary intake of essential FAs, may respond differently to n-3 LCP supplementation. 
Furthermore, in children living under poor environmental conditions, persistent 
subclinical inflammations and recurrent infections contribute substantially to their 
growth failure. n-3 LCP can modulate inflammation and other immune functions 
(discussed in the next section), and through this pathway, there might be a stronger 
effect of dietary n-3 LCP on growth of children living in such settings. 
1.3.3. Immune function and inflammation 
The multiple mechanisms through which n-3 LCPs modulate several aspects of the 
immune system are detailed in previous reviews (119,311,312) and summarized in 
section 1.2.2. Notably, n-3 LCPs exert partly inhibitory effects on inflammatory 
responses including on the activation of different immune cells and also on the 
production of various proinflammatory chemical mediators such as cytokines and 
eicosanoids derived from AA (119,311). EPA also gives rise to less potent alternative 
eicosanoids that compete with proinflammatory eicosanoids derived from AA. Novel 
groups of DHA and EPA derived anti-inflammatory and inflammation resolving 
mediators such as resolvins, protectins, and maresins were also identified by 
previous work (119,311). These compounds are involved in alleviating the degree of 
inflammatory responses and self-limiting inflammation that are important in limiting 
damages to the host tissues and facilitating resolution of inflammation. On the other 
hand, some specific immune functions are promoted by n-3 LCPs, such as 
phagocytosis and bactericidal capacity of macrophages and neutrophils, and T 
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regulatory cells differentiation, indicating that n-3 LCPs are not non-specific immune 
suppressors in general (312).  
Clinical studies of n-3 LCP largely focused on a range of clinical conditions 
collectively referred as inflammatory diseases. These conditions typically share 
characteristics of excessive, inappropriate or on-going inflammation. They are 
subject to investigation based on the hypothesis that the ability of n-3 LCPs to down 
regulate several aspects of inflammation may exert therapeutic effects in these 
conditions. While several positive results were reported by both animal and human 
studies, systematic reviews of human trials found inconclusive evidence for clinical 
benefits of n-3 LCPs in different inflammatory conditions (313–318). Calder (119) 
concluded that dietary n-3 LCPs inducing anti-inflammatory actions may have 
therapeutic use in a variety of acute or chronic inflammatory conditions, whereas 
current evidence on clinical efficacy is reasonably strong for some conditions like 
rheumatoid arthritis, but inconsistent in others like asthma and inflammatory bowel 
diseases (IBD). 
The potential clinical benefits of dietary n-3 LCP in inflammatory conditions is of 
particular interest in relation to the gut damage with underlying chronic immune 
stimulation- called environmental enteric dysfunction (EED)- that commonly occurs in 
children raised in the typically unhygienic conditions of LICs (43,319–321). EED is a 
persistent subclinical enteropathy characterized by villous atrophy, crypt hyperplasia, 
inflammatory cell invasion of the lamina propria and damage to tight junctions, 
resulting in nutrient maldigestion and malabsorption, and a leaky gut that allows 
translocation of bacteria and potentially toxic or allergenic substances which then 
stimulates local and systemic inflammation (43,320,321). The enteropathy generally 
starts early in life, coinciding with the first exposures to complementary foods at the 
age of 4-9 months, and has been strongly implicated as a driver of growth failure 
(322–324). It has been hypothesized that prevalent EED among children in LICs 
could be the reason for previous dietary and health interventions have been only 
partially successful in preventing stunted child growth (319,323). 
In-vitro and animal experiments suggest that dietary (n–3) LCPs may improve small 
intestinal barrier functions (325), and enhance recovery of intestinal tissues after 
inflammation in severe malnutrition and chemically-induced damages (326,327). This 
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potential for n-3 LCPs to improve intestinal wall integrity and resolve mucosal 
inflammation might help in alleviating the persistent enteropathy and associated local 
and systemic inflammation with a potential resultant effect on child growth in LICs. 
Most clinical studies of n-3 LCP on intestinal inflammation focused on IBD (328,329). 
Clinical benefits in IBD may have a role in treating EED, as these conditions share 
key features of enteric inflammation, loss of intestinal architecture and systemic 
inflammation, despite their differences in etiologies and affected population 
(330,331). n-3 LCPs proved to be protective in animal models with experimental IBD 
(332–337). In patients with IBD, fish-oil supplementation resulted in incorporation of 
n-3 LCPs into the affected gut mucosal tissue thereby modifying inflammatory 
mediators profile (338–342). However, clinical effects on gut histology, disease 
activity and relapse are inconsistent (119,317,329,343–347). A meta-analysis 
including 6 RCTs of n-3 LCP therapy in patients with IBD found a marginally 
significant benefit in preventing relapse over 12 months (317). However, the authors 
cautioned about the low overall quality of evidence from this review due to the 
heterogeneity among included studies and two of the well-designed large trials 
showing no benefit and thus, suggested future well-designed large clinical trials. 
In contrast to the bulk of studies on n-3 LCP in relation to IBD and other 
inflammatory conditions, only two trials evaluated the effects of dietary n-3 LCPs on 
early-life EED and related child growth failure. Supplementing fish-oil to Gambian 
breastfed infants between age of 3-9 months did not improve EED and infant growth 
(291). Only a larger increase in linear growth in the intervention group was noticed, 
albeit not statistically significant. Multimicronutrient supplementation with or without 
fish-oil in Malawian children 12-35 months old also found no added benefit of fish-oil 
for the transient modest improvement in EED detected with the multimicronutrient 
intake (348). Overall, both trials did not report beneficial effects of fish-oil 
supplementation on EED and growth. However, biochemical measures of PUFA in 
child blood and maternal milk were not suggestive of a sub-optimal n-3 LCPs status 
of children in both studies. Furthermore, studies of n-3 LCPs as anti-inflammatory 
agents usually used much higher doses than the doses provided in these studies 
(119,317). 
In addition to the anti-inflammatory effects with potential benefits for EED and related 
child growth failure, n-3 LCPs may also contribute to infant immune development. 
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Studies showed that early n-3 LCP exposure influences different immune markers 
that are indicative of a faster maturation of infant immune system (349–352), which 
may result in improved resistance to infection (351). Dietary (n-3) LCPs 
supplementation was also shown to have clinical benefits in both inflammatory and 
infectious conditions in formula-fed infants in Europe and the US (353–355), in US 
toddlers (356) and Thai schoolchildren (357), and in Mexican infants who were 
exposed to prenatal maternal supplementation (358). However, there is limited 
evidence on the effects of dietary n-3 LCP among breastfed children in low-income 
settings who live under poor environmental conditions with high burden of infectious 
diseases. 
1.4. The rationale for this research 
As detailed earlier, poor child growth and development is one of the most pressing 
public health problems in LMICs. Linear growth retardation during the critical period 
of 1,000 days after conception is a marker of multiple pathological changes that are 
associated with increased morbidity and mortality, reduced physical, neurocognitive 
and economic capacity, and an elevated risk of metabolic diseases in adulthood. 
Linear growth failure is the most common form of undernutrition globally, and the 
severe irreversible physical and neurocognitive damage that accompanies stunted 
growth is a major barrier to the development of human capital and economic growth. 
Increasing awareness of its high magnitude and devastating consequences has led 
stunting to receive high priority in the post-MDGs era development agenda. 
The United Nation’s Sustainable Development Goals (SDGs) adopted the resolution 
endorsed by the WHA for maternal, infant and young child nutrition that included six 
global targets, prominent among which is the ambitious target to reduce the number 
of stunted children by 40% in 2025 (58). Although there has been progress in 
stunting reduction globally, many countries are not on track to achieve the stunting 
target. At the current rate of progress, only 26% of the global burden of child stunting 
can be averted by 2025 (56). It has been emphasized that acceleration of current 
progress in LMICs requires effective large-scale nutrition-sensitive programs that 
address key underlying and basic determinants of undernutrition, and scaling up the 
coverage and effectiveness of evidence-based nutrition-specific interventions 
(28,30,32,359). The challenge, however, is identifying which set of priority actions 
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are the most effective to be implemented at scale within the context of limited 
development budgets (56). 
Understanding the proximal, underlying and basic determinants that most explain the 
trend in stunting prevalence in high-burden countries is useful for supporting 
evidence-based decision-making by policy makers and program planners. Previous 
studies tried to address this important question and produced empirical evidence on 
the important drivers behind the observed improvements in childhood undernutrition 
over three decades (detailed in section 1.1.3). Adding to these previous efforts, 
timely revision of the evidence is strongly required to understand the important 
drivers behind the more recent trend for current decision-making. The strength of the 
relationship between stunting and important drivers in the past could change over 
time. In addition, some determinants that were important in past may saturate for 
current and future changes. An updated analysis using newly emerging data is also 
required to provide a more comprehensive list of important drivers, including those 
potential determinants that were not considered in previous analyses due to 
unavailability of data. Furthermore, most of the previous efforts to assess drivers of 
the trend of child stunting have taken a country focus and there are limited studies of 
cross-country trend analysis. However, comprehensive evidence on the drivers of 
child stunting across high burden countries is equally important for decision-making 
at the global and regional levels. Therefore, the first part of this PhD research 
explores a range of basic, underlying, and immediate determinants that explain the 
more recent trend in chronic childhood undernutrition in a set of LMICs.  
One important bottleneck in promoting healthy growth and development of children 
in LMICs is identifying interventions that effectively impact child linear growth. 
Evidence from systematic reviews showed that existing interventions have yielded 
only small to moderate effects on growth which are not large enough to fully 
compensate for the substantial growth deficit that children experience in poor 
settings (360,361). A review of an optimal package of nutrition interventions for high 
stunting burden countries also revealed that recommended nutrition solutions 
combined, even if universally applied, will only partially avert stunting and the 
estimated death and disability due to undernutrition (30). Therefore, while existing 
evidence-based interventions should be implemented at scale, new approaches are 
needed to maximize the impact of nutrition interventions in preventing growth failure. 
Chapter 1: General Introduction 
32 
 
Among others, understanding the range of growth-limiting nutrients and their 
potential for intervention has paramount importance (362). 
Studies of complementary feeding interventions to date have focused on energy and 
micronutrient content of diets and achieved only modest impact on child growth and 
development (361,363). EED occurring at high prevalence among children in LMICs 
has been implicated as an important missing link that mediates and reduces the 
expected benefits from interventions (319,323). The mechanisms contributing to 
growth failure in EED include small intestinal villus atrophy, decreased gut integrity, 
and a chronic gut inflammation that lead to dysbiosis and bacterial translocation, 
systemic inflammation, and nutrient malabsorption. Results from laboratory 
experiments and studies in HICs suggest that n-3 LCPs improve gut integrity, reduce 
inflammation, and enhance maturation of immune system in early-life (discussed in 
section 1.3.3). These reported beneficial effects of n-3 LCPs could result in even 
more important physiological implications for children from LMICs and will ultimately 
contribute to their healthy growth. 
In addition, due to the role of DHA in neurogenesis, synaptogenesis, neurite 
outgrowth and its high incorporation into the brain during early-life, this n-3 LCP is 
considered crucial for early cognitive development. Most evidence suggest that 
endogenous synthesis of DHA is insufficient to support the rapid brain accretion 
during fetal and early postnatal life and therefore, adequate dietary supply of 
preformed n-3 LCP is required to support optimal structural and functional 
development of the CNS during this period (85,88,89,97,173). 
Global estimates of dietary LCPs intakes showed that the n-3 PUFAs supply in 
several LICs are far below the recommended intake levels for pregnant and lactating 
women, and IYC (174,175,180). Furthermore, various factors may increase the risk 
of n-3 FA deficiency among mothers and their infants in vulnerable populations. 
These include depleted maternal stores due to multiparity, higher requirements for 
immune responses facing recurrent infections and persistent subclinical 
inflammations, and deficiency of micronutrients required for PUFA metabolism. 
Previous reviews on FA status and associated functional outcomes among children 
in low-income settings indicated that limited data suggest n-3 FA interventions in 
these settings may yield benefits for health, growth, and development of young 
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children 6-24 months of age, although randomized trials are needed for a conclusive 
association (194,364). 
In Ethiopia, the per capita n-3 LCP intakes from diets and complementary foods are 
reported to be one of the lowest globally (175,179), which provides a favorable 
setting to generate evidence on the impact of n-3 LCP supplementation in young 
children. In the second part of the PhD work, using a randomized controlled trial 
design, we evaluate the efficacy of n-3 LCP supplementation through lactation 
and/or complementary food on growth, morbidity, nutritional status, and development 
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2.1. Aims of the Research 
The overall aim of the PhD study is to generate empirical evidence on important 
proximal to distal factors that can contribute to reduction in child undernutrition in 
LMICs, and assess the role of improved n-3 LCPs intake in supporting healthy 
growth and development of IYC in a rural sub-Sahara African community. 
The hypotheses underlying the studies conducted in the framework of this 
PhD thesis are: 
 Different nutrition-specific interventions and nutrition-sensitive development 
actions may contribute to alleviate the high burden of childhood undernutrition in 
LMICs with different level of impact on the trend in stunting prevalence. 
 
 Due to the very low availability in the food supply, Ethiopian mothers and their 
IYC in rural areas would have a suboptimal n-3 LCP status that can be improved 
by dietary fish-oil supplementation. 
 
 Supplementing lactating women with fish-oil capsules leads to higher n-3 LCP 
concentration in their breastmilk. 
 
 Increased n-3 LCPs intake by IYC through lactation and/or complementary food 
will result in reduced morbidity and inflammation, and improved growth and 
nutritional status. 
 
 Increased n-3 LCPs intake by IYC through lactation and/or complementary food 
will result in higher scores on overall development in the Denver-II test and 
social-emotional development, indicating enhanced neurocognitive 
development. 
2.2. Overview of the study settings 
The results in the current PhD work were generated from two independent studies: i) 
The drivers of stunting reduction in LMICs, and ii) n-3 LCPs supplementation for 
healthy growth and development of IYC in rural Ethiopia (The OME3JIM project). 
2.2.1. The drivers of stunting reduction in LMICs 
This study was subscribed to the call by the European Commission’s Directorate-
General for International Cooperation and Development (DEVCO) to generate 
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evidence on priority areas of action for stunting reduction in 42 LMICs that are 
partners for nutrition support. For this purpose, we modeled the stunting trend in the 
target countries over the last two decades to understand the important drivers behind 
the observed reduction in chronic child undernutrition. Secondary data were secured 
by pooling the Demographic and Health Surveys (DHS) conducted in these countries 
since 2000. The DHS, which has been conducted in several countries for more than 
three decades, is typically characterized by standardized data collection procedures 
across countries and over time, allowing for comparison of results across-countries 
and within-country over time (365). Analysis of potential drivers was based on the 
UNICEF conceptual framework for childhood undernutrition (27) and its recent 
Lancet revision on relevant actions for optimum child nutrition and health shown in 
Figure 1.1 (7). Details on the various indicator variables and their definition and 
analysis approach are presented in the relevant chapter. 
2.2.2. The OME3JIM project 
The OME3JIM project involves a factorial 2X2 RCT aimed at evaluating the effects of 
n-3 LCPs supplementation to lactating mothers and their IYC. The trial was carried 
out from November 2013 to February 2015 in three small districts located under 
Jimma Zone of Oromia Regional State in Ethiopia. 
Country profile 
Ethiopia is a large landlocked country located in the Horn of Africa bounded by 
Eritrea and Djibouti in the north and northeast, Somalia in the east and southeast, 
Kenya and South Sudan in the southwest, and Sudan in west and northwest. The 
country is the second most populous in Africa with an estimated population of 
108,386,391 in 2018, and covers a total area of 1,104,300 km2 (366). Ethiopia is one 
of the least developed countries, globally ranked 173th according to the 2018 United 
Nation’s human development index ranking of 189 countries (367). Agriculture is the 
dominant economy sector employing more than 70% of the labor force and about 
30% of the total population lives below the poverty line earning less than $1.90 a 
day. 
Childhood undernutrition is a major public health problem in Ethiopia with 13% of 
children born with low birthweight and 38% of under-five children stunted in 2016 
(190). One in ten under-five children suffer from acute malnutrition (wasted), and 
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infant and under-five mortality rates are high at 48 and 67 deaths per 1,000 live 
births, respectively. Maternal undernutrition is also high, with 22% of women aged 
15-49 years were found to be exposed to chronic energy deficiency (BMI<18.5 
kg/m2). 
In Ethiopia, almost all children (97%) receive breastfeeding at some point, but only 
58% and 79% of infants under 6 months receive exclusive and predominant 
breastfeeding, respectively (190). Continued breastfeeding is also relatively high with 
92% and 76% of children continue to receive breast milk until their first and second 
birthdays. The feeding practices of only 7% of children aged 6-23 months meet the 
minimum acceptable dietary standards, and only 14% of children had an adequately 
diverse diet. 
Study area 
The OME3JIM project was implemented in three rural subsistence farming districts, 
named Assendabo (total population n = 40,266), Serbo (n = 7,938) and Deneba (n = 
10,428), which are located at ~300 km to the southwest of the country’s capital Addis 
Ababa. The districts are located under the catchment of Gilgel Gibe Health and 
Demographic Surveillance System (HDSS) which is one of the six HDSS sites in the 
country. The HDSS center was established since 2005 with the primary purpose of 
monitoring basic vital events indicators to generate relevant health, demographic and 
socioeconomic information for policies and programs. The center is comprised of 11 
districts surrounding the reservoir of Gilgel Gibe hydroelectric dam covering the area 
within latitudes of 07.4253 and 07.5558oN and longitudes of 037.1153 and 
037.2033oE with midland agroclimatic zone. Study districts were selected because 
their location under the catchment of HDSS, which facilitated obtaining basic 
household and child information, their population size to secure adequate number of 
study subjects, and their proximity and accessibility for the intervention. 
Childhood malnutrition is prevalent in the study area and IYC receive complementary 
diets with low dietary diversity and quality (368,369). Infant and under-five mortality 
rates were reported to be 76 and 104 deaths per 1,000 live births in 2015, and the 
commonest causes of mortality were premature birth, pneumonia, malaria and 
diarrheal diseases (370). 
Chapter 2: Aims of the Research 
38 
 
Descriptions of the implementation of the OME3JIM trial including enrollment and 
follow-up of study participants, the study interventions, and outcome measurements 
are detailed in the relevant chapters. 
 
Figure 2.1. Map of Ethiopia with Jimma Zone (green arrow) under Oromia region 
2.3. Outline of the dissertation 
This thesis can be divided into two parts reporting on two major areas of the PhD 
work. In the first part of the thesis (Chapter 3), using data from 14 LMICs, we 
provide empirical evidence on important nutrition-sensitive and -specific drivers for 
the reduction trend in under-five stunting observed since the turn of the Millennium. 
The second part of the thesis (Chapters 4–6) presents results from an RCT of n-3 
LCPs supplementation of lactating mothers and their children in a rural setting in 
Ethiopia. Chapter 4 reports on the effect of fish-oil supplementation of lactating 
mothers on HM LCPs concentrations and its association with blood concentrations in 
their breastfed children. Chapter 5 evaluates the effect of n-3 LCPs supplementation 
of IYC through lactation and/or complementary food on systemic inflammation, 
morbidity for common childhood illnesses, and growth outcomes. Chapter 6 
investigates the effects of the same intervention on child developmental performance 
outcomes. 
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Finally, a general discussion of the major findings in the various chapters as well as 
recommendations for future research are formulated in Chapter 7. The schematic 
















Figure 2.2. Schematic presentation of the PhD research
Chapter 7: General Discussion and Conclusion 
Chapter 3: Drivers of stunting trend 
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Background: Understanding the drivers contributing to the decreasing trend in 
stunting is paramount to meeting the World Health Assembly’s global target of 40% 
stunting reduction by 2025. 
Methods: We pooled data from 50 Demographic and Health Surveys since 2000 in 
14 countries to examine the relationships between the trends in stunting and 
potential factors at the distal, intermediate, and proximal levels. A multilevel pooled 
trend analysis was used to estimate the association between the change in potential 
drivers at a country level and stunting probability for an individual child while 
adjusting for time trend and important covariates for the individual child, mother and 
household. A four-level mixed-effects linear probability regression model was fitted, 
accounting for the clustering of data by sampling clusters, survey-rounds, and 
countries. 
Results: Stunting followed a declining trend in all countries with an average annual 
rate of reduction of 1.04 percentage points. Among the distal factors assessed, a 
decrease in the Gini coefficient, an improvement in women’s decision-making, and an 
increase in urbanization over time within a country were significantly associated with 
a lower probability of stunting. Improvements in households’ access to improved 
sanitation facilities and drinking water sources, and children’s access to basic 
vaccinations were the important intermediate service-related drivers, whereas 
improvements in early initiation of breastfeeding and a decrease in the prevalence of 
low birthweight were the important proximal drivers. 
Conclusions: The results reinforce the need for a combination of nutrition-sensitive 
and -specific interventions to tackle the problem of stunting. The identified drivers 
help to guide global efforts to further accelerate stunting reduction and monitor 
progress against chronic childhood undernutrition. 




Stunting occurs in more than one in five children of age under-five years, affecting 
149 million children globally (1). Childhood stunting is strongly associated with an 
array of short- and long-term health and economic consequences, including greater 
risks of child morbidity and mortality, developmental deficits resulting in poorer school 
performance and lower productivity and earnings in adulthood, and early-life 
physiological changes contributing to an increased risk of nutrition-related chronic 
diseases into adulthood (3,9,17). Stunting also leads to undesired outcomes in the 
following generation, where newborns from stunted mothers are more likely to be 
small-for-gestational-age with an increased risk of later growth faltering, and 
morbidity and mortality (25). 
In recognition of stunting as an important outcome in itself and as a marker of several 
adverse outcomes, global attention has been directed towards accelerated reduction 
of the high burden of child growth faltering in LMICs (371). In 2012, the WHA 
endorsed global nutrition targets for 2025, including a 40% reduction in the number of 
children under-five years old who are stunted (57). While stunting has declined over 
the last three decades, the current trend in many LMICs is insufficient to reach the 
target for 2025 (56). To reach this target, it is essential to understand the important 
drivers behind the observed trend in stunting reductions in these countries. 
While a great number of studies relied on cross-sectional variations to explore the 
determinants of child stunting (40,372–378), only a few tried to understand which of 
these time-variant factors influence the trend in stunting prevalence over time 
(53,54,59,60,64,379). Moreover, most efforts to assess the trend in stunting reduction 
have taken a country focus and examined contextual drivers (53,54,59,60,64). 
However, comprehensive evidence of stunting drivers across high burden countries 
is equally important for decision-making at the global and regional levels. Only a few 
studies have used a cross-country analysis to explore the association between 
stunting trends and potential drivers over the past three decades (45,52,61,63). 
However, previous analyses were limited by the unavailability of data on some 
important nutrition-related determinants. For instance, the use of per capita energy 
supply may be a distant proxy for the underlying IYCF practice indicators (45,52,63). 
Furthermore, timely revision of evidence on the drivers of the current stunting trend is 
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relevant for decision-making as the strength of the relationship between stunting and 
potential drivers could change over time (59,64). 
In this study, we used a large cross-country dataset of the Demographic and Health 
Surveys (DHS) to understand the association between changes in a range of distal to 
proximal factors and stunting prevalence among under-five children in 14 LMICs 
since 2000. 
Table 3.1. Characteristics of included Demographic and Health Surveys 
Characteristics Statistics 
Surveys, n 50 
Countries, n 14 
Surveys per country, n  
 3 rounds 6  
 4 rounds 8  
Countries with survey years  
 Bangladesh 2004, 2007, 2011, 2014 
 Cambodia 2000, 2005, 2010, 2014 
 Ethiopia 2000, 2005, 2011,2016 
 Haiti 2000, 2005, 2012, 2016 
 Kenya 2003, 2008, 2014 
 Malawi 2000, 2004, 2010, 2015 
 Mali 2001, 2006, 2012 
 Nepal 2001, 2006, 2011, 2016 
 Nigeria 2003, 2008, 2013 
 Rwanda 2000, 2005, 2010, 2014 
 Tanzania 2004, 2010, 2015 
 Uganda 2000, 2006, 2011, 2016 
 Zambia 2001, 2007, 2013 
 Zimbabwe 2005, 2010, 2015 
Total sample size, n 322,320 
Children per survey, mean (range) 6457 (2070–24,505) 
Child age (month), mean ± SD 28.6 ± 17.2 
Child sex (female), % 49.8 
Maternal age (y), mean ± SD 28.7 ± 6.86 
3.3. Materials and methods  
3.3.1. Data source  
We considered data from DHSs conducted in 42 LMICs that are partners for nutrition 
support by the DEVCO. Our trend analysis required data from at least 3 time-points. 
Therefore, the present analysis only utilized data from 14 countries with an adequate 
number of standard DHS rounds since 2000. Countries included in our analysis were 
Bangladesh, Cambodia, Ethiopia, Haiti, Kenya, Malawi, Mali, Nepal, Nigeria, 
Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe (Table 3.1).  
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The DHS has been conducted in several countries for over three decades, providing 
nationally representative cross-sectional data on demographic, health, and nutrition 
information, among others (365). The DHS uses standardized data collection 
procedures across countries and consistent content across survey rounds, allowing 
for comparison of data across-countries and within-country over time. We pooled 
data from 50 DHS rounds in the 14 countries. There were a different number of 
surveys per country and different time spans between surveys for the countries. Data 
were compiled from the official website of the DHS Program accessed with 
permission in November 2018 (https://dhsprogram.com/). Children of under-five 
years who had data on length/height measurements and other relevant information 
available were included in the analysis. 
3.3.2. Variables 
The outcome of interest was the probability of being stunted in under-five children. 
Stunting here is described as binary (stunted/not stunted), defined as a length/height-
for-age z score below 2 SD from the WHO 2006 Child Growth Standards median 
value for the same age and sex (27). Potential drivers for stunting reduction were 
identified based on the UNICEF (27) conceptual framework for the determinants of 
childhood undernutrition and the more recent 2013 Lancet (7) framework for actions 
to improve child nutrition and development. A variable was selected for analysis 
when it was available in the DHS datasets for enough survey rounds, and used as a 
determinant in more than one paper, or mentioned in reviews and/or were found to 
be significant in previous country analyses. We considered three groups of variables 
operating at different levels as distal factors, intermediate health and related services 
utilization factors, and proximal factors (Table 3.2). We considered variables such as 
women’s education, decision-making power and work opportunity as distal factors 
because these factors can influence access to and utilization of the intermediate 
service-related variables. Definition of indicators used in our potential drivers list is in 
line with the DHS statistics guideline (380). Estimates for the association between 
drivers and stunting were adjusted for important demographic and socioeconomic 
covariates for the child, mother, and household, including child age, sex, birth-order 
and birth-interval, maternal age and marital status, household wealth status, and 
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3.3.3. Statistical analysis 
Data management and statistical analyses were conducted in Stata version 14.1 
(StataCorp LLC, Texas, USA) using the High Performance Computing infrastructure 
at Ghent University. For all analyses, associations with a P-value of less than 0.05 
were regarded as statistically significant. Missing indicators for certain survey-rounds 
were imputed based on linear interpolation of the available time-points within a 
country. The aggregate value of stunting and explanatory indicators for each survey-
round in a country was calculated by taking into account the DHS sampling weight, 
using the svyset command in Stata. The pooled annualized rate of change in stunting 
and indicators were estimated by fitting mixed-effects linear regression models using 
country as a random intercept and survey-round as a random slope, and by applying 
weightings based on the population size of each country. 
We followed the trend analysis approach suggested by Fairbrother (381) for analysis 
of outcome at individual-subject level using repeated cross-sectional survey datasets. 
The method allowed us to examine the association between the trend in an indicator 
at aggregate country-level and the risk of stunting at an individual child, while 
adjusting for time trends (survey year) and important demographic and 
socioeconomic covariates for the individual child, mother, and household mentioned 
above.  
We fitted mixed-effects linear probability models with robust variance estimation. A 
four-level random intercept was considered to account for potential sources of 
clustering in our data where individuals (level-1) are nested within the DHS sampling 
clusters (level-2), which in turn are nested within survey-rounds (level-3), and finally, 
survey-rounds nested within countries (level-4). Since an indicator varies both within-
country over time and across countries, we sought to identify separate within-country 
(longitudinal) and between-country (cross-sectional) components for the association 
between an indicator variable and stunting. For this purpose, we simultaneously 
specified in the model the average value of an indicator per country (i.e., representing 
cross-country differences) and the average value of an indicator per survey-round 
within a country (i.e., representing within-country change over time). This within-
between model specification has the additional advantage of minimizing potential 
endogeneity problems in mixed-effects models (382). In order to avoid over-
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adjustment from the inclusion of distal, intermediate, and proximal indicators in a 
single model, we specified three separate multivariable regression models for each 
group of indicators.  
The relationship between an explanatory variable and stunting risk in our four-level 
model is represented the equation below: 
yiktj = β0 + β1xtjM + β2x̅j + β3xiktj + β4timetj + uk + ukj + uktj + εiktj;  
where yiktj is the risk of stunting in child i who is from a DHS sampling cluster k nested 
within a survey for country-year tj, which in turn is nested within a country j. β1 and β2 
give estimates for stunting-indicator associations decomposed into between-country 
(which is estimated from the value of an indicator at a country level using the average 
of all survey-rounds in a country x̅j) and within-country effects (which is estimated 
from the average value of an indicator for each survey-round per country xtjM), 
respectively. Country-year level variables were mean-centered by subtracting the 
value of the country-level variable from the value at survey-round within the same 
country. This allows us to the cross sectional component and the longitudinal 
component to be orthogonal (independent) to each other by construction and their 
effects can be estimated simultaneously with in a model. β3 gives the estimate for the 
association of individual-subject level covariates used for adjustment in the model. β4 
gives the estimate for the time variable as a set of year dummies, which adjust for 
possible simultaneous but unrelated time trends in both xj/xtjM and stunting. Random 
effect components modeling clustering of data by the DHS sampling cluster (uk), by 
country-years (ukj), and countries (uktj), and the residual term for individual child (εiktj) 
are assumed to follow a Gaussian distribution with a mean value of zero. 
3.4. Results 
Our final dataset included 322,320 children of age under-five years from 50 survey-
rounds in 14 countries that were conducted between 2000 and 2016 (Table 3.1). The 
mean ± SD child age was 28.6 ± 17.2 months and 49.8% of children were female. 
The mean ± SD maternal age was 28.7 ± 6.86 years. The number of survey-rounds 
per country were three in six countries and four in eight countries. The average 
sample size per survey-round was 6,457 (range: 2,070–24,505). 
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The trend over survey-rounds for stunting prevalence and the indicator variables 
within the 14 study countries are presented in Figure 3.1 and Annex 1. Stunting 
prevalence followed a declining trend over time in all countries assessed. The overall 
average annual rate of stunting reduction was 1.04 percentage points (pp) (β (95% 
CI): −1.04 (−1.24, −0.84); P < 0.001) with differing slopes among countries (Table 
3.3). Similarly, most of the indicator variables also showed improvements over time 
except in some variables, like women’s work opportunity. 
Figure 3.1. Trends in under-five stunting prevalence by country 
We estimated the associations between the probability of stunting and the variations 
in potential drivers within- and between-countries with the estimate of the within-
country association reported as a proxy measure of the effect of an indicator on 
stunting trend over time (Table 3.4). The Gini coefficient, urbanization, and women’s 
decision-making power were the distal-level indicators found to be significantly 
associated with the change in stunting risk within a country. A SD decrease in the 
Gini coefficient within a country over time was associated with a decreased 
probability of stunting by 1.10 pp (P = 0.008). A 10% increase in the percentage of 
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the population living in urban areas and women with decision-making power was 
associated with a 0.67 pp (P = 0.013) and a 0.36 pp (P = 0.040) decreases in the 
probability of being stunted, respectively. 
Households’ access to improved sanitation facilities and improved drinking water 
sources, and children’s access to all basic vaccinations are the intermediate level 
health and related service determinants that were found to be significantly associated 
with stunting risk overtime. Within a country, a 10% increase in the coverage of 
improved sanitation facilities, improved drinking water sources, and basic child 
vaccinations were associated with decreases in the probability of stunting by 1.40 pp 
(P < 0.001), 1.48 pp (P = 0.003), and 1.74 pp (P < 0.001), respectively. 
Table 3.3. Trends in stunting prevalence and potential determinants across 
survey-rounds (n = 50)1 
Variables Average annualized rate of change Beta (95% CI) P 
Stunting prevalence in under-five children (%) −1.04 (−1.24, −0.84) <0.001 
Gini coefficient −0.01 (−0.02, −0.01) <0.001 
Total fertility rate (average number of births per women) −0.07 (−0.09, −0.05) <0.001 
Urbanization (%) 0.61 (0.21, 1.00) 0.003 
Female primary education (%) 0.21 (−0.49, 0.91) 0.560 
Male secondary education (%) 0.13 (−0.05, 0.30) 0.163 
Women’s decision-making power (%) 2.31 (1.36, 3.26) <0.001 
Women working (%) −0.30 (−0.84, 0.25) 0.286 
Improved sanitation facilities (%) 1.87 (1.02, 2.72) <0.001 
Improved drinking water sources (%) 1.25 (0.66, 1.84) <0.001 
Antenatal care follow-up with ≥4 visits (%) 1.13 (0.53, 1.72) <0.001 
Delivery at health facility (%) 1.82 (1.17, 2.47) <0.001 
Iron supplementation during pregnancy (%) 0.39 (−2.59, 3.37) 0.798 
Children with all 8 basic vaccinations (%) 1.18 (0.98, 1.38) <0.001 
Initiation of breastfeeding in ≤1 day (%) 1.00 (0.66, 1.33) <0.001 
Median duration of exclusive breastfeeding (months) 0.08 (0.04, 0.12) <0.001 
Complementary feeding between ages 6–9 months (%) 0.32 (−0.21, 0.86) 0.239 
Prevalence of reported low birthweight (%) −0.18 (−0.58, 0.23) 0.392 
Prevalence of acute respiratory illness (%) −1.00 (−1.14, −0.86) <0.001 
Prevalence of diarrhea (%) −0.47 (−0.69, −0.26) <0.001 
1Average annualized rates of change (beta coefficients (95% CI)) were estimated using a mixed-effects linear 
model with country as random intercept and time as random slope and using weighting for each country’s 
population size. 
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As for the proximal nutrition and health factors, prevalence of reported low 
birthweight and percent of children with early initiation of breastfeeding were 
significantly associated with changes in stunting risk overtime. A 10% decrease in the 
prevalence of low birthweight over time was associated with a 3.91 pp (P < 0.001) 
decrease in the probability of stunting. A 10% increase in children with early initiation 
of breastfeeding within a country was associated with a 1.17 pp (P < 0.001) decrease 
in the probability of stunting. 




Beta (95% CI) p 
Distal determinants   
Gini coefficient (SD) 1.10 (0.29, 1.91) 0.008 
Total fertility rate (SD) 0.39 (–0.78, 1.56) 0.513 
Urbanization (10%) −0.67 (−1.21, −0.14) 0.013 
Women primary education (10%) −1.12 (−2.42, 0.18) 0.092 
Male secondary education (10%) −1.95 (−5.47, 1.56) 0.275 
Women’s decision making (10%) −0.36 (−0.69, −0.02) 0.040 
Women’s working (10%) −0.72 (−2.58, 1.15) 0.450 
Intermediate service related determinants     
Improved sanitation facilities (10%) −1.40 (−2.17, −0.62) <0.001 
Improved drinking water sources (10%) −1.48 (−2.45, −0.52) 0.003 
Antenatal care follow-up with ≥4 visits (10%) 0.38 (−0.46, 1.23) 0.377 
Delivery at health facility (10%) 0.08 (−1.20, 1.36) 0.907 
Iron supplementation during pregnancy (10%) 0.21 (−0.14, 0.56) 0.240 
Children with all 8 basic vaccinations (10%) −1.74 (−2.53, −0.94) <0.001 
Proximal determinants     
Initiation of breastfeeding in ≤1 day (10%) −1.17 (−1.62, −0.73) <0.001 
Median duration of exclusive breastfeeding (SD) 0.18 (−0.32, 0.68) 0.473 
Complementary feeding b/n age 6–9 months 
(10%) 
0.75 (−0.53, 2.03) 0.250 
Prevalence of reported low birthweight (10%) 3.91 (2.40, 5.43) <0.001 
Prevalence of acute respiratory illness (10%) 1.28 (−1.40, 3.96) 0.349 
Prevalence of diarrhea (10%) −2.73 (−6.12, 0.65) 0.113 
1Beta coefficients (95% CI) are estimated using a mixed-effects linear probability regression model 
with a robust variance estimator and using four-level random intercept accounting for clustering of 
individuals by sampling clusters, survey-rounds, and countries. Separate models were fitted for each 
group of the distal, intermediate, and proximal variables. Models were adjusted for time trend and 
important individual-level covariates including child age, sex, birth-order and birth-interval, maternal 
age and marital status, household wealth status, and place of residence (urban/rural). Bold values 
indicate p < 0.05. SD, standard deviation. 





This study examined a range of distal to proximal factors that might explain the 
observed trend in stunting reduction in 14 LMICs since the turn of the millennium. 
Stunting prevalence followed a declining trend in all countries assessed, with an 
average annual rate of reduction of 1.04 pp. However, this observed reduction is 
below the 3.9% average annual rate of reduction that is expected to meet the WHA 
2025 stunting target, indicating the need for further efforts by the countries and their 
international partners (57).The key indicators that explained the observed trend in 
stunting were improvements in income inequality, urbanization, and women’s 
decision-making power from the distal factors assessed; improvements in 
households’ access to improved sanitation facilities and improved drinking water 
sources, and child immunization rate for basic vaccinations from the intermediate 
service related factors; and a decline in the prevalence of reported low birthweight 
and an improvement in early initiation of breastfeeding from the proximal factors. 
The current finding that investments narrowing economic inequalities among 
households and empowering women are key drivers of stunting reduction is in line 
with the findings from previous studies. In a cross-country analysis of stunting trend 
from 1970–2001, Milman et al. (45) reported that countries with more equitable 
income distribution achieved better stunting reduction. Others also reported that 
increases in household asset accumulation was an important driver of stunting 
reduction in a cross-country study (44) as well as in studies of the trend in individual 
countries with substantial stunting reduction (53,59,60). Improvements in women’s 
decision-making as a key stunting driver in this study is consistent with a previous 
review by Carlson et al. (48) that suggested raising maternal autonomy is an 
important goal for improving children’s nutritional status in LMICs. It is widely 
acknowledged that mothers play a vital role as a primary caregiver of the child, and 
their control over household resources and decision-making is expected to facilitate 
the level of childcare and feeding practices as well as the utilization of health care 
services which are important underlying determinants of child nutritional status and 
health. On the other hand, women’s education, which has been reported as a key 
driver of stunting reduction for over the past three decades (45,52,53,59–61), was 
not found to be important driver in our analysis. In this study, although countries with 
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a better coverage of women’s primary education had significantly lower stunting 
burden, the within-country association was not significant. This may suggest that 
although women’s education has been responsible for the changes in stunting 
prevalence that occurred over the long-term, it has a lesser contribution for the more 
recent changes over the last two decades. This may be due to a lack of substantial 
gains in women’s education coverage in the more recent period in the studied 
countries, as it is indicated by the small nonsignificant change observed in this 
indicator compared to most other indicators in our data (Table 3.3). Another possible 
explanation is that the potential impact of women’s education on stunting trend might 
be partially explained by other closely related indicators in our model, such as 
women’s decision-making power and work opportunity. However, the within-country 
association for women’s education remains nonsignificant after excluding the 
mentioned indicators from the model, suggesting that our previous explanation 
holds. 
This study found that within-country change in stunting risk was associated with 
improvements in households’ access to improved sanitation facilities and improved 
drinking water sources and increased coverage of child immunization, which is 
consistent with findings from previous studies of stunting trend (52,53,59–61). These 
findings are also supported by the growing body of literature that demonstrate 
environmental enteric dysfunction in children living under poor water, sanitation, and 
hygienic conditions is among the most important factors for the high burden of child 
growth faltering in low-income settings (17,42,383). 
This study extends previous trend analysis studies by including more direct measures 
for the proximal determinants of child undernutrition, including the WHO IYCF 
indicators, and prevalences of low birthweight and common childhood illnesses. The 
finding that reductions in the rate of low birthweight was an important driver of the 
changes in stunting prevalence concurs with a previous estimate showing intrauterine 
growth restriction (estimated by low birth weight) accounts for 20% of the stunting 
burden in LMICs (26). From the IYCF indicators assessed, only improvements in 
early initiation of breastfeeding was found to be significantly associated with a 
reduction in the probability of stunting in the 14 countries. We did not find a 
statistically significant association of the trends in stunting with the percentage of 
breastfed children 6-8 months old who started complementary foods or with the 
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median duration of breastfeeding. The mere introduction of solid and semi-solid foods 
may not be a good indicator of the quality of children’s diet which could explain the 
lack of association with this indicator. In this regard, indicators such as dietary 
diversity and the consumption of animal source foods might have been better 
indicators to evaluate dietary quality and its association with child linear growth (34–
37,384–386). However, such indicators are available only in the most recent DHS 
rounds. The lack of association between longer duration of breastfeeding and 
stunting reduction has also been reported previously. It is possible that higher 
reliance on breastfeeding may occur in low-income settings where infants have 
lesser access to diverse diet as well as mothers of infants with poor health and 
growth may decide to continue breastfeeding for a longer duration (39,387,388). 
One important limitation of the current study is that generalizability of the findings is 
limited by the facts that our analysis did not include all relevant countries, such as 
India, which holds almost a third of the world’s stunting burden. Given the cross-
sectional nature of the study, we cannot assure observed associations are causal. It 
was also not possible to consider a time-lag between the indicators and stunting risk 
as our analysis was entirely based on the DHS data, which collects both the 
predictors and the outcome at the same time. However, it should be noted that 
experimental impact evaluations, such as controlled interventions, are extremely 
challenging, if not impossible, to address such holistic research questions addressing 
several drivers of chronic child undernutrition at the level of multiple countries. It 
should be noted that the indicators that were found to be important drivers in the past 
may not necessarily be the ones that will be important in the future due to possible 
changes in indicator-stunting associations and a saturation of some indictors for 
future improvements. For this reason, unlike most previous trend analysis studies, we 
aimed at evaluating the more recent trends since the year 2000. Furthermore, we 
note that most of the indicators found to be important in our analysis have also been 
targeted by the United Nations’ Millennium Development Goals set for 2015 and its 
continuation of the SDGs for the year 2030 (58). Thus, it is possible that with future 
investment, substantial progress can be made on these indicators with a potential 
resultant effect on child stunting reduction. Finally, some of the potentially expected 
drivers, like complementary feeding practice, were not found to be significantly 
associated with stunting reduction in the current analysis, which could be due to the 
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limited progress in these indicators in most of the countries studied. Therefore, we 
cannot exclude the potential that some of these nonsignificant indicators will 
contribute to stunting reduction with future investments improving their status in a 
population. 
3.6. Conclusion 
In conclusion, the current study identified important distal to proximal drivers for the 
observed trend in stunting reduction in 14 LMICs, which is an important input for 
future decision-making to further accelerate stunting reduction and monitor progress 
against chronic childhood undernutrition. Our findings indicate that stunting drivers 
were present both at the distal and intermediate, as well as at the proximal levels, 
suggesting that economic development and nutrition-sensitive interventions, on top of 
nutrition-specific programs, play an important role in reducing the high stunting 
prevalence in these countries. 
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Background: For infants and young children in low-income settings, human milk 
(HM) is the main source of omega-3 (n-3) long-chain polyunsaturated fatty acids 
(LCPs), including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). 
However, the n-3 LCPs concentrations of HM show wide variability, largely 
depending on the maternal intake of marine foods. This may put children living far 
from coastal areas at risk of inadequate intake. We evaluated the efficacy of fish-oil 
(FO) supplementation of lactating mothers on HM n-3 LCPs concentrations in a rural 
setting from Ethiopia. 
Objective: In a sub-study of an individually randomized controlled trial, we evaluated 
the efficacy of fish-oil supplementation of lactating mothers on HM n-3 LCPs 
concentrations in a rural setting in Ethiopia. 
Methods: Mothers (n=360) with children 6-12 months old were randomized to 
receive either intervention FO capsules (215 mg DHA + 285 mg EPA) or control corn-
oil capsules (without n-3 LCPs). In a random subsample of 154 participants, we 
analyzed LCPs in HM and child capillary blood using gas chromatography.. 
Results: Compared to the control, FO supplementation increased HM concentrations 
of DHA by 39.0% (95% CI: 20.6, 57.5%; P<0.001) and EPA by 36.2% (95% CI: 16.0, 
56.4%; P<0.001), whereas the arachidonic acid (AA)/(DHA + EPA) ratio decreased 
by 53.5% (95% CI: -70.2, -36.7%; P<0.001). We also found statistically significant 
association between the changes in (DHA + EPA)/AA ratio in HM and child capillary 
blood (P<0.001). However, HM DHA concentrations remained lower than 
international norms after FO supplementation.. 
Conclusions: FO supplementation improves n-3 LCPs content of HM. Future studies 
should evaluate different doses of n-3 LCPs and consider potential effect modifiers 
such as genetic polymorphism and diet. This trial was registered at clinicaltrials.gov 
as NCT01817634.




Adequate supply of the LCPs of the n-3 series DHA and EPA, and of the n-6 series 
AA are essential for normal growth and development (85,195). DHA and AA 
accumulate rapidly in the cerebral cortex and retina during the brain growth spurt 
which takes place during the first 1,000 days after conception (146,389,390). DHA 
status of infants was shown to relate with visual and neurocognitive development 
(210). In addition, LCPs are precursors of eicosanoids and other lipid mediators 
modulating the expression of genes involved in inflammation processes and other 
immune functions and metabolic control (311,351,391,392). 
HM remains the most affordable source of LCPs for IYC in LMICs as complementary 
diets in these settings are usually very low in preformed LCPs (174,179). The global 
average concentrations of DHA and AA in HM are estimated at 0.37% (SD 0.11) and 
0.55% (SD 0.14) in w/w of total lipids (%TL) (178). The concentration of DHA in HM 
is highly variable and mainly explained by maternal dietary intake of preformed DHA 
found in fish and other marine foods, whereas the concentration of AA is relatively 
stable and less affected by AA in the maternal diet (176–178). Expert groups 
recommend that lactating women should aim for an average daily dietary intake of 
300 mg DHA + EPA from which 200 mg should come from DHA (95,173). There are 
no indications that lactating women with an adequate dietary intake of the precursor 
LA need an additional dietary supply of AA (95). The recommended intake of n-3 
LCPs during pregnancy and lactation can be attained by a weekly consumption of 1-
2 portions of sea fish (95). For those women without access to marine foods, n-3 LCP 
supplementation may be required to ensure this recommended intake. 
In Ethiopia, the LCPs status of HM have not been documented. The per capita DHA 
availability in Ethiopian diet was estimated at 7.0 mg/d, which is one of the lowest 
globally and extremely low to meet the recommended intake during lactation (175). 
Furthermore, the contribution of complementary foods to DHA intake by Ethiopian 
children 6–36 months old was estimated to be negligible (1.1 mg/d), compared to the 
worldwide average (14.6 mg/d) (179). 
We conducted the OME3JIM trial, a 2x2 factorial randomized controlled trial to 
evaluate the effects of n-3 LCPs supplementation of lactating women and/or their 
children 6-24 months of age on child health, growth and development in rural 
Chapter 4: Fish-oil Supplementation and Maternal Milk n-3 LCP 
59 
 
Ethiopia. In a subsample of this trial, we collected HM and child capillary blood 
samples. The purpose of this sub-study was to evaluate the effect of maternal fish-oil 
(FO) supplementation on n-3 and n-6 LCPs concentrations in maternal milk and the 
association between changes in maternal milk and child blood concentrations. 
4.3. Methods 
The OME³JIM trial was conducted from November 2013 to February 2015 in three 
districts of Jimma Zone in southwest Ethiopia. Subsistence farming is the main form 
of livelihood in the study districts, and staple crops in the area are very low in n-3 
LCPs. Mother-infant pairs with singleton infants of age 6-12 months were enrolled in 
the main trial if the infant was breastfeeding and not acutely malnourished (weight-
for-length z score ≥-2 SD and no bilateral pitting edema), and the mother had no plan 
to leave the study area for more than one month during the study period and was 
willing to participate in the trial. Mother-child pairs were excluded from the trial when 
the mother or child had a known chronic illness, was taking other nutritional 
supplements, when the child had a congenital abnormality or severe anemia 
(hemoglobin <7.0 g/dL) at enrolment or during study follow-up. 
Details of the main OME3JIM trial are reported in Chapter 5. In brief, from a total of 
413 mother-infant pairs screened, 360 eligible pairs were enrolled in the main trial 
(Figure 4.1). Study mothers were randomly assigned to either an intervention group 
that received fish-oil capsules (FO, n = 180) or a control group that received placebo 
corn-oil capsules (CO, n = 180). A random subsample of 168 mother-infant pairs 
from both study arms was selected for the HM sub-study. HM samples at baseline 
were available from 154 mothers (n: CO = 82; FO = 72), who were finally considered 
for this study.  
Both the fish-oil and corn-oil capsules were produced as identical airtight soft-gel 
capsules (Biover NV, Belgium). A daily dose of two intervention fish-oil capsules 
provided 500 mg/d n-3 LCPs (215 mg DHA + 285 mg EPA) whereas the control corn-
oil capsules contained no n-3 LCPs. Each capsule additionally contained 5 mg of the 
antioxidant d-α-tocopherol to limit oxidative loss of LCP. The intervention was 
provided for 12 months, with supplements distributed on a monthly schedule and 
compliance monitored through weekly counts of remaining capsules. 
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In addition to the maternal intervention, infants aged 6-12 months of the same 
mothers were individually randomized to either an intervention group that received a 
food supplement fortified with fish-oil (n = 181) or a control group that received the 
same food supplement without fish-oil (n = 179) during the same period. The 
intervention food supplement contained a daily dose of 500 mg n-3 LCPs (169 mg 


















Figure 4.1. Trial flowchart 
A random subsample of 168 mothers was drawn from the main trial (n = 360) and asked to participate in the HM 
sub-study. A total of n = 154 mothers from whom samples were available at baseline were finally considered for 
the HM sub-study. CO, control mothers who received a placebo corn-oil capsules; FO, intervention mothers who 
received fish-oil capsules; HM, human milk. 
Lost to follow-up (n = 14)  
      Refusal (n = 8) 
      Left residence (n = 6)  
 
Sample not available (n = 5) 
 
Assessed at 6 mo (n = 70) 
 
Assessed at 12 mo (n = 63) 
Lost to follow-up (n = 5)  
     Refusal (n = 4) 
     Left residence (n = 1) 
 
Sample not available (n = 12) 
 
Assessed at 6 mo (n = 59) 
 
Assessed at 12 mo (n = 55) 
Random subsample for HM study (n = 87) 
   HM sample available (n = 82) 
Assessed for eligibility (n = 413) 
Excluded (n = 53) 
    Not meeting criteria (n = 36) 
    Declined to participate (n = 17) 
Randomly assigned (n = 360) 
Allocated to CO (n = 180) Allocated to FO (n = 180) 
Random subsample for HM study (n = 81) 
   HM sample available (n = 72) 
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4.3.1. Sample collection and LCP analysis 
HM and child capillary blood samples were collected at baseline, midline (after 6 
months) and endline (after 12 months) of the intervention to determine DHA and EPA 
concentrations. The concentration of AA was additionally considered to evaluate any 
potential influence of n-3 LCP supplementation on n-6 LCP levels. Before collecting 
HM samples, mothers were asked to breastfeed their child for a few minutes to 
establish breastfeeding. Then, study nurses expressed breast milk samples (10-15 
mL) manually or by using manual breast pumps into sterile plastic containers with 
lids. An aliquot of 9 mL homogenized milk sample was pipetted into a 10 mL cryovial 
containing 1 mL of an 0.01% BHT (2,6-Di-tert-butyl-4-methylphenol) acetone solution 
for storage, so as to limit lipolytic and oxidative degradation of milk lipids before 
extraction. Child blood samples were collected using dried blood spot cards. Prior to 
sample collection, blood spot cards (TFN, Munktell) were impregnated with BHT (2,6-
di-tert-butyl-4-methylphenol) to minimize the oxidation of LCPs as previously 
described by Ichihara et al. (393). A large drop of blood from a finger prick was 
collected on preprinted circles on the spot cards and then dried overnight at room 
temperature, and, once dry, inserted into aluminum-coated airtight envelopes with dry 
desiccants before storage. HM samples and dried blood spot cards were collected in 
the field in the morning up to noon (between 9:00 AM and 1:00 PM), and transported 
in cold-chain using cooled bags before storage at -80°C in a central laboratory at 
Jimma University. Samples were later air-shipped on dry ice to a laboratory in 
Belgium and stored at -80°C upon arrival until analyses. 
A total lipids extract was prepared from each HM sample using an aliquot of 50 μL 
homogenized HM according to the Bligh-Dyer method (394), and from each child 
whole blood sample using a disc of 8 mm diameter punched from the blood spot 
cards (corresponding to ±21.8 μL blood) (395) according to the method detailed by 
Bailey-Hall et al. (396). A prior lipid extraction step was performed to guarantee the 
extraction of all lipids from the filter paper. We performed saponification with NaOH 
and methylation into FA methyl esters with BF3 in methanol. Then, FA methyl esters 
were separated by gas chromatography with cold-on column injection (0.1 μL, GC-
FID 6890N, Agilent Technologies) and a FA methyl ester column (CP-Sil 88, 60 m 
length, 0.25 mm ID, 0.20 μm film thickness, Agilent Technologies). We used helium 
as carrier gas (BIP Plus-X50S, Air Products) and applied a programmed temperature 
Chapter 4: Fish-oil Supplementation and Maternal Milk n-3 LCP 
62 
 
gradient (hold at 50°C for 4 min, increase temperature by 25°C/min to 225°C, hold at 
225°C for 25 min). Retention times were compared to the standard (GLC-68 D, Nu-
Chek-Prep), and FAs were quantified relative to the 19:0 FA internal standard. 
4.3.2. Statistical analysis 
A sample size of 144 participants (72 participants/group) was sufficient to detect 
effect size of ≥0.44 SDs on HM LCP concentrations between groups using power of 
80%, type I error of 5%, anticipated attrition of 20%, and ρ=0.50 for the correlation 
between midline and endline measurements. The FA data are presented in mg/L HM 
or blood, as the overall fat content of HM and capillary blood samples could not be 
determined. Data were assessed for equality of variance between groups and 
normality of distribution and log transformation used when necessary. Data were 
summarized using mean (SD) or median (P25, P75) for the continuous variables and 
percentages for the nominal variables. Participant characteristics were compared 
between the HM sub-study sample and the main study sample using t-test and chi-
square test. 
Group differences in HM LCPs concentrations were estimated using a mixed-effects 
linear regression model with the mother as a random intercept to account for 
repeated measurements at the midline and endline assessment. A similar mixed-
effects model was used to assess the relationship in the changes in (DHA + EPA)/AA 
ratios between HM and child blood following the FO intervention. For the latter 
analysis, results are presented separately by the child intervention arms and the 
difference in slope between the two groups was assessed using an interaction term 
between child intervention arm and HM ratios. Models were adjusted for baseline HM 
LCPs concentrations and additional covariates, including household wealth, child age 
and sex, frequency of breastfeeding, maternal age, height, parity and the occurrence 
of pregnancy during study follow-up. For the log-transformed outcomes, the antilog of 
coefficients and CIs were used to express group difference as percent of the control 
group value. 
We followed a modified intention-to-treat analysis which included all mother-infant 
pairs sampled for the HM sub-study and from whom a baseline HM sample was 
available. For this purpose, a multiple imputations procedure under the missing at 
random assumption was employed using chained equations of 50 imputations for the 
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lost-to-follow-up cases. Analysis was conducted using Stata version 14.1 and a two-
sided statistical significance was considered at P value <0.05. 
4.4. Results 
Of the total of 154 mothers who were considered for the HM sub-study at baseline, 
breastmilk samples were available from 129 (83.8%) and 118 (76.6%) mothers at the 
subsequent midline and endline follow-up measurements, respectively (Figure 4.1). 
Baseline characteristics of mothers in the HM sub-study (n = 154) were similar to 
those of mothers in the main trial (n = 360) except that mothers in the sub-study had 
slightly younger infants (Annex 2). Within the HM sub-study, the CO and FO groups 
were comparable in most baseline characteristics. Mothers in the CO group had 
better household wealth status and were slightly taller (Table 4.1). At baseline, 
mothers were on average 25.9 years old (range: 17 - 40 years), had been nursing for 
7.66 months (range: 5.75 - 12.1 months), and 26.6% were primiparous. Median (IQR) 
compliance to daily intake of the maternal capsules (i.e., percent of the actual 
capsules consumed over the prescribed amount of capsules) in the HM sub-study 
was 71.0% (IQR: 51.3, 80.1%) with no significant difference between study groups 
[median (IQR): CO = 67.6% (51.1, 79.6%) vs. FO = 71.7% (54.6, 82.6%); PWilcoxon rank-
sum test = 0.45] (see Table 5.3 in Chapter 5). 
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Table 4.1. Baseline maternal characteristics and HM LCP concentrations1 
Characteristics CO (n = 82)* FO (n = 72)* 
Maternal age, year 25.8 ± 5.43 25.9 ± 4.67 
Child age, month 7.6 ± 1.1 7.7 ± 1.3 
Child sex, female 37 (45.1) 42 (58.3) 
Primiparous  20 (24.4) 21 (29.2) 
Marital status, married 78 (95.1) 70 (97.2) 
Maternal education    
   No formal education 36 (43.9) 41 (56.9) 
   Primary education 34 (41.5) 19 (26.4) 
   Secondary and above 12 (14.6) 12 (16.7) 
Household head education    
   No formal education 26 (31.7) 24 (33.3) 
   Primary education 37 (45.1) 33 (45.8) 
   Secondary and above 19 (23.2) 15 (20.8) 
Household wealth tertiles   
   Lowest 20 (24.4) 33 (45.8) 
   Middle 35 (42.7) 22 (30.6) 
   Highest 27 (32.9) 17 (23.6) 
Breastfeeding frequency   
   4-6 times/day 10 (12.2) 6 (8.33) 
   7-9 times/day 22 (26.8) 16 (22.2) 
   ≥10 times/day 50 (61.0) 50 (69.4) 
Maternal anthropometry    
   Height, cm 158 ± 5.06 156 ± 5.36 
   Weight, kg 50.6 ± 6.48 50.5 ± 7.58 
   Body Mass Index, kg/m2 20.3 ± 2.33 20.8 ± 2.86 
HM LCP   
   DHA, mg/L 70.1 (50.1, 94.3) 74.9 (54.4, 116) 
   EPA, mg/L 24.9 (15.8, 37.3) 24.9 (16.9, 32.8) 
   AA, mg/L 315 (224, 442) 334 (238, 443) 
   AA/∑(DHA, EPA) 3.29 (2.83, 3.59) 3.22 (2.71, 3.70) 
1Data are presented as means ± SDs, n (%), or median (P25, P75). *The control group (CO) included 41 
(50.0%) children, and the intervention group (FO) included 40 (55.6%) children who received an n-3 LCP 
fortified food supplement as part of the child intervention. 
AA, arachidonic acid; CO, control mothers who received placebo corn-oil capsules; DHA, docosahexaenoic acid; 
EPA, eicosapentaenoic acid; FO, intervention mothers who received fish-oil capsules; HM, human milk; LCP, 
long-chain PUFA. 
 
At baseline, there was no significant difference in HM LCP concentrations between 
the study groups (P > 0.10) (Table 4.1). After 6 and 12 months of supplementation, 
however, the DHA concentration in HM was 39.0% (95% CI: 20.6, 57.5%; P < 0.001) 
and EPA concentration was 36.2% (95% CI: 16.0, 56.4%; P < 0.001) higher in the 
FO group compared to the CO group, whereas the AA concentration decreased by 
Chapter 4: Fish-oil Supplementation and Maternal Milk n-3 LCP 
65 
 
17.5% (95% CI: -31.4, -3.74%; P = 0.013) and the AA/(DHA + EPA) ratio by 53.5% 





















Figure 4.2. HM LCP concentrations at baseline, midline and endline of 
intervention in the CO ( ; n = 82) and FO ( ; n = 72) groups. 
Values are expressed as means with their standard error indicated by vertical bars. β (95% CI) for group 
differences in HM LCPs concentration were estimated by fitting a mixed-effects linear model with random 
intercept mother to account for clustering of the midline and endline measurements. Asterisks (*P < 0.05; **P < 
0.01; ***P < 0.001) indicate significant group differences at each measurement-point using a linear regression 
model. Models were adjusted for baseline LCPs values and additional covariates including household wealth, 
duration of lactation, breastfeeding frequency, and maternal age, height, parity and occurrence of subsequent 
pregnancy during follow-up. LCP values were log transformed before analysis and the antilog of coefficients and 
CIs were used to express group differences as percent of the control value. AA, arachidonic acid; CO, control 
mothers who received placebo corn-oil capsules; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FO, 
intervention mothers who received fish-oil capsules; HM, human milk; LCPs, long-chain PUFAs. 
 
The changes in HM and child capillary blood (DHA + EPA)/AA ratios following FO 
supplementation were significantly associated. The association was marginally 
stronger in mother-child pairs where children received no FO in the child intervention 
(β (SE) = 0.25 (0.03); P < 0.001) compared to those who received a FO-fortified food 
supplement in the child intervention (β (SE) = 0.16 (0.03); P < 0.001) (β (SE) for 
interaction = 0.09 (0.04); P = 0.043) (Figure 4.3).
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Figure 4.3. Relationship between the change in HM and child capillary blood 
(DHA + EPA)/AA ratios following the intervention. 
Values are expressed as the difference between midline/endline and baseline as a ratio of baseline values. A 
mixed-effects linear model was fitted to estimate the relationship between HM and child capillary blood ratios, with 
random intercept mother-child pair to account for clustering of the midline and endline measurements. The model 
was adjusted for covariates child age and sex, household wealth, breastfeeding frequency, and maternal age, 
height, parity and occurrence of subsequent pregnancy during follow-up. Data are presented separately for the 
group of mother-child pairs where children did not receive (o & solid line; n = 72) and received (x & dashed line; n 
= 81) FO as part of the child intervention. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid; FO, fish-oil; HM, human milk. 
 
Compared with the global average estimates and other studies (Table 4.2), the 
average DHA concentration in HM of the study mothers was lower both at baseline 
[median (IQR): 74.0 (50.4, 104)] and after FO supplementation [median (IQR): 89.5 
(45.9, 122)]. In contrast, the AA concentration in HM was high at baseline [median 
(IQR): 328 (230, 442)] and normalized towards the global average estimate after FO 
supplementation [median (IQR): 189 (134, 248)].
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Table 4.2. HM DHA and AA concentrations in study mothers compared to global estimates 
provided by meta-analysis of other studies1 
Studies Age range (months) 
 DHA   AA  
 Conc. (mg/L) %TL  Conc. (mg/L) %TL 
Brenna et al. (177) (65 studies from 33 countries) 0.1-18  134* 0.32  197a 0.47  
Fu et al. (178) (78 studies from 41 countries) 0.5-18  147* 0.35  231a 0.55 
Yuhas et al. (176) (9 countries) 1-12  156 0.41  151 0.41 
Current study           
 Before supplementation (FO & CO) 6-12  74.0 na  328 na 
 After supplementation (FO) 18-24  89.5 na  189 na 
1Data are average HM concentrations expressed as the concentration in HM as mg/L (conc. (mg/L)) and as percent total lipids 
as g/100 g HM total lipid (%TL). 
*Values are calculated from percent of total milk FAs assuming 4.2% of HM is composed of FAs(397). 
AA, arachidonic acid; CO, control mothers who received placebo corn-oil capsules; DHA, docosahexaenoic acid; FA, fatty 




We investigated the effect of n-3 LCPs-rich fish-oil supplementation of mothers 
during lactation (6-24 months postpartum) on HM LCP concentrations. Fish-oil 
supplementation resulted in significantly higher HM DHA and EPA concentrations 
and a lower AA/(DHA + EPA) ratio compared to the placebo group. Although fish-oil 
supplementation prevented the decline in HM n-3 LCP concentrations over time, 
which was observed in the placebo group, the daily dose of 500 mg n-3 LCPs (215 
mg DHA + 285 mg EPA) did not result in HM DHA concertation comparable to the 
worldwide norms. A review of previous trials on maternal supplementation using fish-
oil (i.e., DHA + EPA) or DHA alone during lactation showed similar results of 
improved HM n-3 LCPs status (197). 
Due to the lack of a clear consensus on the optimal concentrations in HM, current 
recommendation on DHA intake by lactating mothers is based on observed intake 
levels in previous studies that were required to enrich HM to the global mean DHA 
value of 0.32% TL (~ 134 mg/L) (95,173). A dose of 200 mg DHA/d increased DHA in 
HM from 0.21% TL to the global average when consumed during 4-6 weeks (198) 
and 5 days-12 weeks postpartum (398). HM DHA concentration (89.5 mg/L) in our 
study mothers remained below the global average after receiving a similar dose. The 
relatively smaller increase in our study may relate to different factors. Mainly, the 
stage of lactation is an important difference between the current study and most 
previous studies with stronger impact. Compared to this study, supplementation in 
the other studies usually started no later than a few weeks postpartum and lasted for 
a shorter period. Decline in HM DHA levels over the course of lactation has been 
Chapter 4: Fish-oil Supplementation and Maternal Milk n-3 LCP 
68 
 
described previously including in mothers enrolled in supplementation studies 
(184,186,399–402). Therefore, the relatively lower HM DHA enrichment in our study 
might be due to maternal depletion concurring with the intervention period; i.e., the 
relatively later start at 6 to 12 months postpartum as well as the longer follow-up 
period of up to 24 months postpartum. 
Our results also raise the question of whether current intake recommendation for 
lactating women – which is mainly based on dose-response curves of maternal DHA 
intake and HM levels derived from short-term studies (398) – may need 
reconsideration using data from studies covering the whole period of lactation. A 
higher dose than the recommended intake may be required to achieve optimum HM 
concentrations in this and similar populations, especially during the period of late 
lactation. A previous study using two different doses of DHA supplementation also 
supports this supposition (403). In this study, although dosages of both 200 and 400 
mg DHA/d significantly increased HM DHA compared to a placebo, an average HM 
DHA concentration closer to the global mean was achieved only in the group of 
mothers who received the higher dose of 400 mg/d (HM DHA in placebo vs. 200 vs. 
400 mg DHA/d groups: 58.7 vs. 88.3 vs. 131 mg/L). On the other hand, the safety of 
a very high n-3 LCPs intake through consumption of sea fish or fish-oil supplements 
should be considered carefully with respect to a potential dietary exposure of 
contaminants such as methylmercury and dioxins in the mother and her child during 
pregnancy and lactation (173). 
The extent of HM enrichment following supplementation may also be influenced by 
factors that can affect PUFA metabolism and their transfer to breastmilk or 
elsewhere. Competition between the n-3 and n-6 FA families occurs not only in the 
synthesis of the LCPs from their respective precursors, but also in their incorporation 
into tissues (67,404). The basal AA concentration in HM of the study mothers was 
very high compared to the global mean, albeit within the range of values reported in 
different populations (177,178). The reason for this high value is not clear as intake 
of AA sources – like meat and eggs – is limited in the study area. Alternatively, milk 
AA mainly comes from maternal AA stores (405,406), which in turn could have been 
influenced by long-term high dietary LA intake, possibly from vegetable oils and 
cereals like maize in the staple foods. Studies showed that a high dietary LA intake 
can inhibit the incorporation of preformed DHA into milk lipids (67), which might have 
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potentially attenuated the uptake of supplementary DHA. Additionally, effects of an 
intervention could be modulated by single nucleotide polymorphisms that are 
commonly observed in the FADS gene cluster, suggesting the need for consideration 
of possible differences in the distribution of these gene variants while comparing 
results from different populations. A study in the Netherlands showed that the FADS 
genotype modifies the effect of maternal fish and fish-oil intake on HM DHA 
proportions, possibly due to limited incorporation into breastmilk in women with some 
gene variants (407). Currently, there is no information available on the distribution of 
polymorphisms in the FADS gene cluster in the Ethiopian population. However, the 
very high milk AA in our mothers is not indicative of an important role of genetic 
polymorphism as these gene variants are generally expected to have more effects on 
HM levels of the n-6 than the n-3 PUFAs (98). 
The significant association observed in the changes in n-3/ n-6 LCPs ratio between 
the maternal milk and child capillary blood following the intervention shows that the 
increased maternal dietary n-3 LCP intake improved the status of their breastfed IYC. 
Other studies also noted positive correlations between HM concentrations and child 
n-3 LCP status (402,408) as well as improved child status following supplementation 
of their lactating mothers (409,410). 
The low maternal DHA status in this setting corroborates the findings of previous 
reports on the very low availability of n-3 FA in the Ethiopian diet (174,175). It is also 
an indication of potential risk of a suboptimal status in their breastfed IYC who live in 
a setting where the complementary foods have a negligible contribution to n-3 LCPs 
intake (179). The present study showed the potential of consumption of additional 
DHA by lactating mothers for improving the content in HM and the status of their 
breastfed children. Maternal supplementation with fish-oil or other sources of 
preformed n-3 LCP is one potential intervention approach in Ethiopia considering the 
good coverage of breastfeeding (190) and the challenges of securing adequate 
access to marine foods in one of the world’s most populous land-locked country. 
This study is limited by the absence of maternal dietary intake data which would have 
aided in the interpretation of the effect of the studied doses of DHA and EPA on HM 
concentrations and our understanding of the unexpectedly high AA concentration in 
HM in this population. Furthermore, we were unable to provide the overall fat content 
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of samples due to laboratory procedures and interference from fatty acids coming 
from plastic test tubes. On the other hand, our study had a large sample size and 
relatively low dropout rate compared to similar studies (197).  
4.6. Conclusion 
We demonstrated that fish-oil supplementation of mothers during lactation increased 
HM DHA and EPA content and improved the status of their breastfed children. 
However, HM DHA concentrations of lactating mothers remained lower than 
international norms even after supplementation. It is recommended that future 
studies evaluate different doses of n-3 LCP covering a longer period of lactation as 
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Background: Recurrent infections and inflammation contribute to growth faltering in 
low-income countries. n-3 LCPs may improve immune maturation, resistance to 
infections, and growth in young children who are at risk. 
Objective: We evaluated the independent and combined effects of fish-oil (500 mg 
n–3 LCPs/d) supplementation to lactating mothers and their breastfed children, aged 
6–24 months, on child morbidity, systemic inflammation, and growth in southwest 
Ethiopia. 
Design: A 4-arm double-blind randomized controlled trial was conducted by enrolling 
360 mother-infant pairs with infants 6–12 months old. Study arms were both the 
lactating mother and child receiving fish-oil intervention (MCI), only the lactating 
mother receiving fish-oil intervention and child receiving placebo control (MI), only the 
child receiving intervention and mother receiving placebo control (CI), and both 
mother and child receiving a placebo supplement or control (C). The primary study 
outcome was linear growth using monthly changes in length-for-age z score. 
Anthropometric measurements were taken monthly, and hemoglobin, C-reactive 
protein, and blood LCPs were measured at baseline and after 6 and 12 months of 
follow-up. Weekly morbidity surveillance was conducted throughout the study. 
Results: Fish-oil supplementation significantly increased blood n-3 LCP 
concentration (P < 0.01) and decreased the AA/(DHA + EPA) ratio (P < 0.001) in all 
intervention arms. No significant intervention effect was found on linear growth, 
morbidity, or systemic inflammation. Compared to the control group, a small positive 
effect on monthly changes in weight-for-length z scores was found in the CI arm 
(effect size (95% CI): 0.022/month (0.005, 0.039/month); P = 0.012) and the MCI arm 
(effect size (95% CI): 0.018/month (95% CI: 0.001, 0.034/month); P = 0.041). 
Conclusions: n-3 LCP supplementation of lactating mothers and children did not 
affect child linear growth and morbidity in a low-income setting. n-3 LCP 
supplementation given directly to children modestly increased relative weight gain. 
This trial was registered at clinicaltrials.gov as NCT01817634. 




Stunting occurs in more than a third of children in sub-Saharan Africa and accounts 
for 21% of disability-adjusted life years in the region (3,7). Recurrent infections affect 
energy and nutrient intake and expenditure, compromising child growth (411,412). 
Stunting is associated with environmental enteric dysfunction (EED), a chronic 
inflammation of the small intestine that impairs absorptive capacity and barrier 
functions with subsequent immunostimulation (413,414). The high prevalence of EED 
in children in LICs may explain the lack of large effects from the various nutrition-
specific interventions to prevent child stunting (323). 
n-3 LCPs are known to modulate immune cell functions and inflammatory processes 
(349–351,415), which may lead to a more rapid maturation of the immune system, 
and improved intestinal wall integrity and resistance to infectious diseases in young 
children. In vitro and animal experiments have shown that n-3 LCPs may increase 
intestinal barrier function (325) and enhance recovery of intestinal tissues after 
inflammation (326,327). Dietary LCP supplementation of formula-fed infants (353–
355), older children (356,357), and infants with prenatal maternal supplementation 
(358) led to clinical benefits in both inflammatory and infectious conditions. However, 
there is limited evidence on the impact of n-3 LCP supplementation on breastfed 
children in LICs characterized by very poor hygienic conditions and a high burden of 
infectious diseases. 
The evidence of the impact of n-3 LCP supplementation on child growth is mainly 
based on studies in HICs (212,221,416). Only one study, to our knowledge, 
evaluated the efficacy of fish-oil supplementation to infants in an LIC and found no 
notable effect on growth and morbidity (291). However, the trial was conducted in 
infants with a high intake of n-3 LCPs from breastmilk. Yet a trial in Ghana found that 
a lipid-based nutrient supplement containing ALA, the precursor of n-3 LCPs, had an 
effect on child linear growth that was attributed to the higher plasma n-3 PUFA in the 
intervention group (417). Observational studies in the Congo and Brazil also showed 
that infant growth was positively associated with breastmilk n-3 PUFA concentration 
(418,419). In settings where the intake of n-3 LCP is low and chronic 
immunostimulation contributes to poor growth, an increased n-3 LCP intake could 
improve child growth. 
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HM is the predominant source of n-3 LCPs for infants in LICs (169,174). However, 
the breastmilk concentration of n-3 LCPs is influenced by maternal intake of marine 
foods, which are unavailable to rural populations living far from coastal areas as in 
Ethiopia (95,174,176,177,404,420). In Ethiopia, the total dietary n-3 PUFA supply is 
below the recommended amount for IYC, which poses a further risk as children 
transfer to complementary diets (174). In this study, we hypothesized that increased 
intake of n–3 LCPs through HM and/or complementary food would result in reduced 




The trial was carried out from November 2013 to February 2015 in 3 districts of 
Jimma zone in southwest Ethiopia located 300 km from the capital, Addis Ababa. 
The area lies in a midland agroclimatic zone where subsistence farming is the 
predominant form of livelihood for the population. The main crops produced in the 
area are maize, hot pepper, and teff (a species of Eragrostis native to Ethiopia), and 
staple foods are very low in n-3 LCPs. 
Study participants were identified from the Gilgel Gibe HDSS, which registers all 
births in the study area, and through an additional census conducted by the study 
team. Mothers with infants were invited to a nearby school in each of the 3 study 
districts to be screened for study eligibility. Mothers with a singleton infant of age 6–
12 months were eligible if the infant was not wasted (weight-for-length z score (WLZ) 
≥ −2 SD and presented no bilateral pitting edema), was being breastfed, and the 
mother declared having no intention of leaving the study area for >1 month over the 
coming year. Exclusion criteria included infants or mothers with known chronic illness 
or medical treatment for this purpose, infants with a congenital abnormality that could 
affect feeding or growth, or with severe anemia (hemoglobin <7.0 g/dL), and children 
or mothers taking a nutritional supplement other than the ones provided by the 
project at enrollment or during the follow-up period. 
5.3.2. Study design 
This study was a randomized, double-blind, placebo controlled trial involving child n-3 
LCP supplementation through lactation (maternal intervention) and/or through 
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supplementary feeding (child intervention). Mothers were randomly allocated to 
receive either intervention capsules containing fish-oil or placebo capsules of 
identical appearance containing corn oil. Children of the same mothers were 
randomly allocated to receive either an intervention food supplement containing fish-
oil or the same food supplement without fish-oil as control. Thus, there were 4 study 
arms: lactating mother and child both receiving fish-oil intervention (MCI); only the 
lactating mother receiving fish-oil intervention and child receiving placebo control 
(MI); only the child receiving fish-oil intervention and mother receiving placebo control 
(CI); and both mother and child receiving a placebo supplement or control (C). 
A statistician who was not part of the research team generated a randomization 
scheme for the allocation of the maternal and child interventions. Each unique 
randomization number was randomly allocated to 1 of 6 letter codes for the maternal 
intervention (A, E, I, J, L, T)- 3 letters each for the intervention and the control group- 
using a computer program in permuted blocks. The randomization procedure was 
repeated for the child intervention by randomly allocating each randomization number 
to 1 of 6 letter codes representing the child intervention (B, K, P, V, Y, Z). The 
maternal capsules and the child food supplements were prepared in packages 
containing monthly supplies, and labeled with one of their corresponding letter codes 
by a person not involved in the study. Information regarding the assignment of the 
letter codes to the intervention and control supplements was sealed in an opaque 
envelope and sent to the study director (PK), who locked the envelope away until 
analysis was completed. Before the study started, 2 researchers (AA, MW) sealed 
each of the randomization numbers with the corresponding letter codes of the 
maternal and child interventions into separate opaque envelopes that were marked 
with unique participant numbers to be attributed at study inclusion. At study inclusion, 
a researcher opened the next sealed envelope in the presence of an eligible mother-
child pair (in order of arrival), provided them with the first monthly dose of the 
maternal and child supplements corresponding to the letter codes, and filled out the 
study participation card.


















Figure 5.1. Trial flowchart 
C, both mother & child received placebo; CI, child received fish-oil & mother received placebo; MCI, both mother 
& child received fish-oil; MI, mother received fish-oil & child received placebo. 
 
5.3.3. Interventions 
The maternal intervention consisted of identical airtight gel capsules containing either 
fish-oil (intervention) or corn oil (placebo). Both the intervention and placebo maternal 
supplements were provided by Biover NV. A daily dose of the intervention capsules 
contained 500 mg n-3 LCPs [215 mg DHA + 285 mg EPA]. Each capsule additionally 
contained 5 mg of d-α-tocopherol, an antioxidant. Supplements were packaged in 
small nontransparent polystyrene containers containing a monthly supply of 60 
capsules. 
Assessed for eligibility (n = 413) 
Excluded (n = 53) 
Ineligible (n = 36) 
Refused (n = 17) 
Allocated to C        
(n = 90) 
Randomly assigned (n = 360) 
Lost to follow-up  
(n = 8) 
Included in analysis 
For monthly outcomes  
(n = 89) 
For midterm & endline 
outcomes (n = 83) 
Allocated to MI    
(n = 89) 
Allocated to CI    
(n = 90) 
Allocated to MCI 
(n = 91) 
Lost to follow-up   
(n = 10) 
Lost to follow-up   
(n = 19) 
Lost to follow-up   
(n = 10) 
Included in analysis 
For monthly outcomes  
(n = 88) 
For midterm & endline 
outcomes (n = 82) 
Included in analysis  
For monthly outcomes  
(n = 86) 
For midterm & endline 
outcomes (n = 78) 
Included in analysis 
For monthly outcomes  
(n = 89) 
For midterm & endline 
outcomes (n = 86) 
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The child food supplements were produced by Michiels Fabrieken NV and consisted 
of an extruded corn-soy blend fortified with 19 micronutrients. Both the intervention 
and control food supplements were designed to provide energy and fat equivalent to 
half of the estimated average requirement and micronutrients at a dose of the 
recommended nutrient intake from complementary foods for an 11-months-old infant 
(Table 5.1). Iron was added at a lower dose of 12.5 mg/d. The intervention food 
supplement was additionally enriched with microencapsulated fish-oil, providing a 
daily dose of 500 mg n-3 LCPs (169 mg DHA + 331 mg EPA). The 
microencapsulation of the fish-oil reduced the fishy smell and taste, and minimized 
oxidation of n-3 LCPs. Monthly supplies of the food supplements were packaged 
using nontransparent bags with a protective aluminum coat and with nitrogen injected 
into the internal atmosphere to prevent oxidation. 
The dosage of n-3 LCP in the intervention supplements was designed to achieve a 
substantial increase in blood n-3 LCP (291,421) and took into consideration the 
factorial design where we preferred children not to be exposed to doses >1 g n-3 
LCP. The provision of multimicronutrient-fortified food supplements for children in 
both the control and intervention groups was considered to avoid any hampering 
effect of energy and micronutrients deficiencies on the impact of n-3 LCP 
supplementation. 
Study supplements were transported in a cold chain (6°C) and stored in a cold room 
(<16°C) at Jimma University until distribution. Supplementation was provided for a 
total duration of 12 months through monthly distribution schedules. Mothers were 
instructed to take a daily dose of 2 capsules and provide their child a daily dose of 2 
spoons (±40 g) of the food supplement mixed with preboiled water. They were 
advised to keep the supplement packages closed in a cool and dark place and avoid 
direct cooking of the food supplements.  
Weekly home-visits were conducted by trained project community workers to provide 
counseling on breastfeeding and preparation of supplementary foods, and monitor 
compliance with supplementation. Compliance with the maternal intervention was 
measured by counting the remaining capsules in the supplement container and 
asking mothers about their frequency of breastfeeding during the day prior to the 
home-visit. Child compliance was assessed by collecting weekly data on the amount 
Chapter 5: n-3 LCP Supplementation and Child Growth and Morbidity 
78 
 
of supplementary food remaining in the food bag, i.e., full, three-quarters full, one-half 
full, or empty. Leftover supplements from the previous month were collected during 
the monthly distributions of new supplies.  
Table 5.1. Nutritional composition of daily rations (40 g) of food supplements 
Nutrients Intervention supplement Control supplement 
Energy (kcal) 165 160 
Energy (kJ) 693 671 
Protein (g) 5.9 5.1 
Carbohydrates (g) 24.4 26.1 
Fat (g) 4.7 3.6 
DHA (mg) 169 0.0 
EPA (mg) 331 0.0 
Calcium (mg) 421.8 412.4 
Selenium (μg) 12.3 12.4 
Magnesium (mg) 82.6 79.6 
Zinc (mg) 8.8 8.4 
Iron (mg) 12.7 12.3 
Iodine (μg) 94.4 94.3 
Vitamin C (mg) 30.7 29.8 
Thiamine (mg) 5.7 6.1 
Riboflavin (mg) 0.4 0.5 
Niacin (mg NE) 5.5 5.0 
Vitamin B6 (mg) 0.4 0.3 
Pantothenic acid (mg) 1.9 1.8 
Biotin (μg) 6.7 6.3 
Vitamin B12 (μg) 0.7 0.7 
Folate (μg DFE) 109.5 112.4 
Vitamin A (μg RE) 447.0 458.2 
Vitamin D (IU) 208.5 216.9 
Vitamin E (mg α-TE) 4.2 4.5 
Vitamin K (μg) 9.1 9.9 
1Intervention supplement, corn-soy blend fortified with 19 micronutrients and fish-oil; control 
supplement, corn-soy blend fortified with multiple micronutrients and without fish-oil. 
DFE, dietary folate equivalents; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; NE, niacin 
equivalents; RE, retinol equivalents; TE, tocopherol equivalents. 
 
 
Children in all study arms received deworming medication (500 mg mebendazole) at 
the age of 12 and 18 months. Children and mothers with any illness were referred to 
the nearby health post with a referral slip for the local health extension workers, 
whereas the presence of any danger sign or suspected potential adverse event was 
immediately reported to the researchers.
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5.3.4. Ethical consideration 
The study protocol was approved by the Ethics Committee of Ghent University 
Hospital in Belgium (registration number B670201214299), the Institutional Review 
Board of Jimma University in Ethiopia, and the National Health Research Ethics 
Committee of Ethiopia. The use of study supplements was approved by the Food, 
Medicine and Health Care Administration and Control Authority of Ethiopia. At the 
start of the trial, written consent was obtained from eligible mothers after an individual 
information session detailing the study, voluntary participation and study withdrawal 
in the presence of a community member. The trial was registered at clinicaltrials.gov 
as NCT01817634. 
5.3.5. Outcomes 
The primary study outcome was linear growth as measured by the monthly change in 
length-for-age z score (LAZ) over the 12-months intervention follow-up. Secondary 
outcome measures included monthly changes in WLZ, midupper arm circumference 
(MUAC), and head circumference (HC); the longitudinal prevalence of diarrhea, 
vomiting, fever, acute respiratory illnesses, and any illness that required medical 
attention during the intervention period; the longitudinal development of stunting (LAZ 
<–2), wasting (WLZ <–2), anemia, and systemic inflammation, and blood LCPs 
concentrations at midterm (after 6 months of intervention) and at endline (after 12 
months of intervention). 
5.3.6. Field measurements 
Child anthropometry was recorded monthly at the 3 study sites by teams of trained 
data collectors using calibrated equipment and standardized techniques (422). All 
measurements were done in duplicate by 2 different teams and written down on 
separate forms so that the first measurement could not influence the second. A study 
data-quality manager then compared the duplicate measurements and both teams 
repeated the measurement when there was a difference of ≥0.5 kg for weight, ≥1.0 
cm for length, and ≥0.5 cm for MUAC and HC measurements. Length was measured 
in the recumbent position to the nearest 1 mm using a portable foldable length board 
(SECA 417). Weight measurements were taken together with the mother using an 
electronic scale (SECA 876) to the nearest 50 g. Flexible, non-stretchable measuring 
tapes were used to measure HC (SECA 212) and MUAC (MUAC S0145610, 
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UNICEF) to the nearest 1 mm. Child age was estimated using date of birth data from 
the Gilgel Gibe HDSS, which typically records the dates of birth during the neonatal 
phase. For study sites outside the catchment of the HDSS (16% of the participants), 
date of birth was either copied from birth certificate or recalled using a local events 
calendar. 
Hemoglobin and C-reactive protein (CRP) concentrations were measured on site 
from a single finger prick blood sample by using a QuickRead go instrument (Orion 
Diagnostica) that was calibrated using control kits at the start of every measurement 
day. Anemia was defined as having a hemoglobin concentration <11.0 g/dL and the 
presence of systemic inflammation by a CRP concentration ≥5 mg/L (423). 
Structured questionnaires and observation forms were used to collect morbidity data 
through weekly home-visits. Trained project community workers interviewed mothers 
to estimate the number of days since the last visit, typically during the previous 7 d, 
that the child experienced diarrhea, cough, and vomiting. Diarrhea was defined as 
the occurrence of ≥3 liquid or semisolid stools within a day. The occurrence of an 
illness that required medical attention (hospital or health center visits) was also 
recalled as a proxy for serious illness. Children were assessed for runny nose, fever, 
tachypnea, and difficulty of breathing (grunting or chest indrawing) during each home 
visit. Fever was defined as having an armpit body temperature of ≥37.5°C; tachypnea 
as having a respiratory rate of ≥50 breaths/min for infants and ≥40 breaths/min for 
older children (>12 months). Pneumonia was diagnosed by the concurrent presence 
of cough and tachypnea. Household wealth and hygiene status were assessed by a 
structured questionnaire and observation checklist adapted from the Ethiopian DHS 
wealth index items (190) and a simple hygiene index tool (424). 
Community workers, all female high-school graduates from the local communities, 
were recruited to conduct the weekly follow-up home visits for compliance 
assessment and morbidity surveillance. They received intensive training at the start 
of the study and refresher trainings during the monthly distribution schedules. The 
research team supervised community workers through unannounced monthly home 
visits applying the Lot Quality Assurance Sampling approach (425). Every mother-
child dyad had a study participation card that community workers would sign off after 
a home visit. During the supervision home visits, the number of capsules and the 
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amount of supplementary food would be counted and estimated and compared to the 
weekly report of the community worker. The morbidity record of the community 
workers was also compared against morbidity data collected by study nurses at the 
monthly distribution schedules. 
5.3.7. Child LCPs status 
The procedures for child whole blood samples collection using dried blood spot cards 
and determination of LCPs concentration by gas chromatography are described in 
Chapter 4. 
5.3.8. Statistical analyses 
A sample size of 360 subjects (90/study arm) was required to detect an effect size of 
0.027 on average monthly LAZ changes over the 12 months of follow-up with a 
statistical power of 80%, a type I error of 5%, an anticipated attrition of 20%, and 
assuming a ρ = 0.50 correlation among the repeated monthly measurements (426). 
For the blood LCP analysis, a subsample size of 168 subjects (42 for each study 
arm) enables us to detect an effect size of ≥0.58 on blood LCP concentrations with a 
statistical power of 80%, a type I error of 5%, an anticipated attrition of 20%, and 
assuming a ρ = 0.50 correlation between the midterm and endline measurements. 
Continuous double data entry was performed using EpiData version 1.4.4.4 (EpiData 
Association). Consistency checks and data analyses were conducted using Stata 
version 13.1 (StataCorp LLC, Texas, USA). The average value of the duplicate 
anthropometry measurements was used for analysis, and LAZ and WLZ scores were 
calculated based on the WHO 2006 Child Growth Standards (427).  
Growth curves were fitted for the difference from baseline of the monthly 
anthropometric measurements using a linear mixed-effects model that included child 
as random intercept and intervention exposure time as random slope. Fixed effects 
included intervention group, intervention time, quadratic time, and the interaction 
between intervention group and time; these compare each intervention arm with the 
control arm on monthly linear growth over time. For the outcomes assessed at 
baseline, midterm, and endline, we fitted a mixed-effects linear probability model with 
child level as a random intercept, whereas fixed effects included intervention group, 
intervention time, and the interactions between intervention group and time to 
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compare study arms by the development of an outcome over the 3 measurement 
points. For LCP measurements, a mixed-effects linear model with random intercept 
child was used to estimate the main effect of intervention group on the midterm and 
endline measurements adjusted for the baseline measurement. The main effect of 
time and time by group interactions were not considered in this model because blood 
concentrations reach a level of saturation after only few weeks of supplementation. 
Percentage change from the baseline measurement was also calculated for LCPs 
measurements. We applied log transformations to normalize the heavily skewed LCP 
distributions before analysis. We preferred the use mixed-effects model because it 
allows the use of observations with different length of time between follow-ups; can 
take into account subjects with incomplete data where measurements were missed 
for some follow-up points; and its more robust assumption regarding missing data 
where missing observations are assumed to be missing at random as compared to 
other approaches for analysis of longitudinal data such as multivariate analysis of 
variance and generalized estimating equation . 
Longitudinal prevalence of morbidity outcomes during follow-up were calculated 
using as numerator the total number of days that the outcome was positive, and as 
denominator the total days reported or assessed (428). We used a negative binomial 
regression model to compare the impact of the interventions between study arms, 
adjusting for the total days reported or assessed. Compliance and breastfeeding 
frequency during the study follow-up were compared among study arms using 
Fisher’s exact test for the categorical variables and the Kruskal-Wallis test for the 
continuous variables. 
In the presence of a statistically significant overall group difference, pairwise 
comparisons of each intervention arm against the control arm were conducted, 
adjusting for false discovery rate using the Benjamini-Hochberg method (429). 
Analyses were done based on the intention-to-treat principle, using all children 
initially enrolled into the study. For this purpose, a multiple chained equations data 
imputation was conducted under the “missing at random” assumption. Fifty 
imputations of missing data for cases lost to follow-up were run to estimate the 
regression coefficients. The use of the intention-to-treat principle is one of the most 
accepted analysis strategy for randomized controlled trials recommended by the 
CONSORT statement for clinical trials.. Analysis of all individuals initially randomized 
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allows maintenance of comparability between study groups obtained through the 
randomization, maintains sample size and prevents potential bias due to study 
withdrawal that might relate to the intervention or study outcomes. Compared to the 
per-protocol analysis (i.e. restricting analysis to subjects who complied with the 
intervention), the intention-to-treat analysis can be more conservative and may 
underestimate the potential effect of an intervention because of the inclusion of 
subjects who did not adhere to the intervention. However, the results obtained from 
intention-to-treat analysis can be considered as a representative of what would have 
been found from an intervention in a practical setting. The use of multiple imputation 
approach to the problem of missing data is a proven method of imputation taking into 
account the uncertainty of the estimates by creating several plausible imputed 
datasets and appropriately combining results obtained from each dataset.  
All models were adjusted for sex of the child due to the imbalance among study arms 
at baseline. We also assessed for interactions between child sex and intervention 
group on the study outcomes. All statistical tests were 2-sided with statistical 
significance set at α < 5%.
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Table 5.2. Baseline characteristics of study participants1 
Characteristics C (n = 90) MI (n = 89) CI (n = 90) MCI (n = 91) 
Sex, Females  42 (46.7) 49 (55.1) 36 (40.0) 54 (59.3) 
Age (months) 8.89 ± 2.16 9.18 ± 2.09 8.93 ± 2.10 8.68 ± 2.00 
Maternal age (yrs) 26.0 ± 5.04 25.8 ± 4.82 26.1 ± 5.48 26.3 ± 5.28 
Maternal education     
 
   No formal education 42 (47.2) 44 (50.6) 45 (54.2) 47 (53.4) 
   Primary education 36 (40.5) 29 (33.3) 25 (30.1) 31 (35.2) 
   Secondary and above 11 (12.4) 14 (16.1) 13 (15.7) 10 (11.4) 
Household wealth tertiles    
 
   Lowest 26 (29.2) 33 (37.9) 27 (32.5) 30 (34.1) 
   Middle 30 (33.7) 25 (28.7) 30 (36.1) 31 (35.2) 
   Highest 33 (37.1) 29 (33.3) 26 (31.3) 27 (30.7) 
Hygiene score tertiles    
 
   Lowest 30 (34.1) 26 (30.2) 29 (34.5) 30 (34.5) 
   Middle 31 (35.2) 29 (33.7) 30 (35.7) 25 (28.7) 
   Highest 27 (30.7) 31 (36.1) 25 (29.8) 32 (36.8) 
Maternal height (cm) 157 ± 4.67 157 ± 5.55 157 ± 5.95 157 ± 5.74 
Maternal BMI (kg/m2) 20.2 ± 2.41 20.3 ± 2.50 20.1 ± 2.57 21.0 ± 3.31 
Breastfeeding during previous day    
 
   4-6 times/day 10 (11.1) 6 (6.74) 11 (12.2) 8 (8.89) 
   7-9 times/day 21 (23.3) 28 (31.5) 26 (28.9) 23 (25.6) 
   > 10 times/day 59 (65.6) 55 (61.8) 53 (58.9) 59 (65.6) 
Anthropometric indices      
   Length-for-age z-score -0.99 ± 1.07 -1.03 ± 1.10 -1.08 ± 1.15 -0.97 ± 1.11 
   Weight-for-length z-score 0.26 ± 0.94 0.18 ± 1.04 0.06 ± 0.99 0.09 ± 0.93 
   Head circumference (cm) 44.1 ± 1.79 43.9 ± 1.68 44.0 ± 1.70 43.7 ± 1.71 
   Mid-upper arm circumference (cm) 14.1 ± 1.06 14.0 ± 1.04 13.9 ± 1.15 13.9 ± 1.07 
1Values are expressed as n (%) or mean ± SD.  
BMI, body mass index; C, both mother and child received placebo; CI, child received fish-oil and mother received 
placebo; MCI, both mother and child received fish-oil; MI, mother received fish-oil and child received placebo. 
 
5.4. Results 
From a total of 413 mother-infant pairs screened, 360 were randomly assigned into 
the C (n = 90), MI (n = 89), CI (n = 90), and MCI (n = 91) intervention arms (Figure 
5.1). Three-hundred thirteen (87%) participants completed all 12 months of 
intervention follow-up (C: 91%, MI: 89%, CI: 79%, MCI: 89%). Analyses were based 
on all children with ≥1 follow-up measurement for an outcome, which included 352 
(98%) of children initially randomly assigned into the study for the monthly 
anthropometry outcomes and 329 (91%) children for the outcomes assessed at 
midterm and endline. Study arms were comparable on baseline characteristics of 
participants except that there was an imbalance in child sex (Table 5.2).
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Table 5.3. Compliance to maternal and child interventions by study arms 
Variable  C MI CI MCI P1 
Breastfeeding frequency, n(%)     
   1-3 times/day 0 (0.00) 2 (2.25) 0 (0.00) 5 (5.49)  
0.084    4-6 times/day 12 (13.3) 13 (14.6) 17 (18.9) 8 (8.79) 
   7-9 times/day 61 (67.8) 50 (56.2) 54 (60.0) 57 (62.6) 
   > 10 times/day 17 (18.9) 24 (27.0) 19 (21.1) 21 (23.1) 
Capsules compliance2, n(%)      
   0-25 6 (6.67) 9 (10.1) 13 (14.4) 8 (8.79)  
0.440    26-50 9 (10.0) 10 (11.2) 14 (15.6) 15 (16.5) 
   51-75 41 (45.6) 40 (44.9) 29 (32.2) 31 (34.1) 
   76-100 34 (37.8) 30 (33.7) 34 (37.8) 37 (40.7) 
   Median (IQR) 70.5 (60.6, 79.6) 65.3 (54.7, 81.0) 67.4 (41.8, 81.0) 72.8 (51.4, 82.6) 0.340 
Food supplement compliance2, n(%)      
   0-25 1 (1.11) 3 (3.37) 5 (5.56) 2 (2.20)  
0.700    26-50 8 (8.89) 9 (10.1) 9 (10.0) 12 (13.2) 
   51-75 22 (24.4) 24 (27.0) 25 (27.8) 29 (31.9) 
   76-100 59 (65.6) 53 (59.6) 51 (56.7) 48 (52.8) 
   Median (IQR) 84.1 (67.4, 91.8) 81.0 (62.3, 92.4) 79.0 (62.3, 89.9) 77.4 (59.6, 91.8) 0.450 
1P-values for group difference were obtained from Fisher's exact test for the categorical variables and 
Kruskal-Wallis test for the continuous variables.  
2Compliance is defined as the ratio of the total number of capsules or estimated amount of food 
supplement actually consumed over the total number of capsules or amount of food supplement 
prescribed. 
 
5.4.1. Compliance and effects on LCPs status 
Overall mean ± SD supplementation duration was 11.0 ± 2.88 months, with 11.2 ± 
2.68 months in C, 11.2 ± 2.65 months in MI, 10.4 ± 3.56 months in CI, and 11.3 ± 
2.45 months in MCI intervention arms. Compliance, i.e., the ratio of actual 
supplement consumption over prescribed supplement consumption, was similar 
among study arms for both the child and the maternal supplements (Table 5.3). 
Median (IQR) compliance was 79.7% (IQR: 62.6%, 91.4%) for the child food 
supplements and 69.9% (IQR: 52.2%, 80.4%) for the maternal capsules. The 
average frequency of breastfeeding during the study follow-up was ≥7 times/d in 
84.2% of the study participants with no significant difference among intervention 
arms.
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Table 5.4. Blood LCPs concentration (mg/L) at midterm and endline by study 
arms1 
Outcomes 





Mean ± SD Mean ± SD     
DHA       




Reference group  1.73 
 MI (n = 35) 58.8 ± 23.1 62.6 ± 23.5 13.4 (5.35, 21.4) 0.001* 16.3 
 CI (n = 41) 62.57 ± 24.4 53.3 ± 22.4 10.5 (2.51, 18.5) 0.010* 19.9 
 MCI (n = 46) 63.5 ± 23.1 61.0 ± 18.6 14.2 (6.63, 21.7) <0.001 14.9 
EPA3       




Reference group  35.1 
 MI (n = 35) 8.03 (5.67, 10.5) 7.13 (5.70, 11.3) 1.88 (0.96, 3.68) 0.064 58.9 
 CI (n = 41) 10.0 (6.68, 18.7) 9.78 (7.08, 12.3) 2.97 (1.55, 5.67) 0.001* 116 
 MCI (n = 46) 13.3 (7.55, 22.9) 10.9 (6.70, 16.0) 4.58 (2.44, 8.57) <0.001 129 
N-3 LCP (DHA + EPA)      




Reference group  11.7 
 MI (n = 35) 67.85 ± 26.7 71.3 ± 27.0 15.1 (5.32, 25.0) 0.003* 21.5 
 CI (n = 41) 76.5 ± 32.4 63.9 ± 27.0 15.9 (6.17, 25.6) 0.001* 26.6 
 MCI (n = 46) 80.1 ± 30.9 74.6 ± 25.3 21.5 (12.4, 30.7) <0.001 30.7 
AA       




Reference group  -3.16 
 MI (n = 35) 215 ± 63.6 237 ± 84.6 1.19 (-20.2, 22.6) 0.913 -9.35 
 CI (n = 41) 216 ± 62.0 191 ± 79.5 -22.9 (-43.4, -2.31) 0.029* -13.3 
 MCI (n = 46) 200 ± 58.8 210 ± 55.7 -23.3 (-43.6, -3.01) 0.024* -16.9 
AA/(DHA+ EPA)       




Reference group  1.29 
 MI (n = 35) 3.36 ± 0.83 3.42 ± 0.84 -0.92 (-1.30, -0.54) <0.001 -21.7 
 CI (n = 41) 3.08 ± 0.84 3.26 ± 0.97 -1.17 (-1.54, -0.80) <0.001 -29.1 
 MCI (n = 46) 2.71 ± 1.10 3.04 ± 0.91 -1.45 (-1.81, -1.09) <0.001 -34.6 
1Mixed-effects linear model with child as random intercept and fixed effects child sex, baseline measurement, and 
intervention group. 
2Percent change (median) from baseline value to midterm/endline values.  
3Values are expressed as median (IQR) and because analysis was based on log transformed values, effect sizes 
(95% CI) are expressed as the antilog of coefficients indicating the ratio of the geometric means in an intervention 
arm over the control arm. 
*Significant after correction for multiple testing using the Benjamini-Hochberg method. 
AA, arachidonic acid; C, both mother and child received placebo; CI, child received fish-oil and  mother received 
placebo; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LCP, long-chained polyunsaturated fatty acids; 
MCI, both mother and child received fish-oil; MI, mother received fish-oil and child received placebo. 
 
In the subsample with LCP analysis, compared to the control arm, fish-oil 
supplementation resulted in significantly higher blood DHA concentration in all the MI 
(P = 0.001; increase from baseline = 16.3%), CI (P = 0.010; increase from baseline = 
19.9%), and MCI (P < 0.001; increase from baseline = 14.9%) arms (Table 5.4). 
Blood EPA concentration was also significantly higher in the CI (P = 0.001; increase 
from baseline = 116%) and the MCI arms (P < 0.001; increase from baseline = 
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129%). Blood AA significantly decreased in the CI arm (P = 0.029; decreases from 
baseline = 13.3%) and the MCI arm (P = 0.024; decreases from baseline = 16.9%) 
compared to the control arm. The ratio of AA/(DHA + EPA) also showed significant 
decreases in all the intervention arms (P ≤ 0.001; decreases from baseline = 21.7–
34.6%). 
5.4.2. Effects on growth and nutritional status 
We found no significant effect in any of the intervention arms on the primary study 
outcome linear growth (LAZ) (Figure 5.2). However, a statistically significant group 
difference was detected on ponderal growth expressed as WLZ (P = 0.021). 
compared to the control arm, a small positive effect on monthly WLZ changes were 
detected in the CI arm (effect size (95% CI): 0.022 z scores/month (0.004, 0.039 z 
scores/month); P = 0.012) and the MCI arm (effect size (95% CI): 0.018 z 
scores/month (0.001, 0.034 z scores/month); P = 0.041); whereas no significant 
difference was found in the MI arm. We also found a trend towards larger monthly 
MUAC increases in the CI and the MCI arms compared to the control arm, though the 
differences were not statistically significant. No significant effect of any of the 
interventions was found on the nutritional status of children using stunting, wasting, 
and anemia (Table 5.5). 
5.4.3. Effects on morbidity and inflammation 
The occurrence of systemic inflammation, as determined by CRP concentration 
(Table 5.5), and common childhood illnesses (Table 5.6) were not statistically 
different between study arms. We did not find any adverse effect related to the study 
supplements in all participating mothers and children.




Figure 5.2. Monthly anthropometric growth over 12 months in the C ( ), MI (
), CI ( ) and MCI ( ) arms. 
Plotted values for the difference from baseline of the monthly measurements are estimated from a linear mixed-
effects model with random intercept child and random slope intervention time, with fixed effects that include time, 
quadratic time, intervention group, and time × group interactions adjusted for the sex of the child. P values are for 
group difference on monthly changes of the outcome over time. Effect sizes (95% CI) on monthly changes in WLZ 
were 0.005 (-0.012, 0.022) z scores/month; P = 0.538 in the MI, 0.022 (0.005, 0.039) z scores/month; P = 0.012 in 
the CI, and 0.018 (0.001, 0.034) z scores/month; P = 0.041 in the MCI. 
C, both mother and child received placebo; CI, child received fish-oil and mother received placebo; HC, head 
circumference; LAZ, length-for-age z score; MCI, both mother and child received fish-oil; MI, mother received fish-






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this study, fish-oil supplementation increased blood n-3 LCPUFA concentrations 
and lowered the AA:(DHA + EPA) ratio, indicating tissue uptake of the study 
supplements. We found no impact of the supplementation on child linear growth, 
systemic inflammation, or morbidity except that a small but statistically significant 
positive effect on monthly relative weight gain and a trend towards larger MUAC 
increments were detected in the CI and MCI arms. 
The lack of impact on child linear growth is consistent with previous studies in HICs 
that evaluated n-3 LCP supplementation of lactating mothers or infants 
(212,221,416). We expected a better impact of supplementation on growth and 
morbidity in our setting due to the potential for n-3 LCP to modulate the child’s 
immune response to infectious challenges and inflammation. Nonetheless, we were 
unable to detect an effect on reported morbidity or systemic inflammation using CRP. 
This finding is in agreement with the Gambian study where fish-oil supplementation 
to breastfed infants had no effect on growth, morbidity, inflammation, or gut integrity 
(291). The addition of fish-oil to multimicronutrient supplementation starting from a 
mean age of 24 months also did not improve EED or common illnesses in Malawian 
children (348). In contrast, in 2 RCTs in the United States, the supplementation of 
DHA and AA to infant formula resulted in a delayed onset and lower incidence of 
allergic symptoms and upper respiratory infections (URIs) compared to a similar 
formula without DHA and AA (355). In 2 nonrandomized studies in Spain and France, 
infant formula containing DHA and AA was associated with lower incidence of 
respiratory symptoms and diarrhea (353,354). A lower incidence and shorter duration 
of URI episodes was also reported among Thai schoolchildren (357) and US toddlers 
(356) who received milk containing fish-oil or DHA. 
A number of hypotheses can be put forward to explain the lack of impact of fish-oil 
supplementation on children’s growth and morbidity. It could be argued that n-3 LCP 
status in the study children was already satisfactory and hence the added effect of 
supplementation would be negligible. This hypothesis was proposed by the Gambian 
study where breastmilk substantially contributed to n-3 LCP intake. The lack of 
reference values for LCP status hampers a direct assessment of children’s status. 
However, baseline n-3 LCP concentrations in our children were significantly lower 
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compared to the children from the Gambia. Unlike the Gambian study, our 
intervention increased baseline DHA status by 14.9–19.9% and EPA by 58.9–129%, 
and decreased the AA/(DHA + EPA) ratio by 21.7–34.6%. Thus, it is less likely that 
the children in our study had an optimal n-3 LCP status and possible functional 
benefits associated with increased n-3 LCP status should have been observed in this 
study. 
We anticipated an important impact of n-3 LCP supplementation on morbidity 
symptoms and inflammation in a child population with high exposure to recurrent 
infections. However, the period prevalence of diarrhea in our children was rather low 
(5.2%) compared to previous studies from LICs (2.4–16.3%) (430). The proportion of 
children with systemic inflammation was also much lower in our study (24.2%) 
compared to the n-3 LCPUFA study in the Gambia (44.4%) (291). Hence, we cannot 
exclude that the relatively lower prevalence of morbidity and systemic inflammation in 
the study population might have attenuated the impact of the intervention. 
Impacts on children’s outcomes could also be conditional on the intake of n-3 LCPs 
from other sources. In the control children, blood concentrations of n-3 LCPs 
remained rather stable during the 12 months of follow-up. This was an unexpected 
finding given that breastmilk is the only important source of preformed n-3 LCPs and 
one would expect that breastmilk is gradually replaced by complementary foods, 
which are typically very low in n-3 LCPs. A possible reason for the stable n-3 LCP 
concentrations in this group could be the high frequency of breastfeeding throughout 
the follow-up. 
Finally, it should be noted that the children in both the intervention and control groups 
received multimicronutrient fortified food supplement and deworming medication to 
avoid any hampering of the efficacy of the n-3 LCPs by micronutrient deficiencies and 
intestinal parasite infections. It therefore cannot be excluded that both the 
micronutrients and deworming might have exerted a positive, albeit small, effect on 
child linear growth, thereby possibly diluting the intervention effect. 
The heterogeneous findings on child morbidity between our and the Gambian studies 
and other studies conducted in affluent countries may relate to differences in 
background n-3 LCPUFA status of the study populations and the clinical endpoints 
assessed. It is possible that LCP intake from breastmilk might have provided some 
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protection in our and the Gambian children compared to the exclusively formula-fed 
infants and older children in the other studies. The clinical benefits reported in the 
latter studies might also have been due to n-3 LCPs’ modulating immune response to 
inflammatory conditions rather than infectious diseases. Even in the studies that 
reported benefits for URIs, symptoms associated with allergic and inflammatory 
sensitization could have contributed to URIs being diagnosed at an early age (355). 
Differential effects may also arise from differences in etiologies as animal 
experiments found that dietary n-3 fatty acids can improve or impair the host 
response to infectious challenges depending on the type of pathogen (415). 
Moreover, the effects of n–3 fatty acids on the immune system may vary according to 
dose, age of exposure, and the polarization and profile of the involved immune 
system (T helper, Th1/Th2) (351). 
Our study found that direct fish-oil supplementation to children or combined with 
maternal fish-oil supplementation resulted in higher ponderal growth, indicated by 
increased WLZ rates, and a trend to larger MUAC increments over time as compared 
to the control group. Other RCTs also reported positive impacts of n-3 LCP 
supplementation on BMI, MUAC, skinfold thickness, and waist circumference, 
suggesting changes in body composition (291,431). The competitive roles of n-3 and 
n-6 FAs on the regulation of genes encoding for fat oxidation, thermogenesis, and 
adipose differentiation, demonstrated in animal studies, have been suggested as 
plausible mechanisms for effects on the rate and/or composition of weight gain 
(391,392). On the other hand, the clinical significance of the observed intervention 
effect on ponderal growth of our children requires careful consideration because of 
the small effect size (432). The difference in the rate of weight gain from the C arm 
was 0.5 and 0.6 g/d in the CI and MCI arms, whereas the recommendation for 
nutritionally important weight gain is >3 g/d (433). 
The study has a few limitations that need to be considered. We did not include 
markers of immune cell function and intestinal inflammation, nor indicators of 
intestinal integrity, which impedes a more mechanistic understanding of the 
intervention’s effect on child immune functions. Close surveillance and referral for 
treatment might have an effect of obscuring the usual occurrence of morbidity 
outcomes in the study population. It is also important to note that we had limited 
power to detect small differences in morbidity outcomes with low prevalence 
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estimates. We did not monitor dietary intake other than the food supplements. 
However, previous dietary surveys in the study area indicated that intake of fish and 
other seafoods, the only important sources of n-3 LCPUFA, is rare. Only 1 out of 291 
infants consumed fish during the pre- and post-harvest seasons as measured by 
repeated 24-h dietary recalls (369). 
5.6. Conclusion 
In conclusion, this study adds to the growing body of evidence on the lack of growth 
benefits from n-3 LCP supplementation to IYC. Despite an improvement in n-3 LCP 
status, we did not find a benefit on linear growth or morbidity. n-3 LCP 
supplementation seems to modestly increase body adiposity when given in 
sufficiently large doses.
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Background: The n-3 LCP DHA is essential for optimal brain development. There is 
a lack of evidence on the effect of postnatal n-3 LCP supplementation on child 
development in LICs. 
Objective: We evaluated the efficacy of fish-oil supplementation through lactation or 
complementary food supplementation on the development of children aged 6–24 
months in rural Ethiopia. 
Methods: We conducted a double-blind randomized controlled trial of n-3 LCP 
supplementation for 12 months using fish-oil capsules [maternal intervention: 215 mg 
DHA + 285 mg EPA] or a fish-oil–enriched complementary food supplement (child 
intervention: 169 mg DHA + 331 mg EPA). In total, 360 pairs of mothers and infants 
aged 6–12 months were randomly assigned to 4 arms: maternal intervention and 
child control, child intervention and maternal control, maternal and child intervention, 
and maternal and child control. Primary outcomes were overall developmental 
performance with the use of a culturally adapted Denver II test that assesses 
personal-social, language, fine-motor, and gross-motor domains, and social-
emotional developmental performance using the Ages and Stages Questionnaire: 
Social Emotional at baseline and at 6 and 12 months. We used mixed-effects models 
to estimate intervention effects on developmental performance over time (intervention 
× time interaction). 
Results: The evolution in overall and social-emotional developmental performance 
over time did not differ across study arms (intervention × time: F = 1.09, P = 0.35, 
and F = 0.61, P = 0.61, respectively). Effects did not change after adjustment for child 
sex, age, birth-order, and nutritional status; maternal age and education; wealth; 
family size; and breastfeeding frequency. Children’s developmental performance 
significantly decreased during study follow-up (β (95% CI): −0.03 SD/month (−0.04, 
−0.01 SD/month); P < 0.01). 
Conclusions: n-3 LCP supplementation does not affect overall or social-emotional 
development of children aged 6–24 months in a low-income setting. Follow-up of the 
cohort is recommended to determine whether there are long-term effects of the 
intervention. This trial was registered at clinicaltrials.gov as NCT01817634. 




DHA is an n-3 LCP essential for the structural and functional development of the 
brain (138,434). DHA deficiency during the brain growth spurt has been shown to 
exert deleterious effects on learning, mood, and motor development in animals 
(435,436). 
HM is the predominant source of n-3 LCPs for IYC in LMICs (169,174,404). However, 
the adequacy of the DHA supply remains a concern because breastmilk DHA 
concentrations, which largely depend on the maternal diet, show considerable 
variations across and within populations (176,177,408). Mothers living far from 
coastal areas have limited access to dietary DHA sources to ensure the 
recommended intake of 200 mg DHA/d during lactation, which could be achieved by 
consuming 1–2 portions of sea fish/wk (95,173–175). Furthermore, with the 
introduction of complementary foods, children in LMICs gradually shift from 
dependence on breastmilk to a complementary diet that is often very low in DHA 
(174,179). Although DHA can be synthesized de novo from its precursor, ALA 
(18:3n−3), the conversion is typically very low and is further hampered by a high 
dietary n-6 to n-3 PUFA ratio and common genetic polymorphisms (67,437). Studies 
have confirmed that infant DHA status can be more efficiently improved by 
supplementation with preformed DHA compared with ALA (97). 
Observational studies have shown that breastfed compared with formula-fed children 
have better neurodevelopment, which has been attributed to the lack of preformed n-
3 LCPs in previous infant formulas (135,203). However, it remains uncertain whether 
n-3 LCP supplementation of children born at term can have neurodevelopmental 
benefits because systematic reviews of RCTs did not produce any conclusive 
evidence (210,211,214,217,221). Furthermore, it is currently still unclear whether 
these findings from predominantly HICs can be extrapolated to children living in 
LMICs. LMICs have a higher prevalence of other developmental risk factors, such as 
intrauterine growth restriction, stunting, inadequate stimulation, infections, and poor 
water and sanitation conditions (438). Some studies have reported differential 
responses to n-3 LCP supplementation in which subgroups with a higher 
developmental risk– such as very-low-birth-weight infants and children with reduced 
caregiver interactions and psychomotor stimulation– benefited more from 
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supplementation (277,290,439). This might suggest that any neuroprotective effects 
of n-3 LCP supplementation could be more pronounced among children living in 
LMICs. To date, only one clinical trial in The Gambia evaluated n-3 LCPUFA 
supplementation of breastfed infants in LMICs and found no benefit on cognitive 
development (291). However, the infants had a rather adequate dietary n-3 LCP 
supply, and breastmilk DHA concentrations of mothers were surprisingly high and 
matched those of populations with high fish consumption. 
Ethiopia is a landlocked country and has been estimated to have the lowest dietary 
DHA intake in the world (i.e., 7.0 mg/d per capita) (175). The median DHA intake 
from complementary foods in children aged 6-36 months is estimated at 1.1 mg/d, 
which is negligible compared with the worldwide median of 14.6 mg/d (179,180). 
Thus, breastfed children’s DHA status is expected to be low due to suboptimal DHA 
intakes from complementary foods and breastmilk. In this study, we hypothesized 
that an increased intake of n-3 LCPs would improve developmental performance of 
breastfed children aged 6-24 months in a rural setting in Ethiopia. The intervention 
was delivered through 2 channels: 1) supplementation of children with a 
complementary food supplement enriched with fish-oil and/or 2) supplementation of 
their lactating mothers with fish-oil capsules. 
6.3. Methods 
6.3.1. Subjects and measurements 
This study was a randomized, double-blind, placebo-controlled trial that assessed the 
independent and combined effects of fish-oil (n-3 LCP) supplementation of lactating 
mothers using fish-oil capsules (maternal intervention) and their breastfed children 
using a fish-oil-enriched complementary food supplement (child intervention). The 
trial was conducted from November 2013 to February 2015 in the districts of Deneba, 
Assendabo, and Serbo of Jimma Zone, Ethiopia. Previous dietary surveys conducted 
in the study area showed that a negligible number of IYC consumed fish, whereas 
95% of children continued breastfeeding throughout the second year of life (369). 
Children and their lactating mothers were randomly assigned to receive either the 
fish-oil (intervention) or a placebo control without fish-oil. Thus, there were 4 study 
arms: both mother and child received the fish-oil intervention (MCI), only the mother 
received the fish-oil intervention and her child received a placebo control (MI), only 
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the child received the fish-oil intervention and the mother received a placebo control 
(CI), and both mother and child received the placebo control (C). Study participants, 
development assessors, and researchers remained blinded to the intervention 
allocation until the end of data analysis. The maternal supplements were airtight soft-
gel oil capsules, which, at a daily dose of 2 capsules, provided either 500 mg n-3 
LCPs (intervention: fish oil providing 215 mg DHA + 285 mg EPA) or no n-3 LCPs 
(control: corn oil). The intervention and control capsules were identical in appearance 
(Biover NV). The child complementary food supplements were extruded corn-soy 
blends fortified with 19 micronutrients that were either enriched with a daily dose of 
500 mg n-3 LCPs (intervention: fish oil providing 169 mg DHA + 331 mg EPA) or not 
enriched with n-3 LCPs (control: corn oil) (Michiels Fabrieken NV and Fortitech, Inc.) 
(see details in Chapter 5). 
The primary study outcomes were the performance score on overall development 
using a culturally adapted and standardized Denver II Developmental Screening Test 
(Denver II-Jimma), which assesses personal-social, language, fine-motor and gross-
motor developmental domains, and the performance score on social-emotional 
development using an adapted Ages and Stages Questionnaire: Social Emotional 
(ASQ-SE) (440). Secondary outcomes included performance scores on the individual 
Denver II developmental domains (i.e., personal-social, fine-motor, language, and 
gross-motor development) to evaluate effects on different aspects of child 
development and the risks of suspected global developmental delay (using Denver II-
Jimma) and social-emotional developmental delay (using ASQ-SE) to evaluate 
effects on the proportion of children with poor developmental performance. 
Outcomes were assessed at baseline, midline (after 6 months), and endline (after 12 
months) of the intervention. The Denver II-Jimma has 125 test items that evaluate a 
child’s skills in 4 domains of development (personal-social, fine-motor, language, and 
gross-motor). The number of test items to be administered per domain depends on 
the age and performance of the child as described in the official Denver II manual 
(441). Some of the test items were assessed by maternal report (“report item”), 
whereas others required an observation of the child carrying out the task (“test item”). 
Test items were scored as “pass,” “fail,” “refusal,” or “no opportunity.” “Refusal” 
indicates that a child refused to attempt a “test item” 3 times, and “no opportunity” 
indicates that a child did not have the chance to perform a “report item” at home. 
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Children’s skills in overall development and for each developmental domain were 
then evaluated by applying a scoring approach on a continuous scale. Children’s 
performance scores were calculated as the ratio of the total number of passed test 
items to the total number of test items expected to be passed by ≥75% of same-age 
children in the Ethiopian benchmark (440). Children were also assessed for risk of 
suspected global developmental delay by categorizing each child as “normal,” 
“suspect,” or “untestable” according to the criteria in the official Denver II manual 
(Table 6.1). 
Table 6.1. Screening criteria for global developmental delay and social-
emotional problems 
Outcomes Cutoff criteria 
Global development (Denver II- Jimma, 125 items)1 
   Normal No delay and a maximum of one caution 
   Suspect  > 2 cautions and/or > 1 delay 
   Untestable  > 1 refusal scored as delay or <1 refusal scored as 
caution 
Social-emotional development (ASQ: SE)2 
   Age 3-8 months  (19 items) Total score >45 
   Age 9-14 months  (22 items)  Total score >48 
   Age 15-20 months  (26 items) Total score >50 
   Age 21-26 months  (26 items) Total score >50 
1Delay, test item failed/refused and the child is older than the age corresponding to the 90th percentile of success 
for the item in the Ethiopian benchmark; Caution, test item failed/refused and the child’s age falls on or between 
the 75th and the 90th percentile. 
2Each item is scored according to how frequently the child performs the behavior: most of the time (=0), 
sometimes (=5) or rarely/never (=10), with an additional 5 points if there is maternal concern for the behavior 
being performed sometimes (=10) or rarely/never (=15). 
 
 
The ASQ-SE evaluates a child’s skills in social-emotional development and therefore 
complements the Denver II-Jimma. The ASQ-SE tool contains age specific 
questionnaires including for the age ranges of 3-8, 9-14, 15-20, and 21-26 months 
(35) (442). Each questionnaire contains a set of questions that refer to critical 
adaptive and maladaptive behaviors for the target age interval and focuses on skills 
related to attachment, autonomy, and self-development. The ASQ-SE questionnaire 
was completed by asking the mother how frequently her child performed a given 
behavior (i.e., “most of the time,” “sometimes,” or “rarely/never”), which were each 
assigned a score. Social-emotional performance scores were then calculated as the 
ratio of the sum of all scores over the maximum attainable score on the age-specific 
questionnaire, with a higher value indicating poor developmental performance. Each 
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child was also screened for suspected social-emotional developmental delay using 
the recommended age-specific cutoffs (Table 6.1) (442). 
Two clinical nurses conducted the developmental tests throughout the study after 
receiving 1 month of intensive training, with practical sessions and standardization 
exercises, and a refresher training before the start of midline measurements. Two 
experienced developmental psychologists provided the training and alternately 
supervised data collection in the field. Both nurses worked in all of the 3 study 
districts and were randomly assigned to perform an assessment in order of children’s 
arrival at the sites. Assessments were conducted in quiet and convenient rooms and 
took 30–45 min/child. Assessments were postponed to the next day when a child 
was sick or refused to start the test. 
6.3.2. Statistical Analysis 
A sample size of 360 subjects (90 subject/study arm) was required to detect an effect 
size of 0.038 SDs in monthly change of the overall and social-emotional 
developmental performance score over 12 months of intervention follow-up, 
assuming an autocorrelation of 0.50, 80% statistical power, and a type I error of 5% 
and taking into account an anticipated 20% attrition rate (426). This effect size on the 
monthly change in child development is equivalent to an effect size of 0.12 SDs after 
12 months of intervention using an estimated SD of 0.03 for the mean monthly 
change in child development and an SD of 0.12 for the mean developmental score 
(443). These estimates are derived from a study conducted in a similar population in 
the study area using the same Denver II-Jimma tool (444). Data were entered in 
duplicate using EpiData version 1.4.4.4 (EpiData Association), and consistency 
checks and statistical analysis were conducted using Stata version 13.1 (StataCorp 
LLC, Texas, USA). Developmental performance scores were standardized to z 
scores on the basis of the distribution of the data. The Denver II-Jimma-derived risks 
of suspected developmental delay were categorized as either “normal” or “suspect,” 
with the latter including the “untestable” category. 
The effect of the interventions was assessed with mixed-effects linear regression 
models for the continuous outcomes and mixed-effects linear probability models for 
the binary outcomes, with child identifier as random intercept. The use of linear 
probability models for binary outcomes is well established and allows for a 
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straightforward interpretation of the average intervention effect expressed as risk 
difference using percentage points (445). Fixed effects in the models included study 
arm (C, MI, CI, or MCI), intervention time (in month), and child sex. Child sex was 
added due to an imbalance among study arms at baseline. We evaluated the 
interventions’ effects on the evolution of child developmental performance taken over 
the 3 measurement rounds. For this purpose, we tested interaction terms between 
study arms and intervention time that estimate the difference between each 
intervention arm and the control arm on monthly changes in an outcome over time. 
As a secondary analysis, we analyzed the intervention effect adjusted for relevant 
time-invariant covariates such as child age, birth order, and LAZ score at enrollment; 
maternal age and education; household wealth and family size; and frequency of 
breastfeeding at baseline. We further explored if there were any effect modifications 
of the intervention by our chosen covariates by testing triple interaction terms 
between study arm, intervention time, and a covariate. Analyses were performed by 
the intention-to-treat principle (i.e., including all children initially enrolled into the 
study). For this purpose, we conducted multiple imputations of missing data using 
chained equations under the missing-at-random assumption. Fifty imputations of 
missing data were conducted to estimate the regression coefficients. All of the tests 
were 2-sided, and the level of significance (α) was set at 0.05. 
6.4. Results 
The numbers of mother-child pairs who were screened for eligibility, randomly 
assigned, and lost to follow-up are presented in Figure 6.1. A total of 360 mother-
child pairs were randomly assigned to the study arms and 329 (91%) attended either 
the midterm or the endline developmental test. Eighty-seven percent of the 
participants received all 12 distributions of the supplements. Baseline characteristics 
of study participants were comparable across the study arms, except for an 
imbalance in child sex (Table 6.1). 


















Figure 6.1. Trial flowchart. 
C, control - both mother and child received placebo; CI, child intervention - child received fish-oil and mother 
received placebo; MCI, maternal and child intervention - both mother and child received fish-oil; MI, maternal 
intervention - mother received fish-oil and child received placebo. 
 
Assessed for eligibility 
Excluded (n = 53) 
Ineligible (n = 36) 
Refused (n = 17) 
Allocated to C        
(n = 90) 
Randomly assigned (n = 360) 
Lost to follow-up   
(n = 8) 
Assessed  
at 6 mo (n = 83) 
at 12 mo (n = 82) 
Allocated to MI    
(n = 89) 
Allocated to CI      
(n = 90) 
Allocated to MCI  
(n = 91) 
Lost to follow-up    
(n = 10) 
Lost to follow-up   
(n = 19) 
Lost to follow-up   
(n = 10) 
Assessed  
at 6 mo (n = 81) 
at 12 mo (n = 79) 
Assessed  
at 6 mo (n = 78) 
at 12 mo (n = 71) 
Assessed  
at 6 mo (n = 84) 
at 12 mo (n = 81) 
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Table 6.1. Baseline characteristics of study children and their mothers by study arm1 
Characteristics  
C  
(n = 90) 
MI  
(n = 89) 
CI  
(n = 90) 
MCI  
(n = 91) 
Child sex, female 46.7 55.1 40.0 59.3 
Child age, month 8.89 ± 2.16 9.18 ± 2.09 8.93 ± 2.10 8.68 ± 2.00 
Maternal age, year 26.0 ± 5.04 25.8 ± 4.82 26.1 ± 5.48 26.3 ± 5.28 
Maternal education      
   No formal education 46.7 49.4 51.1 52.7 
   Primary education 41.1 34.8 34.4 36.3 
   Secondary and above 12.2 15.7 14.4 11.0 
Household wealth tertiles     
   Lowest 30.0 38.2 31.1 34.1 
   Middle 32.2 25.8 38.9 36.3 
   Highest 37.8 36.0 30.0 29.7 
Child weight, kg 8.18 ± 1.15 8.15 ± 1.10 8.05 ± 1.08 7.93 ± 1.10 
Maternal height, cm 157 ± 4.67 157 ± 5.55 157 ± 5.95 157 ± 5.74 
Maternal BMI, kg/m2 20.2 ± 2.41 20.3 ± 2.50 20.1 ± 2.57 21.0 ± 3.31 
Breastfeeding frequency, times/d     
   4-6  11.1 6.74 12.2 8.89 
   7-9  23.3 31.5 28.9 25.6 
   ≥10  65.6 61.8 58.9 65.6 
1Values are means ± SDs or percentages.  
BMI, body mass index; C, control - both mother and child received placebo; CI, child intervention - child received fish-oil and mother 
received placebo; MCI, maternal and child intervention - both mother and child received fish-oil; MI, maternal intervention - mother 
received fish-oil and child received placebo. 
 
There was no significant difference between the study arms on the evolution of 
children’s performance score over time for both overall development using the 
Denver II-Jimma (intervention × time: F = 1.09, P = 0.35) and social-emotional 
development using the ASQ-SE (intervention × time: F = 0.61, P = 0.61) (Table 6.2). 
Similarly, we found no significant effect of any of the interventions on developmental 
performance scores on the personal-social, fine-motor, language, and gross-motor 
domains as well as on the risks of suspected global developmental delay (using 
Denver II-Jimma) and social-emotional developmental delay (using ASQ-SE). The 
interventions’ effects on developmental outcomes remained unaffected when we 
adjusted the analysis for relevant covariates such as child sex, age, birth order, and 
LAZ score at enrollment; maternal age and education; household wealth and family 
size; and frequency of breastfeeding at baseline. There was no significant interaction 
between the study arms and our chosen covariates on the developmental outcomes. 
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The age-adjusted overall developmental performance of children significantly 
decreased with time during the study follow-up (β (95% CI): −0.03 SD/month (−0.04, 
−0.01 SD/month); P < 0.01). The prevalences of suspected global developmental 
delay and social-emotional developmental delay were 19.2% and 67.5% at baseline, 
19.7% and 60.6% at midline, and 20.6% and 41.7% at the endline of the study, 
respectively. 
6.5. Discussion 
We previously showed that supplementation with n-3 LCP–rich fish-oil through 
lactation and/or a child complementary food supplement significantly increased child 
blood DHA concentrations by 15–20% and decreased the ratio of arachidonic acid 
(20:4n−6) to DHA+EPA by 22–35% (Table 5.2). However, the results of the current 
study showed no apparent benefit of the supplementation on child developmental 
performance assessed using the Denver II-Jimma and ASQ-SE tests. 
The current study is 1 of 2 trials conducted in an LMIC setting that reports on the 
impact of postnatal n-3 LCP supplementation on child development. Another trial in 
The Gambia found no benefit of direct fish-oil supplementation of breastfed infants 
from ages 3–9 months on cognitive performance using the Willatts’ infant planning 
test (291). Several RCTs in developed countries have examined the effects of n-3 
LCP or DHA supplementation of lactating mothers or infant formulas on different 
aspects of child neurocognitive and behavioral development. Although some of these 
studies reported beneficial effects of supplementation on some aspects of child 
development, others studies that used similar or other developmental tools found no 
differences between intervention and control groups (210,211,214,217,221). Campoy 
et al. (217) and Meldrum et al. (421) proposed that the mixed results from previous 
trials could be due to heterogeneity among studies with regard to the timing, duration, 
and dose of supplementation; the methods used for outcome assessment; the age of 
children at outcome measurement; inadequate sample size; or potential differences 
in the populations studied, such as genetic polymorphisms possibly affecting DHA 
requirements and concentrations in breastmilk. 
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Table 6.2. Developmental performance score and suspected developmental delay in 
children, by measurement round and study arm1 
Outcomes Group Baseline  Midterm  Endline P2 P3 
Developmental performance scores      
Overall development C  1.14 ± 0.12  1.14 ± 0.09  1.10 ± 0.07 
0.351 0.312 
 MI  1.12 ± 0.12  1.12 ± 0.09  1.10 ± 0.07 
 CI  1.12 ± 0.12  1.12 ± 0.08  1.08 ± 0.06 
 MCI  1.13 ± 0.13  1.13 ± 0.10  1.11 ± 0.07 
Social-emotional C  0.35 ± 0.23  0.32 ± 0.20  0.22 ± 0.15 
0.607 0.648 
 MI  0.38 ± 0.24  0.27 ± 0.22  0.23 ± 0.17 
 CI  0.35 ± 0.24  0.32 ± 0.20  0.25 ± 0.15 
 MCI  0.35 ± 0.22  0.30 ± 0.23  0.21 ± 0.15 
Personal-social C  1.31 ± 0.23  1.28 ± 0.23  1.17 ± 0.11 
0.796 0.747 
 MI  1.28 ± 0.23  1.23 ± 0.18  1.18 ± 0.11 
 CI  1.27 ± 0.22  1.25 ± 0.19  1.17 ± 0.10 
 MCI  1.32 ± 0.23  1.29 ± 0.21  1.20 ± 0.10 
Fine-motor C  1.15 ± 0.17  1.09 ± 0.09  1.07 ± 0.07 
0.720 0.771 
 MI  1.12 ± 0.18  1.08 ± 0.10  1.07 ± 0.07 
 CI  1.11 ± 0.16  1.07 ± 0.09  1.06 ± 0.07 
 MCI  1.11 ± 0.21  1.09 ± 0.09  1.08 ± 0.07 
Language C  1.14 ± 0.20  1.10 ± 0.11  1.08 ± 0.16 
0.124 0.131 
 MI  1.10 ± 0.16  1.08 ± 0.10  1.08 ± 0.16 
 CI  1.13 ± 0.20  1.08 ± 0.12  1.03 ± 0.13 
 MCI  1.16 ± 0.20  1.09 ± 0.12  1.09 ± 0.16 
Gross-motor C  1.04 ± 0.12  1.13 ± 0.11  1.08 ± 0.08 
0.787 0.851 
 MI  1.04 ± 0.12  1.12 ± 0.13  1.08 ± 0.08 
 CI  1.04 ± 0.11  1.12 ± 0.10  1.07 ± 0.08 
 MCI  1.04 ± 0.10  1.11 ± 0.14  1.09 ± 0.08 
Suspected developmental delays       
Global DD C  21.1  12.2  22.2 
0.235 0.258  MI  16.9  22.5  18.0 
 CI  18.9  22.2  26.7 
 MCI  19.8  22.0  15.4 
Social-emotional DD C  67.8  67.8  38.9 
0.777 0.811  MI  71.9  52.8  42.7  CI  64.4  64.4  44.4 
 MCI  65.9  57.1  40.7 
1Values are means ± SDs of developmental performance score, and proportions of children with suspected developmental 
delay. Sample size in C (n = 90), MI (n = 89), CI (n = 90), and MCI (n = 91). 
2P-values for the intervention effect on the evolution of an outcome over time (intervention X time interaction), estimated from 
mixed-effects linear models for the continuous outcomes and mixed-effects linear probability models for the binary outcomes 
with child identifier as random intercept and adjustment for child sex.  
3P-values for the intervention effect, estimated from models adjusted for child sex and fixed-effect covariates including child 
age, birth-order and length-for-age Z-score at enrollment, maternal age and education, household wealth and family size, and 
frequency of breastfeeding. 
C, control - both mother and child received placebo; CI, child intervention - child received fish-oil and mother received 
placebo; Global DD, suspected global developmental delay assessed using Denver II-Jimma; MCI, maternal and child 
intervention - both mother and child received fish-oil; MI, maternal intervention - mother received fish-oil and child received 
placebo; Social-emotional DD, suspected social-emotional developmental delay assessed using ASQ:SE. 
Chapter 6: n-3 LCP Supplementation and Child Development 
107 
 
The interpretation of the results of the current study should therefore consider the 
age at which supplementation was provided (i.e., 6-24 months). The intervention did 
not cover the entire period of expected higher brain sensitivity to dietary DHA. Rapid 
brain DHA accretion coincides with the brain growth spurt that spans from the 
beginning of the third trimester of pregnancy to the second year of life, with the 
majority accumulating before the first 12 months of life (146,390). This may suggest 
that supplying DHA prenatally and to younger infants could influence brain DHA 
status and associated functional outcomes more. On the other hand, potential 
impacts in older IYC cannot be excluded because the human brain remains sensitive 
to dietary DHA throughout its protracted developmental phase (446). Increased brain 
DHA exposure during this time may benefit the late-maturing dopamine system of the 
prefrontal cortex, which is selectively influenced by DHA (447) and which reaches 
peak maturation toward the end of the first year and reaches functional maturity at 
12–15 months of age and beyond (448,449). For instance, a DHA supplementation 
study in older children aged 8–10 years showed a significantly higher functional 
activity of the prefrontal cortex in the supplemented group, and erythrocyte DHA 
composition was inversely correlated with reaction time in a sustained attention task 
(154). 
Another important point requiring consideration is that the Denver II-Jimma and ASQ-
SE tools might not be adequately sensitive to detect subtle effects of dietary DHA on 
specific brain functions (137,450). DHA selectively concentrates in the prefrontal 
cortex of the brain region, where cognitive processes involving attention regulation 
and components of short-term and working memory take place (447,449). Thus, tools 
assessing specific cognitive abilities mediated by the prefrontal cortex, such as 
attention and problem solving, might have been more informative about the effects of 
increased dietary DHA intake on brain function (450). Furthermore, the impacts of 
early DHA exposure could be more evident on cognitive abilities that emerge at a 
later age. On the other hand, global developmental tests taken before the age of 2 
years have been shown to have limited predictive validity for later childhood cognitive 
and behavioral performance (451,452). Jensen et al. (263,265) reported benefits of 
maternal supplementation with 200 mg DHA/d during lactation on child development 
at 2.5 and 5 years of age but did not find any impact during infancy compared with a 
control group. Others found that the addition of DHA to infant formula was associated 
Chapter 6: n-3 LCP Supplementation and Child Development 
108 
 
with better performance on several tasks, reflecting discrete aspects of cognitive 
functions between the ages of 3 and 6 years. However, no impact of this enriched 
infant formula was detected using standardized developmental tasks at the age of 18 
months (242). 
Children from the control arm of this study still received DHA through breastmilk. As 
such, this could have diluted the differential impact between the intervention and 
control arms. This contextual element is important to highlight when comparing the 
study results with previous findings from RCTs conducted in weaned infants in which 
control infants received formulas devoid of preformed n-3 LCPs. A review by 
Lauritzen et al. (85) suggested that DHA supplementation is more likely to result in an 
impact on developmental outcomes when children’s basal DHA intake is <70 mg/d. 
From the analysis of baseline breastmilk samples we derived a mean DHA 
concentration of 74.0 mg/L (See Table 4.1 in Chapter 4). With HM being the sole 
predominant source of DHA in this setting and assuming an average breast-milk 
intake of 650 mL/d (453), we estimate that the study children’s average DHA intake 
from breastfeeding would not exceed 50 mg/d. We therefore do not expect that this 
low HM DHA concentration would have masked any potential effects of n-3 LCP 
supplementation in the current study. 
Often, the inadequacy of the studied dose or poor compliance to the intervention is 
an argument to explain the lack of impact of supplementation trials on functional 
outcomes. In the current study, the median (IQR) compliance (i.e., the ratio of actual 
supplement consumption over prescribed consumption) was 79.7% (62.6–91.4%) for 
the child complementary food supplement and 69.9% (52.2–80.4%) for the maternal 
capsules, with no significant difference between the study arms (See Table 5.3 in 
Chapter 5). The frequency of breastfeeding remained high throughout follow-up, with 
an average frequency of ≥7 times/d in 84.2% of the participants. The n-3 LCP dose 
amounts for the maternal and child supplements used were determined on the basis 
of the trade-off between supplying an adequate amount of n-3 LCPs and avoiding 
theoretically possible adverse effects of a high-dose of n-3 LCPs, including the risk of 
immunosuppression among the children exposed to both the maternal and the child 
interventions. Reviews of previous RCTs of infant formula supplementation 
recommend a dose of ≥0.32% DHA of total fat (TF; grams per 100 g TF) to target 
developmental outcomes, an amount based on the global average HM concentration 
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(218,421). The dose of DHA in the child intervention complementary food supplement 
in our study was estimated to be 0.56% TF using the total dietary fat requirement of 
30 g/d for infants aged 7-12 months (453). Even when considering compliance in the 
CI arm (median: 79.0%; IQR: 62.3–89.9%), the dose was ≥0.35% TF in 75% of the 
children. The dose of DHA in the maternal intervention capsules was also aimed at 
achieving an optimum breastmilk DHA content because a previous dose-response 
study showed that a dosage of 167 mg DHA/d was able to enrich breastmilk to 0.32% 
TF in lactating mothers consuming a very low n-3 LCP diet similar to a vegetarian 
diet (398). Furthermore, we addressed the potential for a lack of impact due to an 
inadequate dose by including a study arm who received the combined interventions. 
We found a high risk of suspected developmental delay among children in our study 
sample. In addition, the age-adjusted developmental performance scores of children 
declined during the study follow-up. Poor nutrition and suboptimal child care and 
stimulation practices have been identified as important contributors of poor 
developmental performance in LMICs (9,454). In a recent randomized controlled 
study in our study area, a home-based stimulation intervention was shown to 
significantly improve developmental performance in high-risk children aged <5 years 
(444). Therefore, there is a critical need for identifying appropriate interventions that 
integrate both nutrition and stimulation interventions to mitigate the developmental 
risks in this and other child populations. 
This study has a few strengths and limitations that need to be addressed. First, we 
used the Denver II instrument because it has been culturally adapted and 
standardized to the local context by a previous study conducted in the same study 
area (440). Work by Rubio-Codina et al. (455) showed that this shorter tool can be 
used as a valid and highly feasible substitute of the more-lengthy Bayley Scales of 
Infant and Toddler Development for large-scale field-setting studies in LMICs. On the 
other hand, tests of specific cognitive tasks that can be mechanistically and 
theoretically related to the role of DHA on brain function may have provided more 
understanding of an impact of the intervention. However, the feasibility of 
administering such tests in young children in our study was limited by the field setting 
and the relatively large sample size. Second, we did not monitor dietary intake other 
than compliance to the intervention supplements. However, previous dietary surveys 
found that the consumption of fish and other sea foods was very rare in the study 
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area (369). Finally, we did not assess the impact of n-3 LCP supplementation in 
infants aged <6 months because of the universal recommendation of exclusive 
breastfeeding in this age group and the specific design of this study (i.e., the 
assessment of the concomitant impact of n-3 LCP supplementation through 
complementary foods and breastmilk enrichment). 
6.6. Conclusion 
In conclusion, this study did not find evidence of a positive impact of n-3 LCP 
supplementation on child developmental performance in breastfed children in a low-
income setting. Assessing long-term effects of early dietary n-3 LCP exposure on 
later cognitive and behavioral skills in this population is warranted. 
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Despite the significant steps the world has taken towards improving nutrition and the 
associated burden of disease and impaired quality of life over recent decades, 
millions of children in LMICs are still suffering from the severe consequences of poor 
health and nutrition. According to the global burden of maternal and child 
undernutrition estimates in 2018, more than 149 million under-five children were 
suffering from stunted growth (1). Growth faltering in early-life is associated with an 
elevated risk of mortality, poor neurocognitive development, poor learning capacity 
and productivity in later life, and increased risk of nutrition related chronic diseases 
during adulthood (4). The lifelong consequences that follow poor nutrition in early-life 
is not only a problem that matters to the quality of life of the victims, rather it is a 
cross-cutting agenda impeding economic and societal growth. 
There is a growing consensus that good nutrition during the window period of the 
first 1,000 days of life is critical to achieve full human potential throughout life, and a 
means to break the intergenerational cycle of poverty and inequity. Accordingly, the 
WHA in 2012 endorsed a Comprehensive Implementation Plan on Maternal, Infant 
and Young Child Nutrition with six global targets, which have also been embraced in 
the post-2015 sustainable development agenda (58). Despite this encouraging 
global momentum, recent estimates showed that current progress in reducing child 
undernutrition in many LMICs is inadequate to achieve the WHA global targets (56). 
In the context of the global efforts to improve the health and nutritional status of 
children in LMICs, the current PhD work contributes to two important aspects. First, 
we explored nutrition-specific and -sensitive factors that can contribute to reduction 
in chronic childhood undernutrition in a set of LMICs. Second, in an effort to find a 
new approach that maximizes effectiveness of existing nutrition interventions, we 
evaluated the efficacy of n-3 LCPs supplementation on healthy growth and 
development of IYC from a rural setting in Ethiopia. This chapter presents an 
overview of the major findings, their implications and methodological issues of the 
studies conducted in the PhD thesis, and thoughts for future research and policy 
recommendations to be considered. Various specific aspects of the studies, results, 
and discussions in relation to the literature have already been detailed in the 
previous chapters. Therefore, here the general discussion will be limited to 
considerations from a broader perspective. 
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7.1. Main research findings 
The first study of the PhD thesis examined the relationship between the trends in 
under-five stunting prevalence in 14 LMICs and determinants at the distal, 
intermediate and proximal levels (Chapter 3). Stunting prevalence followed a 
declining trend in all the countries studied at an average annual rate of reduction of 
1.04%. Narrowing income inequalities (i.e. decreases in Gini coefficient), 
urbanization, and women’s empowerment (i.e. improvements in women’s decision 
making in the household) were the determinants at the distal level that explained the 
observed trend in stunting reduction over time. Improvements in households’ access 
to improved sanitation facilities and drinking water sources, and increases in child 
immunization coverage were the intermediate determinants having significant 
contribution for stunting reduction. The important stunting drivers identified at the 
proximal level were improvements in prenatal nutrition (i.e. decreases in prevalence 
of low birthweight) and increases in early initiation of breastfeeding. 
The effects of n-3 LCPs-rich fish-oil supplementation in lactating mothers and their 
IYC 6-24 months old are evaluated in three chapters of the PhD thesis. Fish-oil 
supplementation of lactating mothers resulted in significantly higher maternal milk 
DHA and EPA concentrations and a lower ratio of n-6/ n-3 LCPs compared to the 
control group (Chapter 4). 
Fish-oil supplementation through lactation (maternal supplementation), 
complementary food (child supplementation), and combination of both successfully 
increased child n-3 LCPs status as reflected in the significantly higher blood n-3 
LCPs concentrations and the lower n-6/n-3 LCPs ratios compared to the control 
group. Direct fish-oil supplementation to children or combined with maternal fish-oil 
supplementation also resulted in higher ponderal growth, as indicated by the 
significant increases in WLZ rates and the trends to larger MUAC increments over 
time as compared to the control group. No further effects of the fish-oil intervention 
were detected on the outcomes child morbidity, systemic inflammation (CRP), linear 
growth (LAZ), HC, nutritional status (stunting, wasting and anemia), or on overall and 
social-emotional developmental performance (Chapters 5 & 6). 
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7.2. Implications of the research findings 
7.2.1. Drivers of the trend in child stunting 
Achieving the WHA global target of a 40% stunting reduction between 2010 and 
2025 requires an average annual reduction by 3.9% (57); whereas the average 
annual rate of stunting reduction observed in the 14 LMICs in the current study is 
1.04%. This finding that current trends in these countries is not rapid enough to meet 
the global stunting target calls for the critical need to scale up efforts by the individual 
countries and their international partners. Experiences of countries with success 
stories show that rates of stunting reduction can be accelerated with deliberate 
actions (456–458). The global stunting target was also established using the actual 
experience of emerging countries as a benchmark (57). An important question 
however is which important actions are required to accelerate current progress in 
high burden countries to meet the stunting target for 2025 and beyond. 
Despite its high global prevalence, the mechanisms underlying childhood growth 
faltering and the most tractable pathways for interventions to effectively prevent 
stunting remain a work in progress (362,459,460). From epidemiological studies, it is 
apparent that stunting represents the outcome of a complex array of causal and 
contextual factors as captured in the WHO Conceptual Framework of Childhood 
Stunting (32). Prenatal and postnatal nutritional deficits and poor health such as 
infectious diseases and EED are the proximal determinants of stunting. Linear 
growth failure also occurs within a complex interplay of more distal factors such as 
agriculture and food systems, political stability and economy, access to healthcare 
and education, water and sanitation infrastructure, social support networks, and 
demographics. Preventing childhood growth faltering therefore requires multifaceted 
and multisectoral approaches combining direct nutrition interventions together with 
nutrition-sensitive development that address the underlying and contextual 
determinants of undernutrition (28,32,359). The range of important proximal to distal 
stunting drivers detected in the countries included in this study also affirm this prior 
knowledge on the need for fostering multisectoral efforts.
On top of existing trends, enhanced investment in proven nutrition interventions and 
delivery strategies to reach populations at greatest risk can make a substantial 
contribution to meeting the global stunting target. The Lancet Series (30) on 
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nutrition-specific interventions showed that accelerated gains are possible by 
expanding existing evidence-based interventions in the 34 countries housing 90% of 
the world’s stunted children. The review estimated that about a fifth of the existing 
stunting burden can be averted if a package of ten interventions to address 
undernutrition and micronutrient deficiencies can be scaled up from existing low 
population coverage to 90%. 
Given the complex nature of the problem, it is conceivable that direct nutrition 
interventions alone are insufficient to fully avert the high stunting burden in LMICs. A 
long-term and sustainable improvement in nutrition requires development 
approaches in LMICs address the underlying and contextual factors in which 
undernutrition operates (32). The findings from this study also entail the important 
role of improvements in basic and underlying factors such as income inequalities, 
urbanization, women’s empowerment, water and sanitation infrastructure, and child 
immunization. Investments in development interventions spanning multiple sectors, 
such as agriculture, education, health care, social safety nets, and water and 
sanitation infrastructure, may improve nutrition through boosting agricultural 
production and access to diverse diets, increasing income and purchasing power of 
poor households, fostering women’s empowerment, and improving health status 
(461–463). The central role of nutrition-sensitive development has been highlighted 
in the experience of countries with remarkable achievements in stunting reduction. 
To demonstrate, stunting prevalence in Brazil fell by almost three-quarters between 
1996 and 2006 with socioeconomic inequalities in stunting also reduced 
(456,457,464). This dramatic decline has been associated with concurrent 
improvements in purchasing power of low-income families through targeted 
conditional cash transfer program, improved maternal schooling, virtually universal 
basic health care, and expanded public water supply and sanitation system. 
Similarly, Mexico achieved a substantial stunting reduction which has been linked to 
better targeting and enhanced coverage of a conditional cash-transfer program and 
increased access to health care facilities (458,465). These experiences suggest that 
the scourge of chronic child undernutrition can be reduced rapidly if income among 
the poor rises simultaneously with increased access to basic services. 
Despite the evidence for the potential to reach the global stunting target through 
combination of nutrition-specific and -sensitive approaches, translating this potential 
Chapter 7: General Discussion and Conclusions 
116 
 
into results on the ground seems to be constrained by various factors. There is a 
critical funding gap to expand key nutrition-specific interventions from their current 
negligible coverage in high burden countries. It has been estimated that the scale up 
and maintenance of key nutrition interventions to reach the WHA stunting target will 
cost about US$50 billion over ten years (466). Mobilizing this additional cost requires 
current annual spending to increase from US$2.6 to 7.4 billion, including 
governments in high burden countries on average allocating 3% of their health 
budgets to stunting-related nutrition activities. Current encouraging momentum of 
prioritizing nutrition in the international development agenda should be further 
strengthened to make the case for additional resource mobilization. The strong case 
for investment in nutrition is well-established and nutrition interventions are among 
the most cost-effective development actions. For instance, every dollar invested in 
programs to reduce stunting has been estimated to have a long-term economic 
return of US$18 (467). However, there is a critical need for a greater appreciation by 
decision makers at national and international levels that stunting is not solely a 
consequence of poverty, which is rather a critical barrier to economic development. It 
should also be emphasized that improving nutrition will be a catalyst to achieve 
progress across the other SDGs. Furthermore, accountability mechanisms should be 
put in place to ensure that previous commitments made by all stakeholders for their 
globally endorsed stunting target are acted upon. 
Current efforts on stunting reduction should also be complemented by exploring low-
cost, more effective and scalable solutions within the context of limited funding. 
Delivery platforms and models that increase effectiveness and reduce cost should be 
identified and adopted for large-scale implementation of nutrition interventions. 
Nutrition-sensitive programs can be used to enhance the scaling up and 
sustainability of nutrition-specific interventions. For instance, micronutrient 
interventions such as supplements and specialized fortified food products have 
traditionally been delivered through the health facility platforms. However, an 
integrated approach using additional platforms, such as agriculture, market-based, 
and social protection programs, may help to increase the coverage and cost 
effectiveness of such individual interventions (468). 
Governments and donors invest more in nutrition indirectly, i.e., on nutrition-sensitive 
development spending, than they do on nutrition interventions directly. However, the 
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limited priority for nutrition-related goals and actions, and the gap in evidence-based 
decision-making have constrained development programs from having the desired 
impact on nutritional status. The Lancet Series (28) on nutrition-sensitive 
interventions found that programs in agriculture, social safety nets, schooling, and 
early child development improve several of the underlying determinants of 
undernutrition. However, robust evidence for their impact on nutritional status across 
settings is still scarce. According to this review, the fact that most development 
programs are not originally designed to improve nutrition has resulted in a lack of 
explicit nutrition goals and actions, poor quality of services and/or weak program 
evaluation of nutritional impact. Therefore, there is a critical need for efficient 
multisectoral collaboration to maximize the nutrition sensitivity of development 
activities in LMICs. 
Achieving nutrition impact in more distal interventions is often complex and operates 
through multiple pathways (461–463). To illustrate, the potential impact of improved 
household income on child nutritional status can be warranted in the presence of 
various conditions such as women’s control of household resources, optimal feeding 
practices, and access to basic health services. This implies that in order to reach 
their full potential on nutritional impact, development programs needs to integrate 
nutrition education, health service utilization and women’s empowerment 
components among others. Therefore, future development programs across sectors 
should be proactively reoriented to integrate strong nutrition goals and targeted 
actions grounded in program theory of impact pathways. Furthermore, informing 
investments across development sectors is constrained by the lack of effective 
mechanisms to track the impact of development spending on health and nutrition 
outcomes. Currently, the fraction of stunting that can be averted via nutrition-
sensitive actions alone is unknown as well as the combined or synergistic impact of 
nutrition-sensitive and -specific interventions. In addition to their main program 
outcomes, development programs should understand the program impact pathways 
responsible for impacts on key nutrition and health indicators such as child linear 
growth using appropriate implementation research. 
Further efforts should also be made to fill the gaps in clearly understanding the 
etiology of growth faltering during early-life and related effective nutrition solutions. 
Among others, increasing evidence support the hypothesis that EED, a persistent 
Chapter 7: General Discussion and Conclusions 
118 
 
asymptomatic enteropathy occurring at a high prevalence among children in poor 
settings, plays a central role in the pathogenesis of stunting (324,469,470). However, 
this plausible pathway has been less clearly understood and thus, largely ignored in 
current nutrition interventions. The prevalent EED among IYC in LICs has been 
indicated as the missing link that could hamper the effectiveness of existing nutrition 
and health interventions to promote child growth (470,471). Therefore, research 
exploring effective interventions to prevent and ameliorate the persistent enteropathy 
and its associated growth impairment in children is paramount to achieve a rapid 
stunting reduction in LICs. 
Structural and functional disturbances in EED are associated with nutrient 
malabsorption and a leaky-gut stimulating local and systemic inflammation, which 
are thought to underlie the impaired growth of children in poor settings (43,320–
324,469,470). Studies from laboratory experiments and human subjects in HICs 
indicate that n-3 LCPs may reduce inflammation, improve gut integrity, and enhance 
maturation of the immune system in early-life (as detailed in section 1.3.3). 
Considering the role of intestinal and systemic inflammation in the pathways from 
EED to stunted growth, these potential benefits of n-3 LCP may have important 
implications for optimal growth of IYC in LICs. Furthermore, the importance of an 
adequate supply of n-3 LCP for optimal development of the brain and visual systems 
during pregnancy and infancy is well established (134). 
The fortification of infant formulas with LCPs has been recommended by different 
authorities in HICs, whereas IYC living in LICs relay on breastfeeding as the only 
important source of LCPs. However, the n-3 FAs consumption in several LICs like 
Ethiopia is negligible to meet the adequate intake level recommended during 
pregnancy and lactation to support adequate transfer to the fetus and the infant 
(175). Moreover, IYC in vulnerable populations may have additional n-3 FA 
requirements due to different stressors such as deficiency of micronutrients required 
for essential FA metabolism, and malabsorption and chronic immune stimulation 
incurred by high rates of EED and diarrhea (71,128,191–194). Therefore, n-3 FAs 
may be one dietary limiting factor for optimal child health and development in these 
settings, especially when complementary foods very low in n-3 FAs content are 
introduced. Nonetheless, whether the supplementation of n-3 LCP is required for 
children in low-income settings is one of the least investigated research questions.




7.2.2. n-3 LCP supplementation of infants and young children 
A large number of infant n-3 LCP supplementation studies in HICs have been 
conducted in relation to child growth and development as discussed in Chapter 1. 
Briefly, n-3 LCP supplementation did not improve the growth of term infants in all 
studies considered, while inconsistent results were found in preterm infants. 
Similarly, evidence from RCTs did not show a consistent benefit of n-3 LCP 
supplementation for neurocognitive and behavioral development outcomes. 
However, participants in latter studies were mainly formula-fed infants from HICs that 
cannot be considered comparable with the breastfed IYC studied presently including 
with respect to growth and developmental risks. 
In the present study, we hypothesized that n-3 LCP-rich fish-oil supplementation 
would have an enhanced effect on growth of children in poor settings by modulating 
immune function, resulting in alleviation of intestinal inflammation and chronic 
immune stimulation associated with EED and enhancing maturation of the immune 
system. We also hypothesized that an improved DHA status would enhance 
neurocognitive and behavioral development in IYC. Furthermore, we expected a 
more pronounced effect of the fish-oil intervention on these study outcomes working 
in a country with one of the lowest dietary n-3 FA supply reported globally. 
However, empirical data from the present trial produced remarkably little evidence to 
support the proposed hypotheses that increased n-3 LCPs intake by IYC in a rural 
Ethiopian setting would lead to reduced morbidity and inflammation, and improved 
growth, nutritional status and development. The only positive finding detected on 
functional outcomes is the better ponderal growth in children who received fish-oil, 
as indicated by the small, but statistically significant, increase in relative weight gain 
and the trend towards larger MUAC increments over time. It should however be 
noted that the effect size attained on weight gain is too small to have meaningful 
impact on growth. Similarly, a fish-oil intervention was associated with higher MUAC 
and skinfold thickness in Gambian infants (291) and weight gain in Malawian 
children without improvements in linear growth or nutritional status (348). 
The current study adds to the only two previous efforts in a rural African setting that 
also failed to produce evidence for a substantial benefit of fish-oil intervention on 
child gut integrity, inflammation, morbidity, growth, or cognitive development. A 




Gambian study evaluated a direct supplementation of fish-oil in infants from 3 to 9 
months old (291), and a trial in Malawian children 12-35 months of age used 
supplementation of multimicronutrient powder with fish-oil (348). This study further 
adds to these previous trials by testing different modes of delivery, i.e., 
supplementation through complementary feeding, lactation, and combination of both, 
allowing for a dose-response analysis by comparing the factorial combinations of 
interventions. 
The possible explanation that has been given as to why fish-oil intervention did not 
achieve substantial benefits in the trials in Gambia and Malawi was that most 
children appeared to already have an adequate n-3 FA intake, although this is less 
likely in the present study. Red blood cell and plasma LCP analyses in the former 
trials did not show important n-3 FA deficiencies in the study children when 
compared to normative data from other settings. The average HM DHA level 
(0.77%TF) in the Gambian study mothers was also considerably higher than 
reported in most other populations. A review of 78 studies from 41 different countries 
estimated a global mean HM DHA concentration of 0.35%TF with country level 
values ranging from 0.10 to 0.84%TF (178). The semi-quantitative method used in 
this study to measure blood LCP does not allow us to measure the absolute LCP 
status in children. Our method collect dried blood spots and quantified LCP per 
volume extracted blood. These values are not comparable to values from literature 
reporting the relative LCP status in erythrocyte or plasma phospholipids as percent 
total fat. Given this methodological difference, the ratio of AA/(EPA + DHA) may 
provide a relatively better comparison of our results with others. The ratio of 
AA/(EPA + DHA) in our children at baseline (6-12 months old) as compared to 
plasma FA levels in the Gambian control infants at the age of 9 months show values 
that are almost three times higher (mean ± SD: 4.44 ± 0.73 vs. 1.28 ± 0.31). 
HM DHA level is one way of assessing n-3 FA status in lactating women and DHA 
levels below 0.2%TF (~84 mg/L) have been suggested as indicative of increased risk 
of not supporting optimal infant development (404). From the analysis of baseline 
samples, the average HM DHA level in this study was 74 mg/L, indicating a very low 
maternal status with a potential risk of suboptimal development in their IYC. Dietary 
intake was not monitored in IYC of the current study. However, our earlier cross-
sectional dietary surveys during both the pre- and post-harvest seasons in the same 




population found extremely rare consumption of preformed n-3 LCP sources in the 
complementary diet, with only 1 out of 291 IYC who were studied consumed fish 
(369). In contrast, small fish consumption was reported to be 2.2 times/wk 
throughout the study period in the Malawian children, and 80% of the Gambian 
infants at the age of 9 months consumed some egg yolk or fish. Therefore, neither 
an adequate n-3 LCP intake from breastfeeding nor from complementary diet can be 
a likely explanation for the null results in the current study and potential impact of 
fish-oil intervention, if any exists, should have been noticed better. 
The doses used in this study are very high compared to the adequate intake level 
recommended for older infants and young children, especially considering the 
children who received additional n-3 LCP through both complementary food and 
breastmilk. The dose of DHA in the child food supplement, even after taking into 
account compliance data, was also adequate compared to the dose that has been 
recommended for infant formulas to achieve definitive results on cognitive 
development (detailed in Chapter 6). The optimum dose of n-3 LCP taking into 
account the presence of EED and associated growth faltering remains unknown. It is 
noteworthy that studies of n-3 LCP as a therapeutic agent in chronic inflammatory 
conditions, such as inflammatory bowel disease, typically used much higher doses 
(119,317). However, in this and other similar child populations suffering from 
recurrent infections, the use of such high therapeutic doses raises safety concerns in 
relation to a potential excessive anti-inflammatory responses (472). A review of 
studies in animal models suggested that reduced pro-inflammatory responses due to 
increased n-3 LCP intake can improve or impair resistance to infectious challenge 
depending on the type of pathogen (415). Diminished inflammation due to n-3 LCP 
may reduce tissue damage, which could result in improved resistance against gram-
negative bacteria. In contrast, it may also suppress cell-mediated immunity, which 
could in turn compromise resistance to gram-positive intracellular pathogens. 
On the other hand, it should be recognized that the concentrations of n-3 LCP in HM 
found in our intervention mothers remained below our expectations when 
considering results from previous studies. A dose-response study of maternal 
supplementation during early lactation, which was also used as the basis for 
developing the study dose for our sample of lactating women, showed that DHA 
enrichment of HM to the global average of 0.32%TF (~134 mg/L) is possible through 




intake of at least 167 mg DHA/d (398). The fish-oil intervention using a daily dose of 
500 mg n-3 LCPs (215 mg DHA + 285 mg EPA) in our study significantly increased 
HM DHA concentration by 39% compared to the control. However, the average 
maternal milk DHA enrichment achieved with the supplementation was only 90 mg/L. 
Possible explanations for the relatively smaller effect in our intervention mothers may 
include the later stage of lactation, compliance to supplementation, and other factors 
requiring future investigation. 
A number of factors might have diluted the anticipated impact of the fish-oil 
intervention. Children in both the control and intervention groups have received a 
close surveillance of morbidity and referral to primary health care, a preventive 
deworming medication for intestinal parasites, and a multimicronutrient fortified 
complementary food supplement. Although it cannot be determined in the present 
study design, these intervention components provided by the study setting might 
have some positive effects on the studied outcomes, thereby possibly diluting the 
potential effects of n-3 LCP supplementation in children living under the usual 
setting. The intervention components were considered in the study design for the 
purpose of avoiding any hampering of the efficacy of n-3 LCP by deficiency of other 
nutrients and intestinal parasite infections as well as some of the services usually 
delivered by the routine health care system. More importantly, it is unlikely that a 
single nutrient solution exists to improve the health and nutritional status of children 
in poor settings and from a program point of view, the potential of n-3 LCP 
intervention should be seen within the context of existing health and nutrition 
programs. 
The interpretation of the lack of impact of the fish-oil intervention on child 
development outcomes has been detailed previously (Chapter 6). These include the 
timing and duration of the fish-oil supplementation which did not cover the entire 
period of expected high brain sensitivity to dietary DHA and the chosen assessment 
tools that might not be sensitive enough to detect effects on specific brain functions 
that are thought to be influenced by DHA. However, the Gambian trial also found no 
effect of their fish-oil intervention on early child cognitive development. This trial was 
started at an earlier age and used a wide range of tests of infant attention and 
problem-solving behaviors. Yet the infants in this study were reported to have 
adequate basal n-3 FA status. No other study assessing the effect of fish-oil on 




development of IYC from LICs was found to compare our results to. Only a few 
studies conducted in HICs reported on observed benefits of n-3 LCP 
supplementation on development. However, the infants in these trials were exposed 
to different contextual conditions than IYC in the present study. Children in HIC 
consumed mainly child formula, while children in the present study did not have 
access to such products and were predominantly breastfed. Other contextual factors 
include a different nutrient intake and level of stimulation of the child that can affect 
neurocognitive development. 
An important point for future consideration is that potential impacts of early DHA 
exposure on brain function may become more evident on cognitive abilities that 
emerge at a later age. Jensen et al. (263), for instance, supplemented lactating 
women with 200 mg DHA/d during four months postpartum and found no effect on 
neurocognitive development of study infants at 12 months of age. However, on later 
follow-up at the age of 30 months and 5 years, children of mothers who received the 
DHA intervention had significantly better cognitive development than children of the 
control mothers (263,265). Similarly, a longitudinal follow-up study of children who 
received infant formulas with different doses of DHA from birth to 12 months of age, 
found no effect of the DHA intervention using standardized tests of cognitive 
development at 18 months of age, but later at the age of 3 to 6 years, positive effects 
were detected on specific tests of executive functions, vocabulary, and IQ measures 
(242). These findings, although not consistent across all trials, imply the need for 
continued follow-up of the present study cohort to evaluate any long-term effects of 
the fish-oil intervention on cognitive development. 
Most studies in HICs have been focused on LCPs supplementation during infancy 
and there is limited data relating to older infants and young children. Although not 
successful at having the anticipated impact, this study contributes to the evidence 
during this period when most children in LICs may be vulnerable to n-3 FA 
insufficiency due to the low content in the traditional complementary foods. On the 
other hand, considering the potential correlation between maternal DHA status 
during pregnancy and lactation (189), there is a concern that children in the present 
study might have also had inadequate fetal and early postnatal DHA exposure. 
During this period brain DHA accretion is the most rapid, as such, the potential for 
any impact on cognitive development potentially the largest. Therefore, future 




interventions starting from pregnancy or early lactation may result in more 
observable impacts of n-3 LCP in this population. Furthermore, limited data from 
LICs suggest that a higher n-3 LCP status or supplementation during pregnancy is 
associated with reduced risk of preterm delivery and modest improvements in 
birthweight and length (473–476), which remains a research question for 
investigation in the current population. 
The very low HM DHA concentration observed in our lactating mothers could be an 
indication of a suboptimal child cognitive development (404), which might not be 
captured by the currently tested domains. DHA rapidly accumulates in the brain 
perinatally, and involved in neurogenesis, neurotransmission and protection against 
oxidative stress (85,98,134,136–140). Animal studies show unequivocally that 
dietary n-3 FA deficiency during pregnancy and lactation severely impairs cognitive 
and behavioral performance (138). It has also been shown that maternal n-3 LCP 
intake during pregnancy and lactation and breastmilk DHA content are associated 
with child cognition (477). An international consensus recommends that the daily 
intake of DHA by pregnant and lactating women should reach 200 mg, which can be 
met by weekly consumption of 1-2 portions of fatty-fish (95,173). The HM DHA status 
in this study is consistent with the very low availability of fish and other seafood in 
Ethiopian diet reported previously (175). Therefore, while more trials evaluating the 
effects of an n-3 LCP intervention are required in the future, there should also be 
efforts exploring strategies to increase the n-3 FA intake among Ethiopian women 
during pregnancy and lactation. 
Despite the health and nutrition interventions with or without fish-oil supplementation 
mentioned above, growth and nutritional status of the study children remained poor 
when compared to the WHO standards. The risk of developmental delay was also 
found to be prevalent based on Ethiopian benchmark. Previous energy and 
micronutrient supplementation and health interventions in similar settings generated 
inconsistent results on the prevention of child stunting. Therefore, some authors 
argue that this poor growth is not pathological for these children, but may be a 
beneficial adaptation mechanism allowing the use of limited resources to the best 
advantage (476). However, this claim is unlikely to be true given that child growth 
during the first few months of life is relatively good in most poor settings when infants 
are receiving exclusive breastfeeding and have a limited exposure to adverse 




environmental factors. Several studies have shown that while some children follow 
the optimal growth pattern, others in the same population do not, and this variation in 
growth pattern has been explained by variations in exposure to different factors (40). 
Intraindividual variations in growth patterns have also been shown to depend on 
seasonal changes in food availability and other environmental stressors (478,479). 
Moreover, evidence shows that not only are the stunted children who have an 
elevated risk of mortality, but also the apparently healthy looking children with mild 
growth restrictions (i.e. z-scores between -2 and -1 SD) (480). Therefore, efforts 
exploring effective interventions to prevent the growth restriction and developmental 
delay experienced by children in poor settings should be continued. There is a 
critical need to better understand the causes and mechanisms behind growth 
faltering to assist in the development of effective nutrition interventions. The complex 
interactions between nutrition including essential FAs, the immune system, infection, 
and gut health in relation to growth faltering should be studied using more rigorous 
and mechanistic approaches. 
Finally, there is still limited evidence on the potential impact of n-3 LCP intervention 
in low-income populations under different contextual settings and using different 
intervention approaches. For instance, observed effects of the fish-oil intervention 
may differ in a child population with a different degree of EED, infection and 
associated growth faltering as well as using a different timing, duration, or dose of 
supplementation. Therefore, further RCTs addressing the gaps in the few available 
studies are required before a conclusive remark can be made regarding the potential 
for n-3 LCP supplementation of IYC in low-income settings. Methodological 
considerations and thoughts for future research are discussed in the next sections. 
7.3. Methodological considerations 
In addition to the strengths and limitations that have been mentioned earlier in the 
relevant chapters, we address here general methodological issues requiring 
consideration while interpreting the findings. 
The stunting trend analysis was limited to only potential drivers for which data were 
available in all DHS rounds for all the countries considered. Accordingly, the analysis 
did not consider some important potential drivers for which data were not available in 
the earlier DHS rounds, e.g. all of the IYCF indicators. Including additional indicators 




from other data sources was also constrained by the difficulty of matching the year of 
data in other sources and the DHS rounds which also varied across countries. 
Furthermore, because of the focus on the countries that are partners for nutrition 
support by the DEVCO, this study evaluated the trend in child stunting in only 14 
LMICs. As such, the generalizability of our findings to all relevant countries should be 
considered carefully. 
The OME3JIM study is a well-designed and implemented trial with sufficient 
statistical power to demonstrate a clinically relevant effect on child growth and 
development. The treatment was randomly allocated and concealment strategies 
were well implemented. All outcome assessments were performed blinded to 
treatment allocation and clearly defined study inclusion criteria were used. RCTs, by 
virtue of design, allow for elimination of multiple sources of bias and are therefore 
considered the gold standard for testing a causal hypothesis that a certain exposure 
affects an outcome of interest. On the other hand, even if variability is distributed 
evenly across treatment groups, sample heterogeneity may contribute to nuisance 
variability in study outcomes and potential heterogeneity of treatment effect (481). In 
this respect, participants in this study were recruited from 3 small rural communities 
sharing similar demographic characteristics, livelihoods, diets, IYCF practices, and 
other risk factors. Yet, sample homogeneity might have been affected by the 
recruitment of infants with a wider age interval. We had sufficient statistical power to 
detect clinically important group differences for most outcomes and no secondary 
analysis suggested effect-modification by age. However, we would have been more 
confident about the absence of any age-related differences masking the intervention 
effect provided that all infants were recruited starting from the age of 6 months. 
Another important point requiring consideration is the extent to which the empirical 
data collected in a trial address the theoretically hypothesized effects of an 
intervention (482). Despite various dimensions of growth being measured, the 
present study used morbidity signs and CRP as the only proxy outcomes to evaluate 
effects on child immune function and health. A recent systematic review of evidence 
on the possible pathways from EED to stunting suggests the need for considering 
multiple indicators including markers of gut integrity, intestinal and systemic 
inflammation, and immune cell functions (324). The lack of such indicators in this 




study hampered a more mechanistic understanding of the hypothesized effects of 
the fish-oil intervention. Furthermore, data on the burden of EED and inflammation, 
and the degree to which these conditions contribute to growth faltering in IYC in this 
study would have facilitated extrapolation of current results to children in other 
settings. 
The sensitivity of the chosen methods for development assessment is one frequently 
cited possible reason for the inconsistent results from previous trials. Cheatham et 
al. (137) argue that tests of specific cognitive functions, such as memory, attentional 
control and higher-order cognition, may be more sensitive than global development 
measures to detect effects of DHA on brain function. Empirical data from n-3 LCP 
trials in general remain inconsistent for both the specific and the global cognitive 
tests with beneficial effects also detected in few studies using global development 
tools such as the BSID (232–234,252–254,263). In this study, we decided to use the 
Denver II and ASQ-SE tools of global development because none of the suggested 
specific cognitive tests are adapted for use in Ethiopian IYC and due to the lack of 
previous experience in administering such tests. We found the Denver II and ASQ-
SE practical choices in our research setting as they were culturally adapted and 
validated in the same population as well as Ethiopian benchmark is available for the 
Denver II (440). These tools are also easily standardized for use in the field by non-
expert staff and carried out on a large sample over short time, improving precision of 
measurements and statistical power of the study. 
Finally, although IYC 6-24 months old in this study can be considered representative 
of similar aged children in the studied communities, the generalizability of the 
findings across different circumstances and populations should be carefully 
interpreted. It is not clear whether current results might differ if the fish-oil 
intervention was provided starting from prenatally or early lactation. The burden and 
etiology of EED and associated growth faltering, which were not measured in these 
IYC, may differ across child populations living in different contextual settings. Thus, 
to what extent the present results may be extrapolated to apply to children in other 
populations with a different degree of gut damage and growth faltering is less clear. 
The results might also differ if the doses were altered in magnitude or composition 
(e.g. DHA/EPA ratio) or the study was conducted in a population with a different 
basal diet (e.g. n-6/n-3 FAs ratio) or desaturase enzyme activity. 




7.4. Thoughts for future research 
A few points can be proposed for future research involving n-3 LCP intervention in 
mothers and children based on the previously described study findings and gaps in 
this PhD research, and in relation to existing literature. 
Different intervention: timing and setting 
The current study was aimed at addressing the timing of increased risk of enteric 
infections, and intestinal and systemic inflammation in relation to introduction of 
unhygienic complementary foods and a child’s increased exploration of its 
surroundings. We also opted to limit the possibility that a high rate of exclusive 
breastfeeding in this population may mask effects of a fish-oil intervention provided 
during early infancy. On the other hand, our HM LCP data at baseline suggest that 
the current child population might also have had inadequate DHA exposure to 
support the rapid brain accretion during the fetal and early postnatal periods. 
Therefore, a future study in this population may find a different impact on infant 
cognitive development by conducting the n-3 LCP intervention starting from 
pregnancy or birth. 
The burden of EED and its contribution to impaired growth of children, including the 
different possible pathways, could vary across settings. In this regard, the lack of 
data on the burden of EED in our study population limits extrapolation of the findings 
to children in other rural African settings. The studies in the Gambia and Malawi 
found no substantial benefits of fish-oil intervention despite the presence of a very 
high burden of EED. Yet, children in these studies were reported to have an optimal 
n-3 LCP status. Therefore, it is recommended that future studies replicate these 
trials in a child population with a known combination of a high burden of EED and a 
suboptimal n-3 LCP status. 
Future follow-up of the study cohort 
Potential impacts of n-3 LCP supplementation in early-life may change over time. As 
discussed earlier, effects on brain function may become more evident in cognitive 
and behavioral skills that emerge when these IYC get older. The fact that the global 
development tools used presently may have limited predictive validity for future 
cognitive performance is a further justification warranting future follow-up (452). Such 
a follow-up will also provide insights into any long-term implications of the modest 




effects detected on ponderal growth, including whether these will be sustained, fade 
away, or become more pronounced with time, and relate to other functional 
outcomes in the future. Nutritional interventions, when applied at critical periods in 
early-life, may have the potential to remotely influence or program future health. 
Epigenetic modification may occur with n-3 LCP supplementation in early-life. 
Recent literature suggests that prenatal n-3 LCP supplementation may alter DNA 
methylation in genes involved in diverse biological processes including inflammatory 
and metabolic pathways, which may have a potential implication for inflammatory 
conditions and metabolic syndrome later on (483–485). Although not consistent, a 
few studies conducted in HICs also noted that n-3 LCP supplementation in infancy or 
maternal milk content during lactation may affect later childhood body composition 
and other markers of metabolic risk such as blood pressure and insulin sensitivity 
(486–488). The Gambian study also noted a delayed effect of the fish-oil intervention 
on body composition as shown by the significant increases in MUAC and skinfold 
thicknesses with the latter effect seen only at a continued follow-up after the 
intervention ended (291). It is therefore recommended that the present study cohort 
be followed to examine whether benefits which were not seen in IYC may manifest at 
a later age. 
Additional measurements to be considered in the future 
Future studies of n-3 LCP in the current and similar populations may provide more 
robust evidence by addressing current gaps with regard to various measurements 
mentioned earlier. 
In addition to global measures of child development, specific cognitive skills that 
might be more sensitive to the role of DHA on brain function should be considered in 
future studies as well as in follow-up of the present study cohort. For this purpose, 
current challenges in administering such tests need to be addressed through cultural 
adaptation and validation of various age-specific tests for discrete aspects of 
cognitive function that have been applied in previous n-3 LCP trials in HICs (242). 
Furthermore, variability in relevant factors such as child rearing practices and the 
quality of home environment may modify the potential effects of n-3 LCP intervention 
on child development. In evaluating the effect of a prenatal DHA supplementation on 
child development at the age of 18 months, Ramakrishnan et al. (277) found a 
differential effect of the intervention by the quality of home environment. Therefore, 




future studies should also consider measuring the level of child stimulation practices 
and the quality of home environment for a more rigorous analysis of the intervention 
effect. 
Future studies of maternal fish-oil supplementation in this population should give 
attention to the relatively modest increase in HM DHA concentrations with the 
current intervention. A more mechanistic study in a small sample of lactating women 
may provide a better insight on the optimal dose before conducting a large-scale 
intervention study. For this purpose, a dose-response study applying stable isotope 
tracers and a more rigorous method for monitoring intake from both supplementation 
and basal diet should be considered in the future. 
The potential impacts of n-3 LCP on child immune function and EED could have 
been understood better by using a variety of relevant biomarkers. These include 
markers of intestinal damage and repair, permeability and absorption, microbial 
translocation, and intestinal and systemic inflammation (324). It has also been 
suggested that a combination of biomarkers of intestinal inflammation and 
permeability may explain linear growth deficits better than the use of single 
biomarker (489). Furthermore, as mentioned earlier, n-3 LCP supplementation may 
result in changes in body composition. Therefore, in addition to gross assessments 
of child growth, future studies can capture this potential effect better by using more 
reliable measurements of body composition such as bioelectrical impedance, air 
displacement plethysmography and dual-energy X-ray absorptiometry. 
Finally, emerging evidence on potential interpersonal variations in LCP requirements 
introduced new variables to be considered in the interpretation of n-3 LCP effects on 
child health and development. Lauritzen et al. (98), in a review of evidence from 
recent studies, emphasized that effects of DHA supplementation on the infants’ brain 
may depend on gender and genotype of genes involved in the endogenous 
synthesis of DHA. No statistical evidence was found for differential effects between 
boys and girls in this study. However, to what extent heterogeneity in FADS 
genotype pattern affected the results on development or the other outcomes cannot 
be ascertained at this time. Thus, it would be of great interest to secure data on 
FADS genotype of our subjects in a future study to examine any effect-modification 
of the fish-oil intervention. More importantly, future studies may provide a more clear 




answer on the impact of n-3 LCP supplementation by taking into account these 
factors at the design stage including a priori hypothesized subgroup effects with 
adequate sample size. The use of the Mendelian randomization approach was also 
recommended for evaluation of the role of FADS gene clusters in the association 
between dietary n-3 LCP and functional outcomes (98). 
Future studies of trend analysis 
The double-burden of malnutrition is an emerging public health concern in LMICs. In 
populations undergoing rapid nutrition transition, childhood stunting and overweight 
coexist (490), and evidence showed that nutritionally stunted children may have an 
increased risk of excessive weight gain during nutrition interventions and in later life 
(491). In emerging countries, the challenge ahead is achieving a rapid stunting 
reduction while keeping child overweight/obesity at bay, which has also been echoed 
in the WHA global targets. Thus, it is of great interest that future studies involving 
trend analysis monitor not only the trend in child stunting in LMICs, but also the trend 
in the double-burden of malnutrition at the level of individuals, households and 
countries. This is also critical to understand the shared drivers and identify double-
duty actions for interventions, programs, and policies that eradicate child 
undernutrition without contributing to overweight/obesity and the associated risk of 
nutrition-related chronic diseases (492). 
Other nutrition studies in this population 
This study noted a high risk of growth faltering and developmental delay among 
Ethiopian IYC in rural areas, requiring attention of future research and programs. It is 
also a concern that women have potentially inadequate dietary n-3 LCPs intake 
during pregnancy and lactation, as indicated by the maternal milk DHA content in 
this study which is also in agreement with a previous country level estimates of n-3 
FA consumption (175). Before recommendations on context specific interventions, 
in-depth epidemiological research is required to gain more insight into the important 
health and nutritional contributors underlying the poor growth and development of 
IYC in these settings. The contribution of poor hygiene and sanitation, and 
contaminants in complementary diet to enteric infections and EED as well as the 
different pathways that link EED and growth faltering should be studied in the context 
of the current population. In addition to nutrition and health interventions, studies 
have also shown that child stimulation may have an effect on child development 




(493–495). Therefore, the role of suboptimal child care and stimulation practices for 
child development performance in the current population should be closely 
understood. Furthermore, future studies exploring the association between dietary 
essential FA and various outcomes in pregnant women and IYC will provide more 
insight into the health consequences of the very low n-3 LCP concentration in the 
Ethiopian diet. 
7.5. Policy recommendations 
7.5.1. Acceleration of the trend in reducing chronic child undernutrition 
Meeting the WHA global target of childhood stunting reduction requires acceleration 
of the current progress in many LMICs. Evidence suggests that accelerated gains 
are possible in these countries if the coverage of direct nutrition interventions can be 
scaled-up extensively along with large-scale implementation of nutrition-sensitive 
development programs. However, the realization of this potential requires addressing 
various challenges at different levels. 
Ensuring political and policy commitment for the WHA nutrition targets 
The nutrition society has made great achievements in the past few years in building 
the political and policy commitment that placed nutrition at the center of the SDGs 
agenda. This encouraging momentum should be maintained and further 
strengthened for the globally endorsed nutrition targets to be translated into results 
on the ground. One of the main challenges for a rapid progress in child nutrition is 
the lack of adequate funding to expand key nutrition-specific interventions from their 
current very low coverage in LMICs. Therefore, further political and policy 
commitment should be garnered at all levels to fill the current funding gap through 
rapid expansion and strong coordination of investment from both domestic financing 
and development assistance. Another important challenge is the lack of adequate 
nutrition-sensitive approaches in various development activities in LMICs. It is well 
recognized that sustainable progress in nutrition requires a multisectoral approach, 
and not just the up-scaling of nutrition-specific interventions. However, this requires a 
strong coordination and collaboration between various development actors and 
stakeholders at the international and national level. Decision makers and program 
planners at different levels should be informed that integrating nutrition goals and 
actions across development sectors is a critical input to achieve progress in other 
development targets. Furthermore, there is a need for strong accountability 




mechanisms that will enforce national governments and their development partners 
to meet their commitments for the nutrition targets endorsed globally. 
Maximizing the impact of current interventions 
Acceleration of the progress in reducing child undernutrition requires strategies that 
maximize the impact of existing direct and indirect investment in nutrition. A large-
scale implementation of the proposed package of nutrition-specific interventions and 
reaching populations at most risk should be made feasible by identifying various 
delivery strategies that are effective, low-cost and sustainable. In addition to the 
traditionally used health and nutrition programs, diversification of delivery platforms 
should be considered through the integration of nutrition-specific interventions into 
various development programs. Furthermore, investments in various development 
activities should be exploited to contribute to better progress in nutrition. There is a 
need for enhancing the nutrition sensitivity of distal development programs in LMICs 
so that their potential to deliver on maternal and child nutrition outcomes is 
unleashed. It has been suggested that the nutrition-sensitivity of development 
programs can be enhanced through better targeting of program beneficiaries on the 
basis of nutritional vulnerability, and by incorporating nutrition goals and actions as 
well as strengthening their effective implementation. Development programs should 
also engage women actively by including interventions that protect and promote their 
nutritional and health status, social status and decision making. Additionally, 
investment across different development sectors should follow evidence-based 
decision-making processes that take into account health and nutritional outcomes 
among indicators of overall progress. This can be made possible through 
establishing effective mechanisms to track the impact of investment in various 
development programs on health and nutritional outcomes. 
7.5.2. Improving n-3 fatty acid status in Ethiopian women and children 
The limited available studies from rural African settings did not provide substantial 
evidence to support the routine supplementation of n-3 LCP as an intervention 
strategy to improve child growth and development at this time. However, the 
importance of an adequate supply of n-3 LCP for ensuring optimal development of 
brain and visual systems during early-life is well-established. There is also evidence 
that the dietary supply of n-3 LCP influences pregnancy outcome and a range of 
metabolic and immune functions. The FAO food balance sheet data show that the n-




3 LCP supply in the Ethiopian diet is far below the recommendations for optimal 
health. However, the consequences of this very low intake have received little 
attention so far, despite potential major implications for child development and 
subsequent learning capacity. Policies and programs in nutrition and other relevant 
sectors should take various measures in the future to protect vulnerable groups from 
potential adverse health and functional outcomes due to n-3 FA insufficiency. These 
are discussed in the following sections. 
Evidence on n-3 fatty acid status of vulnerable groups 
Investigating the burden of n-3 FA insufficiency and its health implications is the first 
step to inform and guide relevant policy, strategy and programs. Therefore, the 
dietary intake and status of Ethiopian women of child bearing age and IYC should be 
defined for various PUFAs, and the associated impact on health and nutrition 
outcomes should be estimated. This can be facilitated through existing platforms of 
health and nutrition surveys that are conducted at a regular interval. The Ethiopian 
National Food Consumption Survey in the future may consider reporting dietary 
consumption of various PUFAs in addition to total fat intake. For this purpose, the 
current Ethiopian food composition table, which reports only total fat content of food 
items, should be revised to include FAs profile including PUFA contents. Information 
on PUFA profile of Ethiopian foods is also important for informing consumers and 
various stakeholders, including in the design of food-based dietary guidelines and 
other strategies aimed at improving n-3 FA status. Additionally, measuring PUFA 
status in children and women, including the content in breastmilk, can be 
incorporated into the National Micronutrients Survey. 
Breastfeeding promotion, support and protection 
A key strategy to improve the adequacy of n-3 LCP intake in IYC in low-income 
settings is promotion of universal exclusive breastfeeding in the first 6 months and 
continued breastfeeding up to at least the age of 2 years. Promotion of optimal 
breastfeeding practices is also one of the most effective strategies identified to 
improve child survival in LICs. Ethiopia has made limited progress in this regard. For 
instance, the National Nutrition Program in its second phase (2016-2020) has set a 
target to increase the rate of exclusive breastfeeding by 22% from 58% in 2016 to 
80% in 2020. In contrast, only a 1% increase in the rate of exclusive breastfeeding 
achieved nationally between 2016 and 2019. Therefore, there is a critical need for 




scaling up the coverage and effectiveness of interventions for breastfeeding 
promotion, protection and support in the country. Current programmatic and 
implementation gaps responsible for the limited progress should be identified and 
addressed in the future. A combination of health facility- and community-based 
intervention approaches has been identified as particularly effective in bringing 
sustainable behavioral change in breastfeeding. In this regard, the Community 
Based Nutrition program implemented in the country should be used as a platform 
for a large-scale breastfeeding promotion and support intervention. The outreach 
strategy involving health extension workers and local women peer educators can be 
exploited to reach mothers living in remote areas with limited access to health 
facilities and media, and to mobilize local community participation and support for 
mothers to breastfeed. This approach can also create the opportunity to deliver 
effective messages that are tailored to the specific context including the local social 
norms, and enablers and barriers to breastfeeding. 
Furthermore, breastfeeding promotion should be complemented by strategies that 
create an enabling environment and community support for mothers. Women 
working both in the formal and informal sectors need to be empowered to exclusively 
breastfeed by enacting appropriate maternity protection laws as well as policies that 
encourage breastfeeding in the workplace. Current Ethiopian labor proclamation 
allows only a 3-month postpartum leave, which may require amendment to cover at 
least the exclusive breastfeeding period of 6 months. Furthermore, the use of infant 
formula products may increase in the future with urbanization and increasing 
women’s involvement in the formal work sector. The Ethiopian Government recently 
took an encouraging step by endorsing a directive on infant and follow-up formula 
that will provide the opportunity to encourage and protect breastfeeding if 
implemented effectively. In the future, the directive should also consider protecting 
exclusively formula-fed infants from a potential risk of inadequate brain DHA 
accretion. This can be made feasible by considering the fortification of infant 
formulas with preformed DHA as one of the mandatory criteria for appropriate 
standard of formula products. 
n-3 fatty acid in other nutrition interventions and strategies 
It should be noted that the n-3 LCP composition of breastmilk as well as the transfer 
to the fetus during pregnancy are vulnerable to influence by the maternal diet. Thus, 




even breastfed infants may not be protected from a risk of suboptimal development 
when the maternal dietary intake of n-3 LCP during pregnancy and lactation is very 
low. Furthermore, children become more vulnerable to n-3 FA insufficiency with the 
introduction of a very low content complementary foods. Therefore, additional 
strategies to promotion of breastfeeding are required to improve dietary fat 
composition in support of n-3 FA intake in women and IYC. However, current 
nutrition programs in Ethiopia lack strategies that specifically target the adequacy of 
n-3 FA. Strategies and interventions to improve the quality of complementary foods 
and women’s diet largely focused on energy and micronutrients content with little 
attention given to quality of the FA supply. This is in contrast to the attention that has 
been given to some micronutrients such as iron, zinc, iodine and vitamin A. Future 
efforts for identifying nutrient gaps and developing dietary strategies should look 
beyond total fat intake and consider the adequacy of n-3 FA in the diet. Fish and 
other seafood are the important sources of n-3 LCP in human diet, while the 
precursor ALA can also be obtained from some oils, green leafy vegetables, and 
legumes. Food-based dietary guidelines and nutrition recommendations should 
encourage the consumption of both ALA and preformed n-3 LCP sources by women 
and IYC. Dietary recommendations for Ethiopian women may also consider adopting 
the international consensus on recommended fish consumption during pregnancy 
and lactation. Furthermore, dietary essential FA balance has important implications 
for n-3 LCP adequacy, especially in populations with very low fish consumption. 
Diets high in LA content compromise the endogenous conversion of ALA to n-3 LCP 
and the incorporation of n-3 LCPs into infant and maternal tissues including 
breastmilk. Therefore, formulation of food-based dietary guidelines and nutrition 
recommendations in the future should also take into account the recommended LA 
and ALA balance in the diet. 
The few available intervention strategies that give attention to quality of the FA 
supply such as lipid-based nutrient supplementation (LNS) also miss important 
aspects of n-3 FA metabolism. It should be noted that increasing dietary ALA alone 
may not be an effective strategy to improve the status of n-3 LCP, DHA in particular. 
The metabolic conversion rate of ALA to n-3 LCP is typically low and also influenced 
by genetic profile and background diet including the LA content. The conversion of 
ALA from the diet could be further decreased in populations with inadequate energy 




and fat intake and prevalent micronutrient deficiencies such as iron and zinc. 
Therefore, effective interventions to improve the DHA status of populations at risk 
require a combined approach involving an increased intake of fish and ALA sources 
together with ensuring an optimal balance of essential FAs. LNS products, including 
ready-to-use therapeutic foods as well as the various preventive LNS products for 
IYC and pregnant and lactating women, provide the essential FAs ALA and LA, but 
not preformed n-3 LCP. These products usually contain marginal amounts of ALA 
and a high LA content due to the LA-rich vegetable oils predominantly used to 
increase energy density. As a result, it is unlikely that currently available LNS 
products provide effective protection against n-3 LCP insufficiency and associated 
health outcomes. It is therefore important that future LNS formulations consider 
products fortified with preformed DHA and a lower LA content which could lead to 
enhanced impact of LNS interventions on pregnancy outcomes and child health and 
development. 
n-3 fatty acid supply in the food system 
A sustainable approach to improve n-3 LCP status of vulnerable groups is improving 
the availability, accessibility, affordability, and desirability of fish and other n-3 FAs 
sources in the food system. Ethiopia is a land-locked country depending on inland 
water bodies for domestic fish supply, with an estimated annual yield potential of 
around 94,500 metric tons (496). However, only about 20% of this potential is 
harvested presently and fish consumption contributes to only 1% of the animal 
protein intake in the country. Furthermore, aquaculture production is negligible in 
Ethiopia despite the favorable ecological conditions available for fish farming. It has 
been estimated that year-round farming of coldwater fish species can be achieved in 
the country’s highlands covering 11% of the surface area and there is also additional 
potential for farming an array of coldwater and warmwater species in other parts of 
the country (497). This currently underexploited potential for fish production leaves 
significant room for further development to improve the very low n-3 LCP 
consumption rate in the country. For this purpose, fishery and aquaculture should be 
fully integrated into Ethiopia’s food security policies and plans including in the 
National Agricultural Sector Policy and Investment Framework, and the National 
Water Sector Strategy. The current predominantly artisan fishery production system 
should be improved by providing inputs and transfer of technologies to producers. 




Development of aquaculture should be considered in existing irrigation, farming and 
water harvesting schemes. Although the Ethiopian water bodies support diverse 
aquatic life including more than 180 identified fish species, only few species are 
commercially important. The species with better n-3 LCP content should be identified 
and their production and consumption should be encouraged in the future. 
It is also important to address various challenges in the fish market chain. There is a 
wide spatial variation within the country in terms of the production and market 
availability of fish products, which are mainly driven by access to infrastructure such 
as roads and transportation. Furthermore, most of the population is yet to integrate 
fish into their diet and consumption pattern is seasonal, limited to only few fasting 
months per year. These important limitations in the fish market chain should be 
addressed through expansion of infrastructure, adoption of appropriate post-harvest 
management technologies, and promotion of fish consumption in the population. 
7.6 Conclusive remarks 
Finally, the following remarks are made from this PhD work: 
 The current trend in stunting reduction in LMICs requires further acceleration to 
meet the WHA global target. 
 Current trend in stunting reduction could be further accelerated by a combination 
of economic development and nutrition-sensitive interventions, on top of nutrition-
specific programs. 
 There is a need for more evidence on the potential impact of n-3 LCP 
supplementation on healthy growth and development of IYC in low-income 
settings. 
 There is a critical need to improve the essential fatty acids adequacy in the diets 
of Ethiopian pregnant and lactating women and infants and young children. 
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Annex 1: Trends in stunting drivers by country 
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Annex 2: Comparing characteristics of participants in the HM sub-study 
and all participants in the main trial1 
Characteristics HM subsample (n = 154) Main sample (n = 360) P 
Maternal age, y 25.9 ± 5.08 26.1 ± 5.14 0.68 
Child age, mo 7.7 ± 1.2 8.9 ± 2.1 <0.001 
Primiparous  41 (26.6) 99 (27.5) 0.84 
Marital status, married 148 (96.1) 345 (95.8) 0.89 
Maternal education    0.75 
   No formal education 77 (50.0) 179 (49.7)  
   Primary education 53 (34.4) 133 (36.9)  
   Secondary and above 24 (15.6) 48 (13.3)  
Household head education    0.99 
   No formal education 50 (32.5) 117 (32.5)  
   Primary education 70 (45.5) 165 (45.8)  
   Secondary and above 34 (22.1) 78 (21.7)  
Household wealth tertiles   0.54 
   Lowest 53 (34.4) 120 (33.3)  
   Middle 57 (37.0) 120 (33.3)  
   Highest 44 (28.6) 120 (33.3)  
Breastfeeding frequency   0.84 
   4-6 times/d 16 (10.39) 35 (9.72)  
   7-9 times/d 38 (24.68) 98 (27.22)  
   ≥10 times/d 100 (64.94) 227 (63.06)  
Maternal height, cm 157 ± 5.26 157 ± 5.48 0.97 
Maternal weight, kg 50.6 ± 6.99 50.3 ± 7.61 0.67 
Maternal BMI, kg/m2 20.5 ± 2.59 20.4 ± 2.74 0.61 
1Values are presented as means ± SDs or n (%). P’s comparing study arms using independent 
sample t-test or Pearson’s chi-squared test.  HM, human milk. 
 
 
 
